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Pulmonary arterial hypertension (PAH) is a rare, devastating disease with no 
cure. Current treatment consists of a cocktail of vasodilators which relieve 
symptoms of PAH but do not treat the cause. Thus, there is a need for novel 
drugs that target the underlying pathological causes of PAH. 
PAH is a multi-factorial, but one key contributor is the pro-inflammatory 
cytokine IL-6 which stimulates pro-inflammatory and pro-angiogenic signalling 
mediated by the JAK/STAT pathway. One way in which IL-6 signalling via 
JAK/STAT is inhibited is via SOCS3 in a type of negative feedback loop 
whereby IL-6 induces transcription of SOCS3, which then attenuates further 
JAK/STAT signalling.  
SOCS3 can also be induced by cAMP. This is interesting as prostanoids, a 
type of drug used in the treatment of PAH due to its vasodilator effects and the 
only type to show any efficacy improving the life expectancy of PAH patients, 
acts by mobilising cAMP. Thus, prostanoid stimulation of cAMP could 
potentially limit IL-6 signalling via the induction of SOCS3. This is a novel 
mechanism of prostanoids which has not previously been considered. 
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This study investigated the capability of prostanoids to limit the pro-
inflammatory/pro-angiogenic effects of IL-6 that enable PAH to develop. Initial 
experiments confirmed that vascular endothelial cells responded to 
prostanoids which increased SOCS3 and limited IL-6 signalling activity. 
Further experiments utilising SOCS3 KO endothelial cell models demonstrated 
prostanoid inhibition of IL-6 signalling was due in part to SOCS3. 
In conclusion, this project has confirmed that prostanoids do limit the pro-
inflammatory effects induced by IL-6 and that this is in part due to SOCS3. 
Although the exact mechanism is yet to be discovered, it will be beneficial in 
the treatment of PAH as it provides currently unexploited drug targets which 
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1.1 Pulmonary Arterial Hypertension 
Pulmonary arterial hypertension (PAH) is a rare progressive disorder 
characterised by a remodelling of the small to medium sized (5 to 100 µm in 
diameter (Pappano and Gil Wier 2013)) pulmonary arterioles in the lungs 
resulting in increased pulmonary vascular resistance (PVR) and mean 
pulmonary artery pressure (mPAP). This causes sheer stress on the right 
ventricle (RV) of the heart which initially responds via maladaptive hypertrophy 
through upregulating protein synthesis and cardiomyocyte size (reviewed by 
Ryan and Archer 2014). However, this hypertrophy is not sustainable and 
eventually leads to dilation of the RV reducing its contractility. This results in a 
longer contraction time and reduced RV stroke volume. The RV and left 
ventricle (LV) become unsynchronized causing under filling of the LV and the 
reduced cardiac output characteristic of PAH (Voelkel et al. 2006; Marcus et 
al. 2008). RV function has been suggested as the most important predictive 
factor regarding PAH prognosis and RV failure is the common cause of death 
in PAH (Tonelli et al. 2013; reviewed by Ryan and Archer 2014). 
The pulmonary hypertension (PH) registry of the UK and Ireland published an 
estimated PAH prevalence of 6.6/million and an incidence of 1.1/million in 
2009, with survival rates of 92.7%, 73.3%, and 61.1% for 1-, 3-, and 5-years 
respectively (Ling et al. 2012). A number of registries have published data 

















(Jansa et al. 2014) 
2000-2007 52±17 65:35 89 
US (REVEAL) 
(Benza et al. 2010) 
2006-2009 50±15 80:20 91 
UK and Ireland 
(Ling et al. 2012) 
2001-2009 50±17 70:30 93 
China 
(Jiang et al. 2012) 
2008-2011 38±13 70:30 92 
Europe (COMPERA) 
(Hoeper et al. 2013c) 
2007-2011 65±15 60:40 92 
Germany 
(Gall et al. 2017) 
1993-2011 51±16 65:35 88 
Japan 
(Ogawa et al. 2017) 
1992-2012 33.3±14.4 74:26 98 
Spain 
(Quezada Loaiza et al. 
2017) 
1984-2014 44±14 67:33 92 
Australia/New Zealand 
(Strange et al. 2018) 
2012-2016 57±19 70:30 96 
Table 1.1: A summary of findings from registries published in the past 10 
years  
REVEAL: Registry to Evaluate Early and Long-term PAH Disease 
Management; PH: pulmonary hypertension; COMPERA: Comparative, 
Prospective Registry of Newly Initiated Therapies for Pulmonary 
Hypertension. Adapted from Hoeper and Simon (2014). 
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diagnosis generally occurs during middle age at approximately 50 years of 
age, earlier in Eastern Asian cultures, with females being more susceptible to 
the disorder than males, and 1-year survival rates of 88% – 96%. Average 5- 
year survival rates are 65.4% (Farber et al. 2015), which is much improved 
compared to over 30 years ago with 1-year, 3-year and 5-year survival rates 
in 1981 - 1988 published as 68%, 48% and 34% respectively (D'Alonzo et al. 
1991), however there has been little improvement in the past 20 years.  
1.1.1 Classification of PAH 
PAH is currently classified according to two systems; the New York Heart 
Association (NYHA) functional class classification, used to classify the severity 
of PAH, and the Dana Point clinical classification which categorises PH 
according to similar pathologies. 
DANA POINT Clinical Classification  
The Dana Point clinical classification identifies five categories of PH according 
to pathological findings, haemodynamic characteristics and appropriate 
management; (1) PAH, (2) pulmonary heart disease due to left heart disease, 
(3) PH due to chronic lung disease and/or hypoxia, (4) chronic thromboembolic 
PH, and (5) PH due to unclear multifactorial mechanisms. PAH, and relevant 
sub-categories, are category group 1 (Table 1.2). The prevalence of different 
PAH subgroups are not equal with idiopathic PAH (IPAH) identified as the most 
common form, followed by connective tissue disease (CTD)–associated PAH 
(Hoeper et al. 2017; Strange et al. 2018). HIV-associated PAH and familial 
(f)PAH are the least common forms of PAH (Benza et al. 2010; Quezada 
Loaiza et al. 2017).  
4 
 
Sub-Categories of Dana Point Group 1 Classification for Pulmonary 
Hypertension 
1 Pulmonary arterial hypertension 
1.1 Idiopathic PAH 
1.2 Hereditable PAH 
 1.2.1 BMPR-II 
 1.2.2 ALK-1,ENG,SMAD9,CAV1,KCNK3 
 1.2.3 Unknown 
1.3 Drug and toxin Induced 
1.4 Associated with; 
1.4.1 Connective tissue disease 
 1.4.2 HIV infection 
 1.4.3 Portal hypertension 
 1.4.4 Congenital heart disease 
 1.4.5 Schistosomiasis 
1’ Pulmonary veno-occlusive disease and/or pulmonary 
capillary hemangiomatosis 
1’’ Persistent pulmonary hypertension of the new-born (PPHN) 
  
Table 1.2: DANA POINT subgroups of PAH 
The subcategories of group 1 PH, PAH, according to the updated DANA 
POINT clinical classifications. ALK-1; activin receptor-like kinase 1, BMPR-II; 
bone morphogenetic protein receptor type II protein, CAV1; caveolin 1, ENG, 
Endoglin, KCNK3; potassium channel subfamily K member 3. Adapted from 
Simonneau et al. (2013). 
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NYHA Functional Class Classification 
Also known as the World Health Organisation (WHO) system, this categorises 
PAH into four functional severity classes based on a patient’s ability to perform 
physical activity (Table 1.3). These classifications are used clinically to predict 
prognosis, monitor disease progression and identify the most effective course 
of treatment (Galie et al. 2015). 
1.2 Diagnosis and Monitoring Progression of PAH 
1.2.1 Diagnosis  
Survival analysis has shown that early detection of PAH results in a better 
prognosis and long term outcome (Humbert et al. 2010). Due to a number of 
challenges associated with PAH diagnosis, early diagnosis is not always 
achievable, with an average delay of 27 months between the patient 
presenting with symptoms and diagnosis reported in a French national registry 
(Humbert et al. 2006) and no improvement reported over the following 15 years 
(Frost et al. 2019). Unfortunately, in this time PAH has often progressed and 
prognosis worsens. A diagnostic algorithm devised by Galie et al. (2009b), 
summarising the different stages involved in the diagnosis of PAH (Figure 1.1), 
demonstrates the complexity involved. Initial PAH symptoms (fatigue, 
shortness of breath, angina) are non-specific and often confused with more 
common disorders such as asthma and coronary heart disease (CHD), 
therefore these must be eliminated first. The patient’s history is then explored 
and a physical examination carried out, followed by a number of additional 
tests, such as a chest X-ray and electrocardiogram (ECG) to identify any  
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NYHA/WHO functional classifications of PAH. 
Class I Patients with pulmonary hypertension without limitation of physical 
activity. Ordinary physical activity does not cause dyspnea, fatigue, 
chest pain, or near syncope 
Class II Patients with pulmonary hypertension with slight limitation of 
physical activity. 
Class III Patients with pulmonary hypertension with marked limitation of 
physical activity. 
Class IV Patients with pulmonary hypertension with inability to perform any 
physical activity without symptoms. These patients manifest signs of 




Table 1.3: NYHA/WHO functional classifications of PAH 
NYHA/WHO functional classifications of PAH increasing in severity from Class 
I to Class IV. NYHA; New York Heart Association, WHO; World Health 
Organisation. Adapted from Patel et al. (2012). 
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abnormalities or alterations within the heart, lungs or circulation (Galie et al. 
2015). For absolute confirmation of PAH, a right heart catheterisation (RHC) 
is required to measure the mPAP and pulmonary capillary wedge pressure 
(PCWP), also referred to as the pulmonary artery occlusion pressure (PAOP). 
PAH is defined by mPAP of greater than or equal to 25 mmHg and PCWP of 
less than or equal to 15 mmHg (Galie et al. 2015). PVR values used to be 
considered for the diagnosis of PAH but were excluded to ensure a simpler 
diagnosis (Badesch et al. 2009; Hoeper et al. 2013b).  
Current biomarkers for PAH are not very successful in terms of accuracy or 
predictive value as they are not specific to PAH. Currently, only brain natriuretic 
peptide (BNP), a biomarker for right ventricular dysfunction, and N-terminal 
(NT)proBNP are approved for clinical use (Andreassen et al. 2006; Mauritz et 
al. 2011; Takatsuki et al. 2012). As they are increased only in late stages of 
disease, they are not informative with regards to early stages of PAH. In 
addition, BNP and NTproBNP are both reduced in obesity (McCord et al. 2004; 
Fox et al. 2013), which would undermine any prognostic or diagnostic value of 
these biomarkers in obese PAH patients. Thus, there is an apparent need for 
novel biomarkers such as the anti-apoptotic B-cell lymphoma (Bcl)-xL 
(Chowdhury et al. 2019), or anti-nuclear antibodies (ANAs) which have been 
advised to differentiate CTD- and HIV-associated PAH from IPAH (Pagan et 
al. 2014). Currently, neither of these have been adopted in the clinic. Similarly, 
increased plasma concentrations of the pro-inflammatory cytokine tumour 
necrosis factor (TNF)-α have been suggested as a way to differentiate PAH 
from other types of PH (Saleby et al. 2017), but this is yet to be incorporated 









Figure 1.1: Diagnostic algorithm for the diagnosis of pulmonary arterial 
hypertension 
ALK-1; activin-receptor-like kinase 1, ANA; anti-nuclear antibodies, BMPR2; 
bone morphogenetic protein receptor 2, CHD; congenital heart disease, 
CMR; cardiac magnetic resonance, CTD; connective tissue disease, Group; 
clinical group, HHT; hereditary haemorrhagic telangiectasia, HIV; human 
immunodeficiency virus, HRCT; high-resolution computed tomography, LFT; 
liver function tests, mPAP; mean pulmonary arterial pressure, PAH; 
pulmonary arterial hypertension, PCH; pulmonary capillary 
haemangiomatosis, PFT; pulmonary function test, PH; pulmonary 
hypertension, PVOD; pulmonary veno-occlusive disease, PWP; pulmonary 
wedge pressure, RHC; right heart catheterization, TEE; transoesophageal 
echocardiography; TTE; transthoracic echocardiography, US; 
ultrasonography, V/Q scan; ventilation/perfusion lung scan. Taken from 
Galie et al. (2009b). 
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1.2.3 Monitoring PAH Progression and Patient Prognosis 
It is important to be able to monitor PAH and assess a patient’s response to 
therapy. Although RHC would be ideal with regards to the accuracy and 
reliability of the results, its invasiveness means it is often not practical and 
other clinical markers and non-invasive measures must be utilised instead.  
The 6 minute walk test (MWT) is one way in which this can be done. A healthy 
6 minute walk distance (MWD) is 600 - 700metres. Less than 350 metres 
would be considered a poor outcome and less than 165 metres would be 
associated with somebody with extreme physical limitations (Miyamoto et al. 
2000). Research has found that improving the 6MWD by just 33 metres 
correlates with a better quality of life (QOL) (Mathai et al. 2012). Further to this, 
calculating the heart rate recovery by measuring the heart rate of the patient 
immediately after the 6MWD test and then one minute after enables a better 
assessment of patient’s response to therapy and prognosis than just 
completing the 6MWT alone (Minai et al. 2012). The 6MWT is easy to perform, 
reproducible and, due to minimum special training or equipment required, it is 
inexpensive. Therefore, it is often used in clinical trials as a method to measure 
response to therapy. This is limited as 6MWD results alone are not sufficient 
to predict long-term disease progression (Gaine and Simonneau 2013; 
reviewed by Demir and Kucukoglu 2015). However, the 6MWT is considered 
useful in assessing and managing PAH when used alongside other tests such 
as measuring RV function (van Wolferen et al. 2007; Gaine and Simonneau 
2013; reviewed by Demir and Kucukoglu 2015). 
ECGs allow for non-invasive assessment of the RV structure and function 
including estimation of RV performance index, RV systolic pressure (RVSP), 
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and right atrial pressure (reviewed by Bossone et al. 2013). However, there 
are limitations with ECG. Haemodynamic measurements such as PA systolic 
pressure (PASP) are often underestimated when determined this way, 
therefore resulting in possible misclassification of the severity of PAH (Fisher 
et al. 2009). Thus, although useful in assessing RV function, ECG alone should 
not be used to monitor the disease, nor should it be considered as a 
replacement for RHC in definitive RV assessment. 
Cardiac magnetic resonance imaging (CMRI) is an alternative non-invasive 
method currently used to evaluate changes in RV function and morphology in 
PAH patients (Peacock et al. 2014). Although CMRI provides detailed 
anatomic, functional and haemodynamic information that is considered to be 
more accurate and reproducible than measurements taken via 
echocardiograms (Bottini et al. 1995), it is still advised that both methods are 
used in a complementary manner (Crowe et al. 2018). Novel imaging methods 
such as V/Q single proton emission computed tomography (SPECT) have also 
been used to identify global perfusion defects, which correlated with increased 
mPAP in PAH patients (Chan et al. 2018). 
Novel methods for monitoring PAH development and prognosis indicators 
have been explored. Numerous angiogenic and inflammatory biomarkers have 
been suggested as potential tools to assess PAH severity. Soluble fms-like 
tyrosine kinase-1 (sFlT1), also known as soluble vascular endothelial growth 
factor (VEGF) receptor (VEGFR)1, is an angiogenesis inhibitor found to be 
elevated in PAH in parallel with VEGF-A (Saleby et al. 2017). Increased levels 
of sFlT1 were found to correlate with reduced hemodynamic performance and 
thus, increased PAH severity (Saleby et al. 2017).  
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Pulmonary vasoreactivity, measured via an acute pulmonary vasoreactivity 
test (APVT), has been suggested as an accurate predictor of clinical 
deterioration, measured via NYHA functional class and the 6MWD 
(Hernandez-Oropeza et al. 2018). Those with improved AVPT experienced 
clinical deterioration nearly two years later than those with no improvement in 
pulmonary vasoreactivity (Hernandez-Oropeza et al. 2018). This study only 
recruited CTD-PAH patients from one tertiary care unit producing a relatively 
small, biased sample. However, this still offers a potential non-invasive method 
to measure response to therapy and clinical prognosis in PAH patients. 
Renal dysfunction has also been associated with poor-survival in PAH patients 
(reviewed by Nickel et al. 2017), prompting research into potential biomarkers 
of PAH that reflect that reflect renal function. A 10% decline in estimated 
glomerular filtration rate (eGFR) over a year period predicted poor survival in 
PAH patients independently of 6MWD in over 2000 PAH patients with chronic 
kidney disease (Chakinala et al. 2018). eGFR is calculated using serum 
creatinine levels measured via a blood test. Thus, this is a potential non-
invasive, simple biomarker that could be used for monitoring PAH progression. 
For the most up-to-date guidelines regarding the diagnosis and monitoring of 
PAH the reader is referred to the 2015 ESC/ERS Guidelines for the Diagnosis 
and Treatment of Pulmonary Hypertension (Galie et al. 2015) and Diagnosis 
of Pulmonary Hypertension (Frost et al. 2019). 
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1.3 Pathophysiology of PAH 
PAH is characterised by the remodelling of the PA and the formation of 
plexiform lesions, defined as glomeruloid structures consisting of numerous 
small vessels which form branches in the pulmonary artery and occur due to 
sustained proliferation and activation of local endothelial cells (ECs) and 
smooth muscle cells (SMCs) (Tuder et al. 1994; Jonigk et al. 2011). These 
occur due to an accumulation of molecular alterations within the immediate 
area, including cellular dysfunction, genetic mutations, dysregulation of 
vascular tone, growth factor (GF) signalling and inflammation.  
Much of the research regarding PAH pathophysiology has utilised animal 
models of PAH. Numerous animal models of PAH have been developed 
(reviewed by Sztuka and Jasinska-Stroschein 2017) but two of the most 
commonly used are chronic hypoxia and treatment with monocrotaline (MCT). 
Chronic hypoxia, or exposure of animals to hypoxia for between two and six 
weeks (Stenmark et al. 2006; Burke et al. 2009; Savale et al. 2009; Maston et 
al. 2018), triggers a sustained thickening of pulmonary vascular walls as a 
result of increased pulmonary arterial (PA)SMC hypertrophy and proliferation, 
and increased extracellular matrix (ECM) deposition (Stenmark et al. 2006). 
PAECs also undergo hypertrophy and hyperplasia, resulting in intimal 
thickening (Stenmark et al. 2006). The chronic hypoxia model has been further 
developed by co-injection with Sugen 5416 (Su5416) (20mg/kg) at the onset 
of hypoxia, resulting in a more sustained phenotype of PAH which reproduces 
more of the pathological features observed in human PAH than chronic 
hypoxia alone (Vitali et al. 2014; Penumatsa et al. 2019). Su5416 is a VEGFR-
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2 kinase inhibitor originally developed for the treatment of cancer (Fong et al. 
1999) but clinical trials were not successful and further use of the drug for this 
purpose was not explored (Hoff et al. 2006).  
MCT is a more severe model of PAH with a strong inflammatory component 
that develops three to four weeks after a single intraperitoneal or 
subcutaneous dose (60 mg/kg bodyweight) of MCT (Nogueira-Ferreira et al. 
2015; Sztuka and Jasinska-Stroschein 2017). This is sufficient to modulate 
PAEC and PASMC behaviour resulting in thickening of the PA medial 
hypertrophy and RV hypertrophy (Ghodsi and Will 1981). Although the 
mechanisms responsible for MCT-induced PAH remain unclear (Gomez-
Arroyo et al. 2012), there is evidence to show a role for transforming growth 
factor (TGF)-β (Zakrzewicz et al. 2007; Zaiman et al. 2008). 
Animal models of PAH have come under some criticism due to the differences 
in elevated plasma cytokine levels observed in animal models compared to 
PAH patients (Schlosser et al. 2017). However, many of the changes in cell 
behaviour that contribute to vascular remodelling in human PAH are observed 
in animal models. 
1.3.1 Cellular Dysfunction in PAH 
Cellular dysfunction within pulmonary arterioles is a major contributor to PAH 
development as increased proliferation and migration of PAECs and PASMCs 
results in vascular remodelling and the formation of plexiform lesions (Tuder 
et al. 1994; Cool et al. 1999) causing narrowing of the blood vessels and 
increased mPAP and PVR. PAECs isolated from IPAH patients demonstrate 
increased proliferation and migration in vivo due to an increased sensitivity to 
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GFs and a pro-survival phenotype, as well as altered tube formation, which 
contribute to the formation of plexiform lesions (Masri et al. 2007). Numerous 
pro-survival factors have been implicated in this phenomenon.  
PAECs isolated from IPAH PA were less apoptotic than the healthy controls 
due to increased levels of myeloid cell leukaemia (Mcl-1), an anti-apoptotic 
factor, mediated in this case by IL-15 (Masri et al. 2007). ECs in a plexiform 
lesion are exposed to greater concentrations of pro-growth and pro-angiogenic 
factors such as vascular endothelial growth factor (VEGF), VEGF receptor-2 
(VEGFR2), and hypoxia-inducible factor (HIF)-1α and HIF-1β, and reduced 
levels of pro-apoptotic molecules such as cyclin-dependent kinase inhibitor 
(p27/kip1) (Cool et al. 1999; Tuder et al. 2001). Forkhead box M1 (FOXM1), a 
transcription factor that regulates genes important for cell-cycle progression 
and cell survival, was upregulated in PASMCs from lung tissue isolated from 
PAH patients and in MCT and Su5416/chronic hypoxia (Su/Hx) rat models of 
PAH (Bourgeois et al. 2018). Caspase-3 protein expression, terminal 
deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assays 
and annexin V labelling all confirmed that inhibition of FOXM1 with thiostrepton 
reduced PAH-PASMC survival. This was due to inhibition of FOXM1-mediated 
DNA repair and expression of pro-survival factor survivin (Bourgeois et al. 
2018). Thiostrepton also improved RVSP, mPAP and PVR in MCT and Su/Hx 
rat models of PAH (Bourgeois et al. 2018). Rat pulmonary vascular (V)ECs 
cultured in a hypoxic environment developed apoptotic resistance which was 
not demonstrated by VSMCs under the same conditions (Zeng et al. 2018). A 
luciferase-based assay identified micro (mi)RNA‐195‐5p to be a key factor in 
a mechanism involving SMAD7 and HIF1-α. Finally, human pulmonary 
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microvascular (HPM)ECs exposed to pulsatile shear stress, a model of blood 
flow, developed an apoptosis-resistant hyperproliferative phenotype (Sakao et 
al. 2005). This was confirmed via increased caspase-3, proliferating cell 
nuclear antigen (PCNA), annexin-V and bromodeoxyuridine / 5-bromo-2'-
deoxyuridine (BrdU) labelling demonstrated by immunohistochemical analysis 
and flow cytometry (Sakao et al. 2005).  
Dysfunctional ECs also produce factors that stimulate aberrant SMC 
proliferation (Dewachter et al. 2006), or do not produce the factors that inhibit 
SMC proliferation (Alastalo et al. 2011), enabling PASMC hyperplasia and 
hypertrophy. Control HPASMCs exposed to medium derived from control 
HPAECs underwent increased proliferation. This effect was exacerbated when 
PAECs isolated from PAH patients were used. In addition, endothelin-1 (ET-
1) and serotonin (5-hydroxytrytamine; 5-HT) levels were increased in the 
media of PAH-PAECs compared to control PAECs, but not in PASMC 
(Eddahibi et al. 2006). The significance of ET-1 and 5-HT is discussed in 
Sections 1.3.4.3 and 1.3.4.4 respectively. Pulmonary (P)ECs isolated from 
IPAH patients secreted increased levels of C-C Motif Chemokine Ligand 2 
(CCL2), also known as monocyte chemoattractant protein-1, which is 
potentially responsible for the increased levels of CCL2 in lung tissue of 
plasma of IPAH patients compared to control tissue and plasma, resulting in 
increased monocyte attraction compared to control PECs (Sanchez et al. 
2007). In addition, PASMCs isolated from iPAH patients were more responsive 
to CCL2 than control PASMCs, as determined by their increased migration 
(Sanchez et al. 2007). Thus, abnormally high CCL2 production by ECs in PAH 
may contribute to vascular remodelling by promoting SMC migration and 
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increased inflammation, as CCL2 stimulates inflammatory cell recruitment and 
infiltration (Fuentes et al. 1995; Takahashi et al. 2009).  
Hypoxia-PAH and MCT-PAH mice models have demonstrated increased small 
ubiquitin-like modifier (SUMO)1 expression associated with an increased 
autophagy in mice aortic SMCs (Yao et al. 2019). SUMO1 is part of an ubiquitin 
system that targets proteins for degradation (reviewed by Grillari et al. 2010). 
Increased SUMO1 expression in mouse VSMCs resulted in a greater 
sensitivity to hypoxia-induced proliferation and migration, as well as 
exacerbating the anti-apoptotic signalling, whereas siRNA-mediated silencing 
of SUMO1 expression in human (H)PASMCs was sufficient to reverse 
hypoxia-induced proliferation and migration, and reduce autophagy  (Yao et 
al. 2019). 
A key consequence of EC dysfunction is increased endothelial permeability, 
which has also been associated with PAH. Although the exact impact of 
endothelial permeability on PAH is unknown, it is thought that impaired barrier 
function may enable permeation of GFs and inflammatory mediators through 
the EC monolayer where they can then exert their effects on underlying SMCs 
(reviewed by Zhou et al. 2018). Treatment with thapsigargin, which increases 
calcium levels via the inhibition of calcium uptake by the endoplasmic reticulum 
has been shown to increase EC permeability via the transient receptor 
potential channel (TRPC)4 (reviewed by Ahmmed and Malik 2005), which is 
exacerbated in Su/Hx animal models of PAH (Francis et al. 2016; Zhou et al. 
2016). In addition, bone morphogenetic protein (BMP) receptor type II 
(BMPRII) and caveolin also impact cell permeability (Long et al. 2015; Prewitt 
et al. 2015). This is interesting because bone morphogenetic protein receptor 
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type 2 (BMPR2) and caveolin (CAV)-1 genetic mutations, which will be 
discussed in greater detail (Sections 1.3.3.1 and 1.3.3.2), are associated with 
sensitivity to PAH (Table 1.2; group 1.2.1 and group 1.2.2 respectively).  
In human (H)PAECs, downregulating BMPR2 via siRNA resulted in impaired 
barrier function as measured via a FITC permeability assay (Anderl et al. 2012) 
and increased TNF-α induced neutrophil transmigration though the EC 
monolayer (Burton et al. 2011). In addition, conditional pulmonary vasculature 
Bmpr2 KO mice displayed increased pulmonary vascular leakage compared 
to their WT counterparts (Burton et al. 2011). PECs isolated from mice 
containing a heterozygous Bmpr2 KO mutation also demonstrated reduced 
endothelial barrier function as measured by transendothelial electrical 
resistance (TEER) (reviewed by Srinivasan et al. 2015) and FITC-permeability 
assays (Prewitt et al. 2015). This could be because Bmpr2+/- PECs exhibited 
altered caveolin (CAV)-1 localisation (Prewitt et al. 2015). CAV-1 expression 
has been shown to reduce microvascular permeability in endothelial-specific 
CAV-1 transgenic mice (Bauer et al. 2005). Alternatively, it could be a result of 
increased EMT, as siRNA-mediated BMPR2 silencing in PAECs and PEC 
knockdown of Bmpr2 in mice resulted in the upregulation of EMT markers such 
as α smooth muscle actin (αSMA) (Good et al. 2015). 
Endothelial to mesenchymal transition (EMT), in which ECs sustain a number 
of molecular changes resulting in their transition to a phenotype similar to 
mesenchymal cells (e.g., fibroblasts), also impairs barrier function (Good et al. 
2015). EMT-ECs are present in the vasculature of systemic sclerosis (SSc)-
PAH patients and in Su/Hx animal models of PAH, where they are thought to 
display increased migration but reduced proliferation, and to initiate a pro-
19 
 
inflammatory response due to increased secretion of numerous interleukins 
(IL) such as IL-4, IL-6, IL-13, and IL-18 and TNF-α compared to control PAECs 
(Good et al. 2015). 
To summarise, vascular cells local to PAH pathogenesis undergo clear 
phenotypical alterations that contribute to the vascular remodelling 
characteristic of PAH. Angiogenesis is another crucial event that contributes 
to the vascular remodelling characteristic of PAH (Voelkel and Gomez-Arroyo 
2014). The main driver of angiogenesis is VEGF, a GF whose expression 
levels are increased in plexiform lesions (Tuder et al. 2001). VEGF is one of 
many GFs with an altered expression in PAH. 
1.3.2 Growth Factors in PAH 
Genotyping of nearly 600 PAH patients identified a SNP (rs833061T>C) 
increased in PAH patients compared to controls. Luciferase assays 
determined that rs833061C, a VEGF promoter SNP, promoted VEGF gene 
transcription and protein expression (Zhuo et al. 2017). Thus, increased VEGF 
activity is a potential risk factor for PAH. On the other hand, Su5416 PAH 
models work via the inhibition of VEGFR2 to rapidly initiate EC apoptosis, 
resulting in an accumulation of apoptosis-resistant EC clones that increase 
proliferation resulting in severe plexiform lesions comparable to those 
characteristic of PAH (Mizuno et al. 2012; Nicolls et al. 2012). This suggests a 
complex mechanism where both upregulating and downregulating VEGF 
signalling results in apoptotic resistance and vascular remodelling. 
In the distal pulmonary arteries of PAH patients, expression of platelet derived 
GF (PDGF) and its two receptors, PDGF receptor (PDGFR)α and PDGFRβ, 
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are increased (Perros et al. 2008). This is supported by Humbert et al. (1998) 
who also found increased levels of PDGF in lung biopsies from PH patients 
compared to healthy controls and suggested it may contribute to the initiation 
and progression of PH. In vitro, PDGF can also be utilised as a 
chemoattractant for SMCs (Grotendorst et al. 1982) and stimulates SMC 
proliferation (Ross et al. 1974) suggesting that in the case of vascular injury, 
PDGF may contribute to vascular remodelling by altering normal SMC 
behaviour. 
Similar findings can be seen in animal models of PAH. Treatment with the 
selective PDGF-B blocker NX1975 (2 mg/day) in sheep models of chronic 
intrauterine PH reduced vascular remodelling and RV hypertrophy (RVH) 
(Balasubramaniam et al. 2003). Although there was no significant difference 
in PDGF-A or -B mRNA expression in whole lung homogenates from PH sheep 
compared to healthy control homogenates, increased PDGFR protein was 
present in hypertensive sheep (Balasubramaniam et al. 2003). Unfortunately, 
the effect of selective PDGF-A inhibition was not investigated. In PASMCs 
isolated from rat hypoxia models of PH, thickening of pulmonary artery medial 
walls occurs as a result of PASMC proliferation and is accompanied by the 
upregulation of PDGFR and PDGFR (Jankov et al. 2005). PDGF-BB, a 
major PDGF-betaR ligand,in particular was found to induce DNA synthesis and 
hyperplasia in SMCs, contributing to vascular remodelling (Jankov et al. 2005). 
Treatment with imatinib, a PDGFR inhibitor currently approved for the 
treatment of numerous cancers (Ben Ami and Demetri 2016; Suttorp et al. 
2018), in MCT rats and hypoxic mice models of PAH, reduced pulmonary 
remodelling and RVH (Schermuly et al., 2005). Imatinib has also shown some 
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limited success in the treatment of one human PAH case, a 61 year old male, 
when used alongside normal PAH therapy. Three months of imatinib treatment 
resulted in improved exercise capacity, as measured via the 6MWT, mPAP, 
RV performance and PVR which were sustained 6 months after treatment was 
initiated with no obvious side effects (Ghofrani et al. 2005). This led to a clinical 
trial of imatinib for the treatment of PAH which has now been successfully 
completed [Clinical trial identifier; NCT00902174]. Unfortunately, although 
treatment of human PAH with imatinab was beneficial with regards to improved 
haemodynamics and increased exercise capacity for those who were not 
responding to their current treatment regime, it also caused more severe side 
effects and was associated with increased morbidity (Hoeper et al. 2013a). 
However, this may be a promising therapeutic strategy worth developing in the 
future. 
MCT-PAH rat models were treated with PKI166, a selective epidermal (E)GF 
receptor (EGFR) (HER1 in humans) tyrosine kinase inhibitor, 21 days post 
MCT injection resulting in reduced mPAP and RVH, and increased rat survival 
compared to control MCT-PAH rats (Merklinger et al. 2005). In addition, 
PASMCs isolated from pulmonary arteries of PKI166-treated rats were found 
to have higher rates of apoptosis than controls (Merklinger et al. 2005), which 
suggests blocking EGF signalling has a potential therapeutic benefit in PAH. 
This is supported by research from Dahal et al. (2010) who also treated MCT-
PAH rat models with EGFR inhibitors but in this case they used gefitinib, 
erlotinib, and lapatinib which are currently approved for the treatment of 
cancers (Segovia-Mendoza et al. 2015; Yang et al. 2017). Treatment with each 
drug alone was sufficient to inhibit EGF-induced proliferation of PASMCs 
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isolated from MCT-PAH rats and reduce RVH and RVSP, although not cardiac 
index or systemic atrial pressure, in MCT-PAH rat models (Dahal et al. 2010). 
Only gefitinib reduced vascular remodelling at all doses administered (30 
mg/kg body weight (bw) and 10 mg/kg bw), whereas erlotinib had an effect at 
10 mg/kg bw but not 5 mg/kg bw, and lapatinib had no effect at either 10 mg/kg 
bw or 5 mg/kg bw doses (Dahal et al. 2010). Interestingly, none of the inhibitors 
reduced RVSP, systemic atrial pressure, or vascular remodelling in hypoxia-
PAH rat models (Dahal et al. 2010).  
TGF-β signals through numerous receptors, one of which is endoglin (ENG)-1 
(Chaouat et al. 2004). Mice with a heterozygous ENG-1 mutation (eng+/-) have 
been used to measure the effect of reducing TGF-β signalling (Gore et al. 
2014). In normoxic conditions, neither WT nor eng+/- mice suffered from 
increased RVSP or PA muscularisation, although eng+/- mice did have 
increased macrophage infiltration in the lung. However, post-hypoxia exposure 
eng+/- mice demonstrated reduced RVSP, PA muscularisation and 
macrophage infiltration compared to WT mice (Gore et al. 2014).  
Finally, increased TGF-β mRNA and protein expression have been reported in 
the serum and lung tissue of IPAH patients compared to control samples, and 
in isolated PECs and PASMCs (Gore et al. 2014). Increased TGF-β receptor 
expression was evident in PECs but not in PASMC or lung tissue, although 
this was dependent on the receptor subtype. Conditioned medium from 
cultured PECs was added to PASMCs, resulting in increased PASMC 
proliferation. This effect was exacerbated by treatment of the PECs with TGF-
β (Gore et al. 2014). Taken together, these findings suggest increased TGF-β 
expression in PAH patients, particularly by PECs, results in upregulated 
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PASMC proliferation which contributes to vascular remodelling and the 
development of PAH. This is unsurprising considering associated signalling 
molecules such as BMPR-II are heavily involved in PAH development, with 
BMPR-II mutations the most common of all hereditary (H)PAH cases. 
1.3.3 Genetic Mutations associated with PAH 
HPAH is PAH caused by a genetic mutation and includes familial (F)PAH 
(PAH that occurs in two or more family members) and simplex PAH (one 
occurrence of HPAH in a family) . FPAH is the cause of ≤ 4% of PAH cases 
(Jansa et al. 2014; Benza et al. 2015) and shows genetic anticipation but low 
penetrance (Austin et al. 1993). To classify as FPAH, patients must 
demonstrate the following criteria; a mutation in BMPR2 or another PAH-
associated gene, exclusion of other causes and two or more family members 
with PAH. Generally, the mutations seen in FPAH are germ-line mutations in 
genes that encode proteins of the TGF-β superfamily including BMPR2 (Deng 
et al. 2000), activing-receptor-like kinase-1 (ALK1) (Harrison et al. 2003), 
SMAD1, 4, and 9 (Nasim et al. 2011), and eng (Chaouat et al. 2004). A rare 
mutation in potassium channel subfamily K member 3 (KCNK3) (Ma et al. 
2013) and a CAV-1 mutation (Han et al. 2016) have also been associated with 
FPAH. These and other important PAH-related genetic mutations are 
discussed in reviews by Ma and Chung (2017) and Morrell et al. (2019). 
1.3.3.1 BMPR-II signalling and mutations in PAH 
70% of FPAH patients have a heterozygous mutation in BMPR2 (Cogan et al. 
2006), a 190kb gene that encodes a mature protein containing four functional 
domains; an N-terminal extracellular ligand binding domain, a single pass 
transmembrane domain, an intracellular serine/threonine kinase domain and 
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a C-terminal cytoplasmic domain (Machado et al. 2006). More than 300 
mutations have been identified within all four functional domains of BMPR2 but 
the majority (approximately 73%) are within the serine/threonine kinase 
domain. 70% of identified mutations are nonsense or missense mutations that 
cause premature truncation of the BMPR-II mRNA which is then degraded via 
nonsense-mediated decay (Machado et al. 2006). 
In the presence of a functional receptor, BMPs act as paracrine, autocrine and 
endocrine regulators in numerous systems including the cardiovascular 
system where they regulate cell differentiation, proliferation/apoptosis and 
inflammation (reviewed by Yu et al. 2008; Morrell et al. 2016). BMPs are 
members of the TGF-β superfamily, which also includes growth differentiation 
factors, TGF-β, inhibins and activins. There are over 30 BMP ligands that 
signal via receptor complexes consisting of a type I receptor (T1R) and a type 
II receptor (T2R).  
BMPR-II is a T2R which, when activated by ligand binding, forms a complex 
with specific TGF-β T1Rs including activin-like kinase (ALK)1, ALK-2, BMPR-
IA (ALK-3) and BMPRIB (ALK-6) (ten Dijke et al. 1994a; ten Dijke et al. 1994b; 
reviewed by Horbelt et al. 2012). As previously mentioned, BMPR-II contains 
an intracellular kinase domain which phosphorylates the GS domain, a glycine 
and serine-rich intracellular region of the T1R, upon agonist-stimulated 
formation of the receptor complex (reviewed by David et al. 2007; Heldin and 
Moustakas 2016). This initiates signal transduction via phosphorylation of 
receptor (R)-SMADs (Zhang et al. 2003).  
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There are three types of SMAD; R-SMADs, collaborating (co)-SMADs and 
inhibitory (i)-SMADs (Macias et al. 2015). R-SMADs and co-SMADS contain 
conserved Mad homology (MH)1 and MH2 domains which mediate the 
interaction between themselves and other protein such as T1Rs and 
transcription factors (reviewed by Heldin et al. 1997). R-SMADs 1, 5 and 8 are 
specific to BMP signalling (Hoodless et al. 1996; Chen et al. 1997; Nishimura 
et al. 1998; reviewed by Nishimura et al. 2003) and bind to the T1R via their 
MH2 domain. Upon doing so, R-SMADs are activated via T1R mediated 
phosphorylation of serine residues within the C-terminal SSxS region of the 
MH1 domain (reviewed by Heldin and Moustakas 2016). Once activated, R-
SMADs form a complex with co-SMAD4 which is mediated by the MH domains 
(Zhang et al. 1997; Qin et al. 2001), triggering the translocation of the R-
SMAD/co-SMAD complex to the nucleus where it is able to regulate the 
transcription of target genes (Figure 1.2) (reviewed by Liu et al. 1996; 
Massague et al. 2005).  
TGF-β competes with BMP to bind to TGF-β T1R and together they regulate 
numerous functions such as cell growth, differentiation, migration and 
cytoskeletal organisation in a cell-type specific manner. TGF-β signalling 
stimulates cell proliferation and increases inflammation, whereas BMP 
signalling promotes a more pro-apoptotic, anti-proliferative phenotype (Zhang 
et al. 2003; Yu et al. 2008). Thus, a loss of BMPR-II results in imbalanced TGF-






Figure 1.2: The bone morphogenetic protein signalling pathway. 
BMP mediated activation of BMPR-II, resulting in phosphorylation of the T1R 
and consequential phosphorylation of R-SMAD within its SSxS domain. 
Activated R-SMADs form a complex which co-SMAD4 which then translocates 
to the nucleus to initiate transcription of target genes. BMP; bone 
morphogenetic protein, BMPR-II; BMP receptor II, co-SMAD; collaborating 
SMAD, GS; intracellular glycine and serine-rich domain, Id-1; DNA-binding 
protein inhibitor, I-SMAD; inhibitor SMAD MH; mad homology, P; 
phosphorylated residue, R- SMAD; receptor-SMAD, T1R; type 1 receptor, 
T2R; type 2 receptor, VEGF; vascular endothelial growth factor. 
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Immunohistochemistry of lung sections isolated from PAH patients has 
revealed significantly lower BMPR-II, SMAD1 and SMAD 5 expression 
compared to control lung sections, especially in tissue from patients carrying 
BMPR2 mutations (Atkinson et al. 2002). This is supported by RNA 
sequencing of PAECs isolated from IPAH patients that identified numerous 
BMPR-II associated genes were downregulated in IPAH-PAECs compared to 
control PAECs, even in the absence of a BMPR-II mutation (Rhodes et al. 
2015). 
In ECs, BMP4 binding to BMPR-II results in increased EC proliferation and 
migration, and reduced EC apoptosis, thus enabling PA remodelling and the 
progression of PAH (Teichert-Kuliszewska et al. 2006). Conversely, in the 
main and lobar arteries BMP inhibits cell growth, whereas in the smaller PA 
involved in PAH, BMP2 and BMP4 stimulate proliferation via extracellular 
signal-regulated kinase (ERK)1/2-and p38 mitogen-activated protein kinase 
(MAPK)-dependent (Yang et al. 2005) and SMAD-independent pathway 
(Nasim et al. 2012). This is most likely due to the expression of different SMAD 
subtypes. Further to this, BMP-2 and BMP-7 were shown to induce apoptosis 
via downregulating B-cell lymphoma-2 in control PAMSCs (Zhang et al. 2003). 
PASMCs isolated from primary (P)PH patients undergoing lung transplantation 
expressed less BMPR-II than control cells and were more resistant to BMP-
mediated apoptosis (Zhang et al. 2003). This supports the theory that 
apoptotic-resistance in ECs and SMCs results from downregulated BMPR-II 
signalling.  
There is a body of work in rodent models of PAH examining the impact of 
bmpr2 mutations. Reduced levels of BMPR-II mRNA and protein expression 
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have been found in the lungs of rodents with hypoxia-induced PH (Takahashi 
et al., 2006). Mice with a bmpr2 mutation resulting in a dominant loss of BMPR-
II in SMCs developed PAH with PA wall remodelling (West et al., 2004), while 
EC-specific bmpr2 KO in mice results in elevated RVSP, RVH and vascular 
remodelling determined via αSMA staining in the small arteries (30-70 μm in 
diameter) compared to WT mice (Hong et al., 2008). Conversely, adenoviral 
delivery of a bmpr2 transgene to the pulmonary vascular endothelium 
improved RVH and PVR, and slowed down pulmonary arterial muscularisation 
in rat MCT models of PAH compared to a control adenovirus (Reynolds et al. 
2012). In contrast, other research has shown adenoviral delivery of bmpr2 in 
MCT-induced PAH in rats was found to have no effect (McMurtry et al., 2007). 
Mice with a Bmpr2+/R899X mutation, which mimics the p.R899X premature stop 
BMPR2 mutation seen in human disease, demonstrated greater TGF-β activity 
in both normoxic and hypoxic conditions (Nasim et al., 2012). This resulted in 
increased cell proliferation of mouse PASMCs via TGF-β-mediated modulation 
of the MAPK signalling cascade (Nasim et al. 2012). In addition, Bmpr2+/R899X 
mice developed an age-associated increase in RVSP that was not present in 
control mice (Long et al. 2015). Neither Bmpr2+/R899X mice or control mice 
experienced RVH, but Bmpr2+/R899X mice did demonstrate increased 
muscularisation of peripheral lung pulmonary arteries (Long et al. 2015). 
These effects were reversed by treatment with BMP9, which was found to 
restore BMPR-II downstream signalling and to limit increased RVSP and RVH 
in MCT-PAH rat models (Long et al. 2015). Finally, PASMCs isolated from PAH 
patients carrying the p.R899X mutation demonstrated an anti-apoptotic, pro-
survival phenotype due to increased Bcl-xL resulting from impaired BMPR-II 
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signalling (Chowdhury et al. 2019), although interestingly, PAECs isolated 
from the same patients demonstrated increased EC apoptosis resulting from 
reduced Bcl-xL expression. This suggests a cell-specific effect of BMPR-II 
dysfunction which results in the preferential expression of Bcl-xL, as opposed 
to the pro-apoptotic Bcl-xS, in PASMCs but not PAECs (Chowdhury et al. 
2019). 
In summary, it is clear that loss-of-function BMPR2 mutations enable PAH 
development. However, although heterozygous Bmpr2 mutations in mice 
exacerbate the effects of lipopolysaccharide (LPS) and 5-HT on PASP, RVH 
and vascular remodelling, Bmpr2 mutations alone are insufficient to produce a 
PAH phenotype (Long et al. 2006; Soon et al. 2015) suggesting a BMPR2 
mutation may just increase a person’s susceptibility to the disorder. 
1.3.3.2 CAV-1 mutation 
CAV-1 mutations have been considered in this research due to the 
identification of a novel SOCS3-Cavin-1 interaction (Williams et al. 2018) 
which will be further explored in the context of PAH in Chapter 6. 
Two frameshift heterozygous mutations, c.474delA (p.P158PfsX22) and 
c.473delC (p.P158HfsX22), in CAV-1 have been associated with PAH (Austin 
et al. 2012; Han et al. 2016). CAV-1 codes for the CAV-1 protein which is 
required for the synthesis and stability of caveolae. Caveolae are small 
invaginations within the plasma membrane that have numerous roles including 
mechanoprotection, signal transduction, transcytosis, and lipid homeostasis 
(reviewed by Cheng and Nichols 2016). In ECs, caveolae have been shown to 
protect cells from membrane damage resulting from increased cardiac output 
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via caveolar disassembly, which involves ATP- and actin-independent 
flattening of caveolae (Sinha et al. 2011; Cheng et al. 2015), triggering a 
dissociation of cavin proteins from the caveolar complex (Sinha et al. 2011). 
Cavins are a family of four key proteins (cavin-1-4) which, in conjunction with 
caveolins, form the core structure of caveolae and regulate their stability and 
function (Liu and Pilch 2008; McMahon et al. 2009; Hayer et al. 2010; reviewed 
by Lamaze et al. 2017). 
Therefore, loss of caveolin-1 expression in VECs results in a loss of caveolae 
which increases vulnerability to mechanical damage. As EC dysfunction is a 
key factor in PAH, this may at least partly explain why a CAV-1 mutation results 
in susceptibility to PAH. SMCs, fibroblasts and microvascular ECs isolated 
from CAV-1 KO mice displayed no morphologically distinct caveolae 
invaginations (Zhao et al. 2002) and, although viable, CAV-1 KO exhibited 
spontaneous dilated cardiomyopathy, RV hypertrophy and increased mPAP 
compared to WT mice (Zhao et al. 2002). 
In patient cases of CAV-1-associated PAH, caveolin-1 and caveolae appear to 
be expressed at normal levels in patient cells, and to co-localise as expected 
(Han et al. 2016). The key difference between cells isolated from CAV-1-
associated PAH patients and healthy controls is reduced co-localisation 
between caveolin-1 and cavin-1 (Han et al. 2016). The key effects of this are 
yet to be determined but it is most likely to increase susceptibility to mechanical 
damage due to reduced caveolae stability. 
In CAV-1 KO mice, exposure to hypoxia results in RV failure associated with 
increased RVH consistent with interstitial fibrosis and elevated endothelial 
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nitric oxide synthase (eNOS) activity, but interestingly not increased RVSP 
(Cruz et al. 2012). In VEC and VSMC-specific CAV-1 KO mice and SMC-
specific CAV-1 KO mice displayed reduced contraction in response to high-
potassium-induced cell contraction and increased cardiac hypotrophy in both 
ventricles in comparison to WT cells, with EC-CAV-1 KO mice affected more 
than SMC-CAV-1 KO mice (Murata et al. 2007). In addition, EC-CAV-1 KO 
mice demonstrated increased eNOS activity compared to SMC-CAV-1 KO 
mice and control mice (Murata et al. 2007). The significance of eNOS activity 
will be discussed in Section 1.3.4.2. 
In NIH-3T3 fibroblasts, 293T cells, a derivative of human embryonic kidney 
(HEK) 293 cells which is highly transfectable, and COS-7 cells, caveolin-1 was 
shown to negatively regulate the TGF-β/SMAD signalling pathway (Razani et 
al. 2000; Razani et al. 2001). This provides a potential alternative mechanism 
in which a CAV-1 mutation enables the development of PAH. 
BMPR2 and caveolin have both been linked with mediators of vascular tone, 
in particular NO and ET-1 which are considered key for PAH development and 
are targets for treatment. 
1.3.4 Mediators of Vascular Tone in PAH 
There are three main mediators of vascular tone that primarily contribute to the 
increased vessel constriction seen in PAH; prostacyclin (PGI2), NO and ET-1. 
These are also the target of current PAH therapy (Section 1.6) (reviewed by 





PGI2 is part of the prostaglandin family of lipid mediators and induces 
vasodilation via paracrine signalling. An unstable 20-carbon unsaturated 
carboxylic acid with a cyclo-pentane ring (Vane and Botting 1995), PGI2 is the 
main product of arachidonic acid metabolism in ECs (reviewed by Vane et al., 
1990). Arachidonic acid is oxidised to form hydroperoxy endoperoxide which 
is then reduced to hydroxyl endoperoxide (PGH2). Both of these reactions are 
catalysed by cyclooxygenase (COX)1 and COX2 (reviewed by Gryglewski 
2008). PGH2 is then converted to PGI2 by prostacyclin synthase (PGI2S) (Vane 
and Corin 2003). Prostaglandins binds to one of nine prostaglandin receptors 
(prostaglandin D2  receptor (DP)1, DP2, prostaglandin E2 (PGE2) receptor 
(EP)1, EP2, EP3, EP4, prostaglandin F receptor (FP), prostaglandin I2 receptor 
(IP), and the thromboxane receptor (TP) which are all rhodopsin-like G-protein 
coupled receptors (GPCRs) (reviewed by Tsuboi et al. 2002). PGI2 binds to 
and activates the IP subtype of prostaglandin receptors (Woodward et al. 
2011).  
GPCRs have three extracellular N-terminal loops, seven transmembrane α-
helical domains, three intracellular loops and a C-terminal intracellular tail 
(Midgett et al. 2011). It is within the seven transmembrane helices that ligand 
binding occurs, upon which a G protein is activated which in turn binds and 
activates adenylyl cyclase (AC). AC catalyses the formation of cAMP from ATP 
which then activates protein kinase A (PKA) (Figure 1.3) (Namba et al. 1994) 
resulting in SMC vasodilation, as well as inducing anti-thrombotic and anti-
inflammatory effects (Figure 1,3) (Moncada et al. 1976; Haynes et al. 1992; 
Murata et al. 1997). When released by ECs, PGI2 either binds to the IP on the 
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surface of SMCs to induce vasodilation, or it is quickly degraded into the 
inactive metabolite 6-ketoprostaglandin Fα (Vane et al. 1990). At physiological 
temperature and pH, PGI2 has a half-life of three - four minutes (reviewed by 
Whittle and Moncada 1984; Gryglewski 2008). Prostacyclin also acts via IP 
and cAMP to inhibit SMC proliferation (Clapp et al. 2002). 
PGI2, IP and PGI2S are reduced in PAH patients (Christman et al. 1992; Tuder 
et al. 1999). Stearman et al. (2014) utilised PCR to genotype PGI2S gene 
promoters in over 300 individuals and identified a number of gene variants that 
resulted in a range of transcriptional activity including promoting gene 
expression and inhibiting it. Healthy individuals, in this case those not suffering 
from PAH, were found to have more active versions of the PGI2S promoter 
compared to PAH patients.  
In mice, PGI2S over-expression has been found to protect against hypoxia 
induced PAH (Geraci et al. 1999) and disrupting the PGI2S gene results in the 
thickening of vascular walls in the kidney and lungs contributing to the 
development of vascular disorders (Yokoyama et al. 2002). IP KO mice 
exposed to chronic hypoxia developed more severe PAH compared to WT 
mice as evidenced by increased RVSP values and RV hypertrophy 
(Hoshikawa et al. 2001). IP KO mice also developed significant medial wall 
thickening post-hypoxia, versus WT mice (Hoshikawa et al. 2001).  
Taking all these findings into account, reduced PGI2 signalling, either as a 
result of alterations to PGI2S expression or PGI2 signalling, can result in a 









Figure 1.3: A summary of the prostacyclin, nitric oxide and endothelin-1 
signalling pathways in pulmonary arterial hypertension 
PGI2 binds to the IP activating AC which converts ATP to cAMP. cAMP induces 
PKA-mediated effects (vessel dilation). L-arginine is converted to NO by 
eNOS. NO binds to sGC which converts GTP to cGMP. cGMP induces PKG-
mediated effects (vessel dilation). ET-1 binds to ETAR to induce it’s effects 
resulting in vessel constriction. AC; adenylyl cyclase, eNOS; endothelial nitric 
oxide synthase, ET; endothelin, IP; prostaglandin I2 receptor, NO; nitic oxide, 
PAH; pulmonary arterial hypertension, PGI2; prostacylin, PKA; protein kinase 
A (cAMP-dependent protein kinase, PKG; protein kinase G (cGMP-dependent 
protein kinase) sGC; soluble guanylyl cyclase, SMC; smooth muscle cell. 
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PGI2 also binds to peroxisome proliferator-activated receptors (PPARs), and it 
is via PPARα (Biscetti et al. 2009) and PPARβ (Piqueras et al. 2007) that PGI2 
stimulates production of VEGF, encouraging the vascular remodelling 
characteristic of PAH. Conversely, activation of PPARγ in rat MCT-PAH 
inhibits PASMC proliferation, therefore reducing vascular remodelling, right 
ventricle systolic pressure (RVSP) and RV hypertrophy, thereby inhibiting PAH 
development (Zhang et al. 2014). This suggests an alternative PGI2 
mechanism that could be either protective or detrimental in the context of PAH 
depending on the subtype of PPAR activated. 
1.3.4.2 Nitric Oxide 
In EC, eNOS catalyses the oxidation of L-arginine to form NO and L-citrulline 
in the presence of oxygen, NAPDH and co-factors such as tetrahydrobiopterin. 
NO is a vasodilator that binds to soluble guanylyl cyclase (sGC) in SMCs. sGC 
converts GTP into 3',5'-cyclic GMP (cGMP) which activates cGMP-dependent 
protein kinase, PKG (Figure 1.3) (reviewed by Zuckerbraun et al. 2011). 
PKG is a serine/threonine-directed protein kinase predominantly found in the 
lung, cerebellum, platelets and SMCs which acts via phosphorylation of target 
proteins to regulate their activity (reviewed by Carvajal et al. 2000). One such 
protein is myosin light chain phosphatase which, alongside myosin kinase, 
modulates the level of active myosin. Myosins are motor proteins important in 
cell contraction and migration (Matsumura and Hartshorne 2008). PKG also 
regulates vascular SMC proliferation via phosphorylation and activation of 
vasodilator-stimulated phosphoprotein (VASP) (Chen et al. 2004). 
Interestingly, PKG mediates NO-induced inhibition of VSMC growth via 
phosphorylation of VASP at serine 239, however VASP serine 157 
37 
 
phosphorylation by PKA stimulates DNA synthesis and cell proliferation (Chen 
et al. 2004). NO also inhibits SMC proliferation by inactivating RhoA, a small 
GTPase involved in the ERK1/2 pathway. Whether SMCs are pro- or anti- 
proliferative depends on the activation state of RhoA, with GTP-bound active 
RhoA stimulating cell proliferation (Zuckerbraun et al. 2007). 
Reduced expression of eNOS, and therefore impaired NO production, in the 
lungs is characteristic of PAH (Giaid and Saleh 1995). PAECs isolated from 
lung tissue of PAH patients were also found to produce less NO than cells from 
healthy controls (Xu et al. 2004), contributing to pulmonary vasoconstriction 
and increased PASMC proliferation. Conversely, eNOS was upregulated in 
ECs within plexiform lesions and PA present in lung tissue of PPH patients 
compared to control lung tissue (Mason et al. 1998). This was supported by 
(Nickel et al. 2011), who also found increased eNOS mRNA expression in 
plexiform lesions compared to expression levels in healthy PAs. Although, 
expression of eNOS does not necessarily correlate with increased NO 
signalling, modulating eNOS expression has been shown to have an effect in 
animal models of PAH. 
Homozygous eNOS-deficient (eNOS-/-) mice were more sensitive to 2 weeks 
exposure to hypoxia than WT mice, according to RVSP values (Fagan et al. 
1999). Although end-point RVSP was the same in eNOS-/- and WT mice after 
4 weeks exposure to hypoxia (Fagan et al. 1999). eNOS-/- mice were also more 
susceptible to vascular remodelling with a two-fold increase in vessel wall 
thickness after 4 weeks of hypoxia exposure versus eNOS-/- mice maintained 
in normoxic conditions, whereas WT mice showed no change in vessel wall 
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thickness when exposed to normoxic conditions, 2 weeks of hypoxia or 4 
weeks of hypoxia (Fagan et al. 1999).  
Interestingly, eNOS activation has also been linked to both BMPR-II and 
caveolin-1 signalling. In bovine (B)PAECs, BMP-induced cell migration was 
found to be via PKA-mediated phosphorylation of eNOS at serine 1179 
(human; serine 1177) (Gangopahyay et al. 2011). In BPAECs and HPAECs, 
BMPR2 mutations attenuated eNOS phosphorylation, whereas PAECs from 
healthy controls still demonstrated eNOS activity under the same conditions, 
suggesting BMP is activating PKA and eNOS via BMPR-II in these cells 
(Gangopahyay et al. 2011).  
With respect to caveolins, eNOS was found to co-localise with caveolin-1 in 
bovine aortic ECs (BAECs) but with caveolin-3 in rat cardiac myocytes (Feron 
et al. 1996). Also in BAECs, tyrosine phosphorylation of eNOS as a result of 
oxidative stress resulted in reduced catalytic activity of eNOS (Garcia-Cardena 
et al. 1996). Interestingly, phosphorylated eNOS was found to co-localise with 
caveolin-1 (Garcia-Cardena et al. 1996), and a potential regulatory relationship 
in which caveolin-1 provides negative allosteric regulation of tyrosine 
phosphorylated eNOS specifically within the oxygenase domain of eNOS, but 
not the reductase domain, was also identified (Ju et al. 1997). As discussed, 
CAV-1 KO mice are viable but develop PH (Zhao et al. 2002) (Section 1.3.3.2), 
however these mice also exhibit a significant increase in systemic NO levels 
resulting from an increase in eNOS activity (Zhao et al. 2002). Although, these 
experiments do not define whether increased eNOS activity is a cause of the 
cardiac changes observed or a result of them, further experiments utilising 
CAV-1-/-, eNOS-/- mice showed silencing eNOS activity was sufficient to 
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prevent the increased RVSP and medial thickening demonstrated by CAV-1 
KO mice (Zhao et al. 2009). In another study, CAV-1 KO mice display an 
altered lung phenotype, smaller alveoli and wide septa, which was rescued via 
treatment with the NO synthase inhibiter, NG-nitro-l-arginine methyl ester (L-
NAME) (Wunderlich et al. 2008). L-NAME also improved lung function, 
measured via oxygen saturation, haemoglobin and haematocrit levels, RVH, 
systolic pulmonary artery pressure, and exercise capacity in CAV-1 KO mice 
(Wunderlich et al. 2008). 
Combined, this research demonstrates a complex role for NO, with eNOS KO 
or inhibition protecting from the development of spontaneous PH in mice due 
to CAV-1 KO, whilst also enabling PAH in hypoxia-induced mice models. 
Potentially, eNOS will have different effects depending on its localisation in the 
cell and how it is activated. 
1.3.4.3 Endothelin-1 
ET-1 is a vasoactive peptide 21 amino acids in length formed from ‘big ET-1’, 
a 39 amino acid long peptide which is converted to ET-1 by endothelin 
converting enzyme-1 (ECE-1) (Yanagisawa et al. 1988). ET-1 binds and 
activates G protein-coupled receptors ETAR and ETBR. ETAR is predominantly 
found on VSMCs and myocytes whereas ETBR is found on SMCs and ECs 
(reviewed by Chester and Yacoub 2014). In SMC cells, ET-1 binding to both 
ETAR and ETBR stimulates vasoconstriction as well as mediating SMC 
proliferation, migration and hypertrophy (Figure 1.3) whereas in ECs, ET-1 
appears to have an opposing effect, acting via ETBR to increase NO and PGI2 
production and stimulate vasodilation (Migneault et al. 2005; Sauvageau et al. 
2007). Thus, although vasodilatory drugs are non-selective antagonists of both 
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ETAR and ETBR, they inhibit ET-1 mediated vasodilation in ECs due to their 
greater affinity for ETAR (reviewed by Rubin and Roux 2002; reviewed by 
Cheng 2008). 
Increased levels of ET-1 have been found in PAH lungs, circulation and plasma 
versus healthy controls (Rubens et al. 2001) and is correlated with greater PVR 
and structural abnormalities (Giaid and Saleh 1995; Bressollette et al. 2001). 
Compared to control cells, PAH PASMCs also demonstrate a greater response 
to ET-1 with regards to Ca2+ influx, a marker of SMC contraction and a critical 
second messenger involved in the regulation of cell proliferation and gene 
expression (Berridge 1993; Landsberg and Yuan 2004), as well as cell 
constriction (Yu et al. 2013). 
Like NO, ET-1 also has links with BMPR-II. In HMVECs, silencing of BMPR2 
via siRNA resulted in increased ET-1 mRNA and protein expression due to 
BMP signalling mediated by ALK2 as opposed to BMPR-II  (Star et al. 2013).  
1.3.4.4 Serotonin (5-HT) 
Like ET-1, 5-HT stimulates vasoconstriction but, when not properly regulated, 
it also initiates abnormal EC-SMC interaction. In chronic-hypoxia induced PAH 
mice models, mice with inactive 5-HT receptors were resistant to hypoxia-
induced increase in blood pressure and vascular remodelling (Launay et al. 
2002). In addition, a 5-HT inhibitor, fluoxetine, was able to reduce PASMC 
growth resulting from incubation in EC derived medium, and tryptophan 
hydroxylase, an enzyme involved in 5-HT synthesis, was increased in ECs 
isolated from IPAH patients compared to control ECs  (Eddahibi et al. 2006). 
Finally, the use of anorectic drugs such as fenfluramine, a selective serotonin 
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reuptake inhibitor (SSRI), is an established cause of PAH (reviewed by 
Montani et al. 2013). 
To summarise, dysregulation of vascular tone contributes to the development 
of PAH and, aswill be discussed, form the basis of current PAH therapies. The 
role of inflammation in the development of PAH is becoming better understood 
(reviewed by Cohen-Kaminsky et al. 2014; reviewed by Groth et al. 2014), 
supported by the knowledge that auto-immune diseases or diseases that 
trigger an inflammatory response like CTD, HIV and schistosomiasis infection 
are associated with PAH (Table 1.2; subgroup 1.4.1, 1.4.2, and 1.4.5 
respectively). Through this, potentially novel drug targets may be identified. 
1.3.5 Inflammation and PAH 
A number of inflammatory factors, such as interleukins, and immune cells, 
including B and T lymphocytes, macrophages, and dendritic cells, are present 
in human PAH and PAH animal models (Savai et al. 2012; Oguz et al. 2014; 
Kumar et al. 2015; Parpaleix et al. 2016).  
Bromodomain protein 4 (BRD4), an epigenetic reader which enables 
transcriptional activity of target genes, in particular pro-inflammatory genes 
increased in PAH such as IL-6, TNF-α and CCL2, is overexpressed in distal 
pulmonary arteries and coronary arteries of human PAH tissue (Meloche et al. 
2015), and in the coronary arteries of MCT-PAH rat models (Meloche et al. 
2017). In human coronary artery SMCs isolated from PAH tissue, BRD4 
overexpression triggered pro-proliferative/anti-apoptotic behaviour which was 
reversed by treatment with BRD4-inhibitor JQ1 (Meloche et al. 2017). 
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Downregulating BRD4 via treatment with miR-204 mimics, a negative regulator 
of BRD4, also reversed Su/Hx-induced PAH (Meloche et al. 2015). 
In T-cells from PAH patients, fractalkine, a chemokine that promotes 
chemokine receptor 1 (Cx3CR1)-expressing leucocyte recruitment, is 
upregulated compared to control cells (Balabanian et al., 2002). Fractalkine 
and CX3XR1 are also overexpressed in the lungs and PA from an MCT-rat 
model of PAH (Perros et al. 2007), where they were found to induce 
proliferation of rat PASMCs, suggesting a complex role in disease progression. 
The expression of cytokines regulated on activation, normal T cell expressed 
and secreted (RANTES) and CCL2, which are chemoattractants for 
monocytes and T-cells, are also increased in PAH lung compared to control 
tissue (Dorfmuller et al. 2002; Sanchez et al. 2007). They are thought to 
contribute to inflammation and remodelling by attracting monocytes to the 
pulmonary endothelium (Sanchez et al. 2007).  
Inhibition of nuclear factor - kappa B (NF-B), a family of transcription factor 
complexes that stimulate cytokine production, in the MCT-PAH rat model 
protected against vascular remodelling, as measured by medial wall thickness 
and elastin and collagen hyperplasia (Bai et al. 2017). It also limited 
inflammation, as evidenced by reduced levels of intercellular adhesion 
molecule (ICAM-1) and IL-6.  
Interleukins are a group of cytokines that elicit a wide range of immune and 
inflammatory- responses (reviewed by Akdis et al. 2016). Several interleukins 
important in PAH progression have been identified. Overexpression of cardiac-
specific IL-1α is sufficient to cause concentric left ventricle hypertrophy in mice 
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(Nishikawa et al. 2006), and a study by Parpaleix et al. (2016) identified that 
IL-1 receptor-1 (IL-1R1) is highly expressed in the lungs of hypoxic mice 
models of PAH and IPAH patients. In addition, treatment with an IL-1R1 
antagonist was found to reverse MCT-induced PAH and inhibit IL-1β-induced 
PASMC growth (Parpaleix et al. 2016). 
TNF-α has previously been mentioned as a pro-inflammatory cytokine 
increased in PAH that contributes to inflammatory cell infiltration and vascular 
remodelling (Burton et al. 2011; Good et al. 2015; Saleby et al. 2017). In 
PASMCs, TNF-α was found to reduce BMPR-II expression via downregulation 
of BMPR2, resulting in increased cell proliferation (Hurst et al. 2017). 
Additionally, in MCT and Su/Hx rat models of PAH, inhibiting TNF-α action with 
either a recombinant human TNF-α receptor antagonist or the clinically 
approved anti-TNF-α drug etanercept improved mPAP, RVSP and RVH (Wang 
et al. 2013; Hurst et al. 2017). In addition, increased plasma TNF-α levels in 
PAH patients correlated with increased body pain (Matura et al. 2015). Similar 
results were seen in patients with increased IL-6 plasma concentrations who 
also reported increased pain, fatigue, anxiety and depression (Matura et al. 
2015). Interestingly, TNF-α had no effect on mental-wellbeing symptoms. This 
was measured via patients self-assessing their own physical and mental well-
being and did not include data on other contributing factors such as alcohol 
intake and diet. 
Chronically elevated levels of IL-4 have been shown to cause cardiac fibrotic 
and left ventricle remodelling and dysfunction in mice (Kanellakis et al. 2012; 
Peng et al. 2015). There is also evidence to suggest IL-4 has a causal role in 
the development of SSc-PAH, as IL-4/IL-13 knockout mice are protected 
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against SSc/(TGF)-β induced PH. However, this effect is only seen with a 
combined deficiency as neither IL-4 nor IL-13 knockout alone is sufficient to 
offer protection (Kumar et al. 2015).  
IL-13 acts predominantly via the phosphorylation and nuclear translocation of 
signal transducer and activator of transcription (STAT)3 and STAT6 to inhibit 
PASMC proliferation and ET-1 production by PASMCs (Hecker et al. 2010). 
IL-13 receptor-α 2 (IL-13Rα2), a decoy receptor for IL-13, overexpression in 
PASMCs inhibits IL-13-mediated anti-proliferative effects, STAT 
phosphorylation and suppression of ET-1 production. This is reversed when 
IL-13Rα2 expression is reduced via siRNA-mediated knockdown (Hecker et 
al. 2010). Interestingly, IL-13Rα2 is highly expressed in the lungs of IPAH 
patients and in hypoxia-induced PAH mice where it has been shown to 
contribute to pulmonary vascular remodelling via the inhibition of IL-13 
signalling (Hecker et al. 2010). This suggests that IL-13 is protective when 
acting via IL-13Rα1, but upregulation of IL-13Rα2 enables PAH progression 
due to the abrogation of IL-13/IL-13Rα1 signalling.  
IL-10 also appears to provide protection against PAH. Four weeks of treatment 
with adeno-association virus-IL-10 vector in rat models of MCT-induced PAH 
was sufficient to ameliorate mPAP and RVH resulting from MCT treatment, 
and improved rat survival (Ito et al. 2007). It also inhibited MCT-induction of 
TGF-β and IL-6, reduced the accumulation of macrophages, inhibited vascular 
cell proliferation and improved survival. In addition, pre-treatment with IL-10 
inhibited TGF-β induced PASMC proliferation, although not IL-6-induced 
proliferation (Ito et al. 2007). 
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This body of research make a clear case that inflammation may contribute to 
the development of PAH. Further evidence for this can be seen in numerous 
studies that link increased IL-6 signalling with the initiation and progression of 
PAH. 
1.4 IL-6 signalling in PAH 
1.4.1 IL-6 signalling via JAK/STAT 
IL-6 family cytokines consist of four straight α-helices (A,B,C,D) which are 
joined by four loops (two large and two smaller) so that IL-6 helices reside in 
an ‘up, up, down, down’ formation (Figure 1.4) (reviewed by Somers et al. 
1997; Bravo and Heath 2000). Specific ‘sites’ on the cytokine surface enable 
IL-6 association with the receptor complex (Figure 1.4). Site I, found within the 
C-terminal of the AB-loop, binds to the cytokine binding molecule (CBM) of the 
α-receptor unit. Site II, formed centrally between helices A and C, interacts 
with the first signal transducing receptor (gp130). Site III is recognised by the 
IgG-like domain of the second signal transducing receptor (gp130, LIFR or 
OSMR) which is then recruited to the complex (Savino et al. 1994; Clackson 
and Wells 1995; Paonessa et al. 1995; reviewed by Heinrich et al. 1998). 
IL-6 binds to a receptor complex consisting of the α-receptor-subunit (IL-6Rα) 
and the signal transducing subunit, a gp130 homodimer (Murakami et al. 
1993). IL-6Rα consists of an N-terminal IgG-like domain followed by a CBM 
made up of two fibronectin (FN)III-like domains which contain a membrane-
proximal WSXWS motif and four cysteine residues (Bazan 1990). The CBM 




Figure 1.4: The crystal structure of IL-6 
The structure of IL-6 showing the four α helices A (red), B (green) C (yellow), 
D (blue), and the connecting loops (grey). The positions of sites 1, 2 and 3 
which are involved in the formation of a receptor complex with IL-6Rα and 
gp130 have also been highlighted.  Adapted from Bravo and Heath (2000). 
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membrane-proximal WSXWS motif and four cysteine residues (Bazan 1990). 
The CBM resides in loops within the hinge region of the receptor and is 
involved in ligand recognition (Yawata et al., 1993). All of the functional 
domains of IL-6Rα are positioned extracellularly, with just a short cytoplasmic 
tail of 82 amino acids residing inside the cell (Figure 1.5) (reviewed by Heinrich 
et al. 2003). 
Signalling via membrane-bound (mb)IL-6Rα is known as classic signalling; 
however IL-6 trans-signalling via a soluble form of the IL-6Rα (sIL-6Rα) also 
occurs. With the exception of some leucocytes and hepatocytes (Hirata et al. 
1989; Wang and Fuller 1994; Rojkind et al. 1995), most cells do not express 
mbIL-6Rα. Thus, sIL-6Rα enables IL-6 trans-signalling to occur in cells such 
as vascular cells which do not express mbIL-6Rα. Interestingly, it has been 
shown that PASMCs from distal PAs of IPAH patients express significantly 
more mbIL-6R than healthy PASMCs suggesting that both classic and trans-
signalling is active within the remodelled vascular of PAH (Tamura et al. 2018). 
sIL-6Rα is produced mainly via proteolytic cleavage of mbIL-6Rα. A disintegrin 
and metalloprotease (ADAM)-10, ADAM-17 and the metalloproteases soluble 
meprin α and membrane-bound meprin β have all been shown to trigger 
ectodomain shedding of the receptor in vitro (Mullberg et al. 1993; 
Schumacher et al. 2015; Riethmueller et al. 2016; Arnold et al. 2017). 
Alternative splicing of IL-6Rα mRNA to produce sIL-6Rα can also occur (Holub 
et al. 1999), but its contribution to the generation of sIL-6Rα is relatively minor 
(Lust et al. 1992; Rose-John 2012). sIL-6Rα is comprised of the functional 
ectodomain of mbIL-6Rα but is not tethered to the plasma membrane (Figure 







Figure 1.5: The structural domains of IL-6Rα, sIL-6Rα, gp130, STAT3 and 
SOCS3 
Structural domains of mbIL-6Rα, sIL-6Rα, gp130, JAK, STAT and SOCS3. 
CBM; cytokine binding molecule, DBD; DNA-binding domain, ESS; extended 
SH2 domain, FERM; 4.1, ezrin/radixin/moesin, FN; fibronectin, gp130; 
glycoprotein 130, IgG; immunoglobulin, mbIL-6Rα; membrane bound IL-6 
receptor α, JH; JAK homology, sIL-6Rα; soluble IL-6 receptor α, KIR; kinase 
inhibitory region, STAT; signal transducer and activator of transcription 
SOCS3; suppressor of cytokine 3, ULD; oligomerisation domain. 
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binding to ubiquitously expressed membrane-bound gp130 dimers. A short 
stalk region which resides in close proximity to the plasma membrane in mbIL-
6Rα and in the COOH-terminal of sIL-6Rα has also been described which 
regulates IL-6 proteolysis by ADAM proteins, and enables the sIL-6R/IL-6 
complex to bind to gp130 (Baran et al. 2013).  
Gp130 shares a similar extracellular structure to IL-6Rα but with three addition 
FNIII domains (Figure 1.5) which are crucial for ligand binding and signal 
transduction (Horsten et al. 1995). Deletion of the three addition FNIII domains 
results in a receptor unable to signal (Kurth et al. 2000). In the intracellular 
region of gp130 are two box domains, a di-leucine motif and a number of 
relevant tyrosine residues (Figure 1.5), important for gp130/Janus kinase 
(JAK) association (reviewed by Heinrich et al., 1998). The box1 domain is a 
proline rich area of the protein essential for JAK binding (Haan et al. 2000). 
The box 2 domain contains a number of hydrophobic amino acids followed by 
positively charged amino acids. Although not critical for JAK binding, the box 
2 domain does appear to stabilise the gp130/JAK association as in the 
absence of the box 2 domain, JAK will only bind when overexpressed (Haan 
et al. 2002).  
JAK is comprised of an N-terminal FERM (four point-one, ezrin, radixin and 
moesin) domain which is important in associating with the receptor (Hamada 
et al. 2000), an SH2 domain, and a C-terminal kinase domain that is regulated 
by a pseudo-kinase domain which precedes it (Figure 1.5) (reviewed by 
Heinrich et al., 2003). JAKs are constitutively bound to the membrane in an 
inactive state as the pseudo-kinase domain on one JAK inhibits the other and 
vice versa. Upon formation of an IL-6/IL-6Rα complex, JAK undergoes a 
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conformational change which relieves this inhibition, enabling the tyrosine 
kinase domains of the receptor-bound JAKs to trans-phosphorylate adjacent 
key tyrosine residues at positions 1034 and 1035 of human JAK1 (Toms et al. 
2013; Shan et al. 2014). This fully activates both JAKs, resulting in the 
phosphorylation of specific tyrosine residues at positions 767, 814, 905 and 
915 within the cytoplasmic tail of human gp130 (Brooks et al. 2014), which act 
as docking sites for STATs to associate via their SH2 domains (Figure 1.6) 
(Stahl et al. 1995; Hemmann et al. 1996). 
There are seven STAT family members in humans; 1, 2, 3, 4, 5a, 5b and 6 
which share an N-terminal oligomerisation domain, followed by a DNA-binding 
domain, a linker domain, a SH2 domain and a C-terminal transactivation 
domain which contains relevant tyrosine and serine residues (Figure 1.5) 
(reviewed by Heinrich et al., 2003). IL-6/gp130 signalling mostly occurs via 
phosphorylation of  STAT3 (Hemmann et al. 1996). 
Two monomeric STAT3 molecules undergo a short-lived association with the 
YXXQ motif of gp130 which is mediated by the STAT SH2 domain and requires 
phosphorylation of tyrosine residues on gp130 (Stahl et al. 1995; Novak et al. 
1998). Binding of STAT3 precedes STAT3 tyrosine 705 phosphorylation by 
JAK, which triggers dimerization of the two STAT3 molecules, a process which 
is also mediated by the STAT3 SH2 domain (Shuai et al. 1994), triggering the 
translocation of STAT3 to the nucleus (Milocco et al. 1999). Gp130-mediated 
phosphorylation of serine 727 in STAT3 also occurs, and is critical for the 
recruitment of transcriptional co-activators and target gene transcription 








Figure 1.6: IL-6 induction of the gp130/JAK/STAT signalling pathway  
IL-6 induction of the gp130/JAK/STAT signalling pathway via the trans-
signalling pathway. IL-6 and sIL-6Rα form a complex extracellularly prior to 
binding to membrane- bound gp130. Local JAK molecules are activated and 
phosphorylate the gp130 cytoplasmic tail (relevant tyrosine residues have 
been highlighted). STAT3 binds to phosphorylated residues on the gp130 tail, 
triggering STAT3 phosphorylation and translocation to the nucleus where it 
initiates target gene transcription. DUSP10; dual specificity phosphatase 10, 
gp130; glycoprotein 130, ICAM1; intracellular adhesion molecule 1, IL-6; 
interleukin 6, JAK; janus kinase, P; phosphorylated tyrosine residue, sIL-6Rα; 
soluble IL-6 receptor α, SOCS3; suppressor of cytokine signalling 3, STAT; 
signal transducer and activator of transcription, VEGF; vascular endothelial 
growth factor, VEGFR2; VEGF receptor 2, Y; tyrosine residue.  
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non-phosphorylated stable STAT3 homodimers have also been found to exist 
in the absence of gp130/STAT activation (Braunstein et al. 2003). 
STAT3 target genes tend to promote a pro-inflammatory and pro-survival 
environment, which is why STAT3 hyperactivity is associated with numerous 
cancers (reviewed by Carpenter and Lo 2014). For instance, the anti-apoptotic 
proteins Mcl-1 and survivin are upregulated as a result of JAK/STAT3 activity 
in human myeloma cells and human breast cancer cells respectively (Puthier 
et al. 1999; Gritsko et al. 2006). On the other hand, the well-established p53 
gene, which is a key anti-oncogene that initiates apoptosis, is repressed by 
STAT3 in BALB/c 3T3 fibroblasts and mouse embryonic fibroblasts (MEFs). 
Transcription of the pro-inflammatory mediators, dual specificity phosphatase 
10 and caspase-1 is mediated by STAT3 in human T-helper 17 cells (Tripathi 
et al. 2017), and the pro-inflammatory C-reactive protein (CRP) is upregulated 
as a result of IL-6 activation of STAT3 in human hepatoma Hep3B cells (Zhang 
et al. 1996). The adhesion molecules ICAM-1 and vascular cell adhesion 
molecule (VCAM-1) are also upregulated post-IL-6 treatment in human 
umbilical vein ECs (HUVEC). In addition, STAT3 has been shown to directly 
induce VEGF gene transcription in NIH3T3 fibroblasts, SCK mammary 
carcinoma, and B16 melanoma cell lines (Niu et al. 2002), as well as in gastric 
cancer cells where it was shown to enhance cell growth and invasion capacity 
(Zhao et al. 2016), thus enabling angiogenesis.  Although, many of these 
findings have been found in cancer cells and not vascular cells, it still presents 




SH2-containing protein tyrosine phosphatase 2 (SHP2) and Src family kinases 
(SFK) also bind to cytokine-activated gp130 (Kim et al. 1998; Taniguchi et al. 
2015). SHP2 binds to JAK-phosphorylated tyrosine 759 (human; mouse 
tyrosine 757) of gp130 to activate the ERK1/2 and phosphatidylinositol 3-
kinase (PI3K) pathways (Schaper and Rose-John 2015). ERK1/2 is also 
activated by PAH-associated BMPR2 mutations and causes increased 
proliferation of PAECs (Awad et al. 2016). PI3K is associated with PA 
remodelling in animal models of PAH via PASMC proliferation and increased 
deposition of ECM proteins (Xia et al. 2016). In the intestinal epithelium, SFK 
binds to gp130 within amino acids 812-827 to activate Yes-associated protein 
(YAP) (Taniguchi et al. 2015). Although the IL-6/gp-130/SFK pathway has yet 
to be studied in vascular cells, YAP activation in PA adventitial fibroblasts can 
increase PAEC and PASMC proliferation via a self-amplifying, regulatory loop 
with miRNA-130/301, contributing to ECM remodelling in PAH (Bertero et al. 
2015).  
Thus, IL-6 signalling results in the transcription of pro-inflammatory, pro-
angiogenic and pro-survival genes which, when not properly regulated, have 
the potential to cause cellular dysfunction and disease such as PAH. 
1.4.2 Evidence of IL-6 signalling in the development of PAH 
IL-6 is overexpressed in the serum and lungs of IPAH patients (Humbert et al. 
1995; Soon et al. 2010). IL-6 trans-signalling activity in 26 PAH patients was 
compared to healthy controls via ELISA to quantify IL-6, sIL-6R and soluble 
(s)gp130 plasma concentrations. Sgp130 is a naturally occurring inhibitor 
found in human plasma that is generated by translation of alternately spliced 
gp130 mRNA and functions as a specific inhibitor of IL-6 trans-signalling as it 
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binds to IL-6/sIL-6R complexes to block binding to membrane-bound gp130 
(Narazaki et al. 1993; Diamant et al. 1997; Jostock et al. 2001). Sgp130 levels 
did not differ between patients but IL-6 and sIL-6R levels were elevated in PAH 
patient plasma compared to controls (Jasiewicz et al. 2015). Thus, in the 
absence of increased levels of sgp130, there is a potential for increased trans-
signalling.   
Plasma IL-6 concentrations > 2.3 pg/ml correlated with clinical deterioration as 
measured by levels of BNP (Casserly and Klinger 2009), ventilator efficiency, 
the cardiopulmonary exercise test and the 6MWT (Jasiewicz et al. 2015). In 
contrast, levels of sIL-6R and sgp130 did not correlate with patient 
deterioration. Additionally, elevated serum levels of IL-6 are inversely 
correlated with RV function, cardiac index, and stroke volume (Prins et al. 
2018). However, no correlation has been found between serum IL-6 levels and 
mPAP or PVR, which are key measurements used to diagnose PAH 
suggesting IL-6 may have a greater impact on RV dysfunction than the PA 
remodelling initially involved in disease development. 
As previously mentioned, increased IL-6 plasma concentrations correlate 
negatively with QOL, with patients reporting increased pain, tiredness and 
mental health issues (Matura et al. 2015). Plasma IL-6 concentrations are also 
associated with patient survival, with IL-6 levels of > 9 pg/mL resulting in a 5-
year survival of 30% compared with 63% 5-year survival for patients with levels 
≤ 9 pg/mL (Soon et al. 2010). In this PAH cohort, cytokine levels were 
considered a more accurate measure of prognosis than traditional methods 
such as the 6MWD and haemodynamics. A major limitation of these studies is 
that they assess correlative relationships between IL-6 and specific outcomes. 
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As such, they cannot define a causative role for IL-6 in PAH progression. 
Regardless, evidence demonstrates IL-6 is a good biomarker for monitoring 
prognosis in PAH and thus its inclusion should be considered for current 
monitoring.  
PAECs isolated from PAH patients demonstrated increased tyrosine 705 
phosphorylation of STAT3 and increased STAT3 activity, measured via the 
expression of arginase-II, a STAT3 regulated gene essential for EC 
proliferation, compared to control cells (Masri et al. 2007). Likewise, in 
HUVECs IL-6 signalling induced STAT3 mediated induction of the pro-
inflammatory CCL2 (Zegeye et al. 2018). This was found to be a result of IL-6 
trans-signalling specifically as STAT3 tyrosine 705 phosphorylation only 
occurred post-treatment with IL-6/sIL-6Rα, not with IL-6 alone. 
There is a bulk of animal research that provides more conclusive evidence for 
a causative role of IL-6. In mice subject to chronic hypoxia, IL-6 mRNA levels 
in the lung peak after 2 days and return to normal after 7 days, consistent with 
positive IL-6 immunostaining in the intima and medial layers of PAs and small 
arteries 2 days post-hypoxia (Hashimoto-Kataoka et al. 2015). Treatment with 
the monoclonal rat anti-IL-6R antibody MR16-1 post-hypoxia reduced medial 
wall thickness and RVSP compared to untreated mice (Hashimoto-Kataoka et 
al. 2015). Similar results have been shown in IL-6-/- mice exposed to 2 weeks 
chronic hypoxia which demonstrated significantly lower RVSP and RVH 
compared to WT mice (Savale et al. 2009). Distal pulmonary vessel 
muscularisation and macrophage recruitment were also reduced in IL-6-/- 
versus WT mice. However, these changes occurred in the absence of any 
58 
 
significant effects on the expression of pro-inflammatory markers such as 
ICAM-1 and VCAM-1 (Savale et al. 2009).  
A mouse model in which an IL-6 transgene was specifically overexpressed in 
the lung (Tg+) displayed spontaneous elevated RVSP versus WT mice which 
was exacerbated following chronic hypoxia, with the RVSP of Tg+ mice more 
than double that of WT controls (Steiner et al. 2009). Under normoxic 
conditions, Tg+ mice also displayed RVH compared to control mice, which was 
increased following chronic hypoxia. In contrast, there was no change in RVH 
for WT mice in hypoxic versus normoxic conditions (Steiner et al. 2009). This 
was due to an increased muscularisation of the pulmonary vascular bed in Tg+ 
mice which was not apparent in WT animals. In addition, Tg+ mice 
demonstrated partial or complete occlusion of the arterioles in normoxic 
conditions which was aggravated after exposure to hypoxia (Steiner et al. 
2009). This was due in part to IL-6 stimulation of PAEC proliferation which was 
associated with an upregulation of VEGF in PA walls, causing the formation of 
occlusive and concentric plexiform lesions. Inflammatory cell infiltration, 
evidenced by the presence of CD3+ T cells, was also observed in normoxic 
Tg+ mice, and which may have contributed to the observed vascular 
remodelling (Steiner et al. 2009). In contrast, no intimal thickening was 
detectable in WT mice under normoxic conditions, and inflammatory cell 
infiltration was only detectable after chronic hypoxia, albeit not to the same 
extent as Tg+ mice (Steiner et al. 2009). Based on these findings, the authors 
concluded that increasing lung-specific expression of IL-6 was sufficient to 
replicate many pathological features seen in PAH patients (Steiner et al. 2009).  
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In rat-MCT models of PAH, treatment with SC 144 hydrochloride, a gp130 
inhibitor which binds to gp130 causing gp130 serine 788 phosphorylation 
resulting in gp130 deglycosylation and preventing STAT3 phosphorylation (Xu 
et al. 2013), or with miR-125a-5p agomir, to target STAT3 activity, improved 
symptoms such as mPAP, RVSP and RV hypertrophy in a rat MCT model of 
PAH (Huang et al. 2016; Cai et al. 2018). VEGF and PCNA levels were also 
reduced in MCT-treated rats administered SC 144 hydrochloride compared to 
control rats. Similarly, limiting IL-6 signalling via treatment with the IL-6 inhibitor 
MR16-1, which blocks the IL-6R, or with the gp130 inhibitor sgp130Fc, in 
hypoxia-PAH mouse models protected rodents from hypoxia induced 
inflammatory cell infiltration into the lung and improved RVSP and RVH 
(Hashimoto-Kataoka et al. 2015; Maston et al. 2018). 
Research by Brock et al. (2009) demonstrated that IL-6 also signals via STAT3 
to control the miRNA-17/19 cluster in HPAECs to post-transcriptionally 
regulate BMPR-II protein expression. This may be one potential explanation 
for reduced BMPR-II expression in PAH even in the absence of a BMPR2 
mutation. A negative feedback loop between IL-6 and BMP signalling in human 
PASMCs and in mice has also been identified (Hagen et al. 2007). This is 
supported by a study in mice which illustrated that short term loss of BMP 
signalling alone was not sufficient to produce a pro-inflammatory environment, 
however when treated with LPS, PASMC from PAH patients and from 
Bmpr2(+/-) mice did exhibit increased IL-6 activity and a greater inflammatory 
response than that seen in the healthy/WT controls (Soon et al. 2015) 
Combined, these studies demonstrate a crucial role for IL-6 in multiple PAH 
animal models and a potential link between IL-6 and BMP signalling, a key 
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signalling pathway affected by the majority of PAH-associated mutations 
(Section 1.3.3.1). This suggests therapeutically targeting the IL-6 pathway 
might be effective in reducing the inflammation and vascular remodelling 
characteristic of PAH. A review by Heinrich et al. (2003) discusses three 
factors involved in naturally terminating the IL-6 signalling pathway; protein 
tyrosine phosphatases (PTPs), protein inhibitor of activated STAT (PIAS) and 
suppressor of cytokines signalling (SOCS). PTPs phosphorylate key 
components in the signal transduction cascade. PIAS are co-transcriptional 
regulators of the JAK/STAT pathway; PIAS1 inhibits STAT1 and PIAS3 inhibits 
STAT3. The SOCS family comprises 8 different proteins (SOCS 1-7 and 
cytokine-inducible SH2 domain protein (CIS)) but SOCS3 is responsible for 
the inhibition of IL-6 signalling (reviewed by Croker et al. 2003; Babon et al. 
2014). SOCS3 is of particular interest because as well as limiting IL-6 
signalling, it has also been linked with downregulation of TGF-β (Kinjyo et al. 
2006), improved caveolae stability (Williams et al. 2018), and cAMP signalling 
(Gasperini et al. 2002), which have all been associated with PAH (Sections 
1.3.3.1, 1.3.3.2 and 1.3.4.1 respectively). 
1.4.3 SOCS3 inhibition of JAK/STAT signalling 
SOCS3 contains an N-terminal kinase inhibitory region (KIR) and a central 
SH2 domain which are common to all SOCS proteins (Figure 1.5) (Naka et al. 
1997), plus an extended SH2 subdomain critical for binding to gp130 and JAK, 
and a C-terminal SOCS box responsible for targeting bound proteins for 
proteasomal degradation (Babon et al. 2006). SOCS3 is expressed at low 
concentrations in resting cells but is upregulated by IL-6 via the JAK-STAT 
pathway. It then inhibits further signalling by binding to phosphorylated tyrosine 
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759 within activated human gp130 (tyrosine 757 in mice). Whilst in this position 
the KIR region of SOCS3 is in close enough proximity to receptor-bound JAKs 
to inhibit tyrosine kinase activity, thus attenuating downstream activation of 
STAT3 (Figure 1.7) (Babon et al. 2012; reviewed by Babon et al. 2014).  
In VSMCs, overexpression of SOCS3 attenuated IL-6/interferon (IFN)γ 
induced cell migration and proliferation via the inhibition of STAT3 
phosphorylation and consequent STAT3-mediated transcription of 
inflammatory cytokines (Xiang et al. 2013). Thus, there is precedent to 
consider increasing SOCS3 expression to limit the effects of IL-6 signalling. 
1.5 cAMP induction of SOCS3 
As previously discussed, upon activation of a GPCR an active Gαs protein is 
released, activating membrane-bound enzyme AC which converts ATP in to 
cAMP (Section 1.3.4.1). cAMP acts through three effector proteins (PKA, 
exchange protein directly activated by cAMP (EPAC), and cyclic nucleotide 
gated (CNG) ion channels) to control a number of processes including 
endothelial barrier function and VSMC proliferation and vasodilation to 
maintain normal vascular function and suppress inflammation (Fukuhara et al. 
2005; reviewed by Roberts and Dart 2014). 
EPAC proteins are guanine nucleotide exchange factors specific for Rap that 
mediate a number of cell functions and signalling pathways such as endothelial 
barrier function, ERK1/2 signalling, SOCS3 induction and cardiac gap junction 




Figure 1.7: SOCS3 inhibition of JAK/STAT signalling 
SOCS3, induced by IL-6 in a type of negative feedback loop, binds to tyrosine 
759 on the gp130 tail. Once bound, the KIR region of SOCS3 is in close 
enough proximity to JAK to inhibit kinase activity, thus attenuating gp130 
phosphorylation. As STAT3 molecules require phosphorylated tyrosine 
residues, they are no longer able to bind to gp130 thus further phosphorylation 
and activation of STAT is attenuated. gp130; glycoprotein 130, IL-6; interleukin 
6, JAK; janus kinase, KIR; kinase inhibitory region, sIL-6Rα; soluble IL-6 
receptor α, SOCS3; suppressor of cytokine 3, STAT; signal transducer and 
activator of transcription. 
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EPAC1 is widely expressed (de Rooij et al. 1998) while EPAC2 expression is 
restricted to the adrenal glands, pancreatic β-cells, liver and discrete areas of 
the brain (Ueno et al. 2001). Both EPAC isoforms contain an N- terminal 
regulatory domain consisting of a dishevelled/EgI-10/pleckstrin (DEP) domain 
responsible for targeting EPAC (Ponsioen et al. 2009), and either one or two 
cAMP-nucleotide binding domains (CNB) (Dao et al. 2006). The catalytic 
region consists of a Ras-exchange motif (REM) domain, a Ras-association 
(RA) domain, a CDC25-HD domain and the COOH terminus (Figure 1.8A). 
The CDC25-HD domain is responsible for binding to GDP-bound Rap1 and 
Rap2, which is then stabilised by the REM domain (Rehmann et al. 2003). 
In the absence of cAMP, EPAC resides in an inactive state with the regulatory 
region preventing the catalytic region from binding to Rap1/2; however upon 
cAMP binding to the CNB, EPAC undergoes a conformational change resulting 
in the CDC25-HD domain of the catalytic region being able to bind Rap1 and 
Rap2 (Figure 1.8B) (Rehmann et al. 2006) which, with the help of the REM 
domain, activates Rap via the exchange of GDP for GTP (Rehmann et al. 
2003). 
EPAC is able to induce SOCS3 expression in MEFs via rapid mobilisation of 
the transcription factor CCAAT/enhancer binding proteins (C/EPB)β resulting 
in SOCS3 gene transcription independently of PKA (Yarwood et al. 2008). In 
COS-7 cells, cAMP mediated EPAC1 induction of SOCS3 in a PKA 
independent manner (Borland et al. 2009). PKC inhibitors, however, did 
significantly reduce cAMP mediated SOCS3 induction (Borland et al. 2009), 





Figure 1.8: Structural domains of EPAC1 and EPAC activation by GTP 
A) Structural domains of EPAC1. DEP; dishevelled/EgI-10/pleckstrin domain; 
CNB, cAMP-nucleotide binding domain, RA; ras-associated domain, REM; 
Ras-exchange motif (REM) domain. B) The conformational change of EPAC 
when activated. cAMP binds to the regulatory (Reg) domain to expose the 
catalytic (Cat) domain of EPAC which is then free to activate Rap1 and Rap2. 




In HUVECs, aortic ECs, and MEFs, forskolin (Fsk), which directly binds and 
activates AC, reduced IL-6-mediated STAT3 tyrosine 705 and ERK1/2 
phosphorylation (Sands et al. 2006; Woolson et al. 2009). Treatment with 8-
(4-chlorophenylthio)-2′-O-methyladenosine-3′,5′-cyclic monophosphate (8-
pCPT), an EPAC-selective activator had the same effect (Sands et al. 2006), 
whereas a PKI inhibitor had no effect on Fsk-mediated inhibition of STAT3 or 
ERK1/2 activation (Woolson et al. 2009), suggesting this to be an EPAC-
dependent mechanism. In support of this mechanism in HUVECs, treatment 
with the EPAC1 agonist N-(2,4-dimethylbenzenesulfonyl)-2-(naphthalen-2-
yloxy)acetamide (I942) was sufficient to induce SOCS3 and limit IL-6-mediated 
STAT3 phosphorylation in an EPAC1-dependent manner (Wiejak et al. 2019).  
cAMP has also been shown to inhibit IL-6 signalling via SOCS3-independent, 
PKA-dependent mechanisms. In rat ventricular myocytes, activation of PKA 
stimulated phosphorylation of SHP2 on threonine 73 and serine 189 to inhibit 
its activity (Burmeister et al. 2015). Activation of PKA in human dermal 
fibroblasts and MEFs has also been shown to rapidly inhibit IL-6 stimulation of 
ERK1/2 but not STAT3 (Sobota et al. 2008). This was measured via a 
reduction in ERK1/2 -mediated CCL2 expression, and was shown to occur via 
an EPAC1-independent mechanism that may involve rapid PKA-mediated 
phosphorylation of c-Raf (Sobota et al. 2008).  
Thus, modulation of SOCS3 expression by cAMP may be one way in which to 
limit IL-6 signalling. This is interesting because epoprostenol, a type of 
prostanoid and one of a cocktail of drugs used in the treatment of PAH that 
acts via cAMP-mediated activation of PKA, is  the only drug currently used in 
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the treatment of PAH to have any efficacy in improving survival rates (Sitbon 
et al. 2002). 
1.6 Treatment of PAH 
The primary aim of current PAH treatments such as prostanoids, 
phosphodiesterase-5 (PDE-5) inhibitors and endothelin receptor antagonists 
(ERAs) is to re-establish normal PGI2, NO and ET-1 signalling respectively 
(Table 1.4). They are typically administered in combination to induce 
vasodilation and relieve symptom of PAH but have their drawbacks such as 
side effects and complex administration procedures (reviewed by Badlam and 
Bull 2017; Huang et al. 2019). 
1.6.1 Prostanoids 
Prostanoids are PGI2 analogues that activate the IP to increase intracellular 
cAMP levels (reviewed by Gryglewski 2008). Their best characterised role is 
induction of vasodilation, however PGI2 has also been shown to have anti-
proliferative (Asada et al. 1994), anti-inflammatory (Aronoff et al. 2004; 
Takayama et al. 2006) and anti-thrombotic (Moncada et al. 1976; Zhang et al. 
2016c) effects. Although all prostanoids have been shown to be beneficial in 
improving functional class, exercise tolerance and pulmonary haemodynamics 
(Waxman and Zamanian 2013), treatment with them is associated with side 
effects such as headaches, flushing, jaw pain and diarrhoea. In addition, like 
PGI2, they have short half-lives and therefore require complex administration 

















normal PGI2 levels 
Eproprostenol 
Administered via a continuous IV 
catheter, half-life < 5 min. Only drug 
to improve life expectancy of PAH 




subcutaneously via micro-infusion 
pump, also IV and inhaled. Oral 
administration shown to have no 
clinical benefit. Half-life = 4hrs. 
Results in haemodynamic 
improvement and increased 
exercise capacity (reviewed by 
Seferian and Simonneau 2013)  
Treprostinil 
Diolamine 
Oral - two or three times daily. 
Improves 6MWD and dyspnea after 
16 weeks. Additional adverse 
effects of extremity pain, 
hypokalaemia and abdominal 
discomfort (Jing et al. 2013; 
Enderby and Burger 2015). 
Beraprost 
Oral, clinical effectiveness not 
sustained after 12 months. Only 
licenced in Japan and South Korea 
(Barst et al. 2003). 
Ilaprost 
Inhaled, clinical benefit not 
sustained after 5 years, 
retrospective study showed no 
clinical benefits and a poor survival 

























17 weeks of treatments -> 30.0% 
reduction in PVR. Side effects - 
headache, jaw pain, nausea, 


















Improves 6MWD, pulmonary 
haemodynamics and WHO 
functional class after 1 year of 
treatment (Galie et al. 2005; Rubin 
et al. 2011). 
Tadalafil 
Improves 6MWD and pulmonary 
haemodynamics after 16 weeks 



















Bind to sCG -> 
increased levels of 
cGMP 
Riociguat 
Oral - three times daily. Improves 
6MWD, WHO functional class and 
pulmonary haemodynamics after 
12 weeks of treatment. (Ghofrani 
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ETB receptors to 
inhibit ET-1 
Bosentan 
Oral, reduces PVR, risk of hepatic 














receptors to inhibit 
ET-1 
Sitaxentan 
Moderate clinical efficacy but 
removed from market due to high 
risk of acute liver failure (Lavelle et 
al. 2009). 
Ambrisentan 
Improves 6MWD and WHO 
functional class. Has lower hepatic 
toxicity compared to bosentan 










Target ETA and 
ETB receptors to 
inhibit ET-1 
Macitenton 
Better receptor binding, enhanced 
affinity and tissue penetration, and 
longest duration of receptor 
blocking compared to other ERAs. 
Reduced morbidity and mortality 
after 3.5 years of treatment in 
human trials at a 10mg daily dose 








Table 1.4: A summary of the drugs currently approved for the treatment 
of PAH 
A summary of the different kind of drugs currently approved for the treatment 
of PAH with details of the method of action, specific examples of drugs and 
their clinical effectiveness. 6MWD; 6 minute walk distance, ERA; endothelin 
receptor antagonists IV; intravenous, NO; nitric oxide, PAH; pulmonary arterial 
hypertension, PDE-5; phosphodiesterase-5, sCG; soluble guanylyl cyclase, 
WHO; World Health Organisation. 
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A meta-analysis for total mortality identified the prostanoid epoprostenol as the 
only therapy to demonstrate some efficacy in improving survival rates, with a 
70% mortality risk reduction (Galie et al. 2013). Unfortunately, due to its short 
half-life, epoprostenol must be administered via continuous IV administration 
resulting in additional risks associated with indwelling catheters such an 
infection or pump malfunctions. As a result of this, epoprostenol is only 
recommended for WHO functional class IV patients who have not responded 
to previous monotherapy or combination therapy (Greig et al. 2014). 
Epoprostenol was approved for use in the clinic in 1995 (Sitbon et al. 2002). 
Since then other prostanoids, such as beraprost sodium (BPS) and treprostinil, 
have been developed to try and overcome some of the limitations of 
epoprostenol administration. 
Treprostinil, a worldwide approved synthetic prostanoid analogue, can be 
administered in numerous ways but the preferred method is subcutaneously 
via a micro-infusion pump. Intra-venous and inhaled forms of treprostinil have 
also shown some clinical success, however oral administration had no clinical 
benefit (reviewed by Kumar et al. 2016). Treatment with treprostinil has been 
shown to increase a patients exercise capacity, monitored via the 6MWT, and 
improve a patients hemodynamic capabilities and WHO functional class in 
adults and children (Jing et al. 2013; Levy et al. 2018). In 2017, a successful 
method of implanting an IV infusion system for treprostinil was developed 
(Waxman et al. 2017). Although, the long term benefits of this have yet to be 
established.  
An oral version of treprostinil has also been developed. Treprostinil diolamine 
is administered orally at a dose of 0.25 mg twice daily or 0.125 mg three times 
71 
 
daily depending on how well the patient tolerates it (Tapson et al., 2012). In 
initial clinical trials, treprostinil diolamine improved 6MWD and dyspnea after 
16 weeks of treatment (Tapson et al. 2012; Jing et al. 2013). However, 
although administering the drug in this manner is less complex, there were 
additional side effects associated including extremity pain, hypokalaemia and 
abdominal discomfort (Enderby and Burger, 2015).  
BPS has a half-life of 30-45 minutes and was developed to provide an oral 
prostanoid option. In animal models, treatment with BPS appeared promising 
with regards to improving arterial lesions and inhibiting thrombosis (Murai et 
al. 1989), as well as inhibiting the production of cytokines such as IL-6, IL-1 
and TNF-α by alveolar macrophages (Miyata et al. 1996). Although initially 
effective in reducing mPAP and PVR in WHO functional class I and II human 
patients, and improving a patient’s 6MWD, these clinical benefits were not 
sustained after 12 months of treatment. BPS is currently only licenced for use 
in Japan and South Korea (reviewed by Melian and Goa 2002; Barst et al. 
2003). 
Selexipag, a non-prostanoid IP agonist has also been developed to address 
the challenges with the short life half of prostanoid analogues. Selexipag is a 
pro-drug which is metabolised to its active form [4-((5,6-diphenylpyrazin-2-
yl)(isopropyl)amino)butoxy]acetic acid (ACT-333679) by carboxylesterase 1. 
In initial clinical trials, patients demonstrated improved mPAP, PVR and 6MWD 
after 17 weeks of treatment (Simonneau et al. 2012). Side effects were similar 
to those seen with traditional prostanoids, with headaches, jaw and extremity 
pain, nausea, and nasopharyngitis reported (Simonneau et al. 2012). Later 
clinical trials reported that although the risk of PAH-related complications was 
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significantly lower with selexipag than with placebo, there was no difference in 
mortality rates (Sitbon et al. 2015). 
1.6.2 Emerging developments in PAH therapies 
Despite the number of drugs approved for the treatment of PAH, the main 
target is vasodilation and there is little currently being done to target the 
numerous other factors that contribute to PAH progression. Thus, there is an 
opportunity to develop novel therapies that provide relief or prevention from 
other key abnormalities characteristic of PAH such as chronic inflammation, 
EC dysfunction and TGF-β/BMP signalling imbalances by reversing the 
pathological changes that occur. 
1.6.2.1 Targeting the TGF-β/BMP signalling pathway 
An imbalance in the TGF-β/BMP signalling pathway which favours proliferation 
is characteristic of PAH (Section 1.3.3.1), making it a potential therapeutic 
target. A high-throughput screen utilising a luciferase assay of genes in a 
mouse carcinoma cell line identified tacrolimus, also known as FK506, as an 
activator of BMPR-II signalling (Spiekerkoetter et al. 2013). Tacrolimus was 
able to induce DNA-binding protein inhibitor (Id-1), a measure of BMPR-II 
activity, in the absence and presence of BMP ligands. Tacrolimus is currently 
prescribed after organ transplantation for immune suppression via the 
inhibition of calcineurin. However, it was also found to bind to FK-binding 
protein-12 (FKBP12), thus limiting FKBP12-mediated inhibition of BMP 
signalling (Spiekerkoetter et al. 2013). In both animal models of PAH and  cell 
culture experiments, tacrolimus was able to rescue EC dysfunction and tube 
formation, as well as reverse the development of pulmonary vascular lesions 
characterised by neointimal formations (Spiekerkoetter et al. 2013). 
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Tacrolimus is currently undergoing clinical trials to assess the benefit in PAH 
patients (Spiekerkoetter 2016), with low doses of tacrolimus appearing 
beneficial so far (Spiekerkoetter et al. 2015).  
Numerous other potential therapeutic targets have been identified (reviewed 
by Badlam and Bull 2017; Satoh et al. 2018), however as we know 
epoprostenol to have shown the most efficacy in improving life expectancy we 
propose investigating potential targets of prostanoids. Prostanoids act via 
cAMP elevation, and as cAMP has been shown to induce SOCS3 and limit IL-
6 signalling (Section 1.5), the potential of therapeutically targeting the IL-6 
signalling pathway was investigated. 
1.6.2.2 Targeting the IL-6 signalling pathway 
As discussed, IL-6 signalling activity plays a crucial role in the development of 
PAH (Section 1.4.2). Although, IL-6 has been discussed as a therapeutic target 
in PAH (reviewed by Pullamsetti et al. 2018; reviewed by Durham et al. 2019), 
there are no current guidelines to target IL-6 signalling in the treatment of PAH. 
Clinically approved JAK inhibitors, such as tociluzimab, and anti-IL-6 
therapies, such as tofacitinib and baracitinib, are currently used in the 
treatment of inflammatory diseases including rheumatoid arthritis and 
ulcerative colitis (Bonovas et al. 2018; Taylor 2019)   
There has been one reported example of a patient suffering from PAH 
associated with Castleman's disease where the patient (31 year old, female) 
was treated with tocilizumab in addition to steroids and conventional PAH 
therapy and demonstrated significant clinical improvement compared to 
conventional therapy alone (Arita et al., 2010). This supports the potential of 
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larger re-purposing studies to test the efficacy of anti-IL-6 therapies in the 
treatment of PAH, but also supports that targeting IL-6 may be an additional 
mechanism of action in prostanoid treatment of IL-6 which should be further 
explored.  
1.7 Hypothesis 
Taking all this into consideration, we propose that an important mechanism by 
which cAMP-mobilising prostanoid drugs limit PAH is by inhibiting IL-6-
mediated pulmonary inflammation and remodelling via cAMP-induced SOCS3 
inhibition of IL-6 mediated JAK/STAT signalling (Figure 1.9). Therefore, this 
study aims to further characterise the role of prostanoid-mediated inhibition of 













Figure 1.9: Hypothetical inhibition of IL-6 trans-signalling activity by 
prostanoid-mediated cAMP induction of SOCS3. 
We propose prostanoid drugs act via IP to elevate cAMP, inducing SOCS3 
gene transcription via an EPAC1 dependent, PKA independent mechanism. 
SOCS3 then inhibits IL-6 signalling via binding to the phosphorylated tyrosine 
759 residue of gp130, attenuating JAK activity and thus preventing further 
phosphorylation of gp130 and STAT3 molecules, thus reducing STAT3 gene 
transcription activity and the promotion of IL-6 mediated pro-inflammatory and 
pro-angiogenic genes that contribute to the development of PAH. cAMP; cyclic 
adenosine monophosphate, DUSP10; dual specificity phosphatase 10 
EPAC1; exchange protein directly activated by cAMP 1, gp130; glycoprotein-
130, ICAM1; intracellular adhesion molecule 1, IL-6; interleukin 6, IP; 
prostaglandin I2 receptor, JAK; janus kinase, KIR; kinase inhibitory region, 
PKA; protein kinase A (cAMP dependent protein kinase), SOCS3; suppressor 
of cytokine signalling 3, sIL-6Rα; soluble IL-6 receptor α, STAT3; signal 
transducer and activator of transcription 3, VEGF; vascular endothelial growth 
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FITC (Sigma Aldrich (Merck Biosciences, UK), Cat # FD40S) was kindly 
provided by Dr W. Roberts (School of Clinical & Applied Sciences, Leeds 
Beckett University). 
Sheep polyclonal anti-GFP serum was generously provided by Professor G. 
Milligan (Institute of Molecular Cell & Systems Biology, University of Glasgow) 
and was used in a 1 in 2000 dilution. 
2.2 Methods 
2.2.1 Cell culture 
All cells were cultured at 37⁰C, in 5% (v/v) CO2 in a humidified atmosphere 
using a cell culture incubator. HPAECs (cat. no. CC-2530) were purchased 
from Lonza. HPMECs (cat. no. C-12281) were purchased from Promocell. 
Both cell types originated from males aged 55 and 64 respectively. Angio-
sarcoma derived endothelial (AS-M.5) cells and AS-M.5 SOCS3 knockout cells 
(Krump-Konvalinkova et al. 2003) were kindly provided by Dr J.J.L. Williams 
(Institute of Molecular, Cell and Systems Biology, University of Glasgow) and 
Mr N.A.S. Alotaiq (Institute of Cardiovascular Medical Sciences, University of 
Glasgow) (Williams et al. 2018). 
2.2.1.1 Maintenance and passage of human pulmonary arterial 
endothelial cells 
HPAECs were maintained as monolayers in Endothelial Cell Growth Medium 
(EGM-2) which was purchased as a bulletkit comprising Endothelial Basal 
Medium (EBM-2) and EGM-2 SingleQuot Kit Supplement & Growth Factors 
and made up as recommended by the supplier. Cells were maintained in T75 
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tissue culture flasks and media was replenished every 48 hours. Cells were 
sub-cultured at approximately 80-90% confluency. 
For cell passage, medium was aspirated from the HPAEC monolayers which 
were then washed twice with 5 ml/flask of pre-warmed Dulbecco’s PBS. PBS 
was discarded and HPAECS were treated with 2 ml trypsin-EDTA at room 
temperature until cells detached, this was aided with gentle tapping. Cell 
detachment was monitored under the microscope. The trypsin was then 
inactivated via dilution with 10 ml EGM-2 and HPAECs were re-suspended by 
gentle trituration using a sterile 10 ml disposable pipette and transferred to a 
50 ml falcon tube. HPAECs were centrifuged at 500g for 5 minutes at room 
temperature to pellet cells and the supernatant was discarded. HPAECs were 
then re-suspended in 5–12 ml fresh EGM-2 and gently mixed using a sterile 5 
ml disposable pipette. 10 µl of the cell suspension was counted using a 
haemocytometer and the total number of cells was calculated. The desired 
number of cells were then seeded in the required tissue flasks and fresh EGM-
2 media was added to make a total volume of 12 ml, 3 ml or 2 ml in T75, 6 cm 
dish and 6-well plates respectively. HPAECs were not used past passage 10 
as cells developed an elongated morphology and lost their characteristic 
cobblestone appearance. Additionally, at passages greater than 10 HPAECs 
demonstrated slower growth and a reluctance to reach confluency. 
For cryogenic storage, cell pellets were prepared as previously described and 
then re-suspended in foetal bovine serum (FBS) supplemented with 10% (v/v) 
DMSO. Cells were immediately frozen at -80⁰C overnight before being 
transferred to liquid nitrogen. To thaw frozen cells, cell stocks were rapidly 
defrosted at 37⁰C and transferred in to a sterile T75 tissue culture flask 
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containing 12 ml of pre-warmed fresh media for incubation overnight to allow 
cells to attach. Media was replenished the following day and the cells were 
maintained as described above.  
2.2.1.2 Maintenance and passage of human pulmonary microvascular 
endothelial cells 
HPMECs were cultured and maintained in Endothelial Cell Growth Medium 
MV which was purchased as Endothelial Cell Growth Medium and Endothelial 
Cell Growth Medium supplement kit and made up as recommended by 
suppliers. Cells were maintained in sterile T25 tissue culture flasks in 10 ml 
media which was replenished every 3 - 4 days as required. Cells were sub-
cultured at approximately 70% confluency. Cell passage and cryogenic 
storage of HPMECs was completed using the same protocol described for 
HPAECs apart from 1 ml trypsin-EDTA was used to detach the cells and 5 ml 
Endothelial Cell Growth Medium MV supplemented with 10% FBS was used 
to inactivate the trypsin. HPMECs were not used past passage 7 as at 
passages greater than this it was observed cells were less able to attach to 
the cell culture flasks or grow to confluency. 
2.2.1.3 Cell culture of immortalised angiosarcoma derived endothelial 
cells 
 AS-M.5 cells (Krump-Konvalinkova et al. 2003) were cultured and maintained 
as described in section 2.2.1.1. The passage number of AS-M.5 cells was 




2.2.2 Transfection of cells 
2.2.2.1 Lentiviral titres 
Lentivirus titres of pLV[shRNA]-mCherry:T2A:Puro-U6>hSOCS3 and 
pLV[shRNA]-mCherry:T2A:Puro-U6>Scramble shRNA were performed by F. 
Moshapa (School of Pharmacy and Medical Sciences, University of Bradford) 
in human embryonic kidney (HEK) 293 cells to determine optimum 
transduction concentration. 6-well plates were seeded with HEK 293 cells at a 
density of 2x105 cells per well in Dulbecco Modified Eagle Medium (DMEM)-
high glucose containing 10% (v/v) FBS, 2 mM L-glutamine, 100 units penicillin 
and 0.18 mM streptomycin in 0.9% NaCl and incubated overnight in the cell 
culture incubator.   
Serial dilutions of pLV[shRNA]-mCherry:T2A:Puro-U6>hSOCS3 and 
pLV[shRNA]-mCherry:T2A:Puro-U6>Scramble shRNA lentivirus were 
prepared ranging from 1x10-2 - 1x10-6 in polybrene (8 μg/ml)-containing media. 
Media was then gently aspirated from the cells and replaced by 1 ml of the 
relevant lentivirus dilutions. The 6-well plates were then gently rocked to mix 
the virus evenly and incubated overnight in the cell culture incubator, before 
replacing the lentiviral media with fresh media containing the relevant 
antibiotic. Cells were then maintained in antibiotic-supplemented media for 10 
days before washing with PBS and adding 1 ml of crystal violet solution prior 
to incubation for 10 minutes at room temperature. The crystal violet solution 
was then removed and cells were washed 3 X with PBS prior to counting the 
blue stained colonies at 40x magnification. The lentiviral titre was then 
calculated by multiplying the number of colonies per well by the dilution factor, 
and expressed as transforming units per ml (TU/ml). 
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Lentiviral titre of pLV(Exp)-EGFP:T2A:puro-EFIA>mcherry ultra-purified and 
pLV(Exp)-Puro-CMV-0RF_705bp was performed by Dr J.J.L. Williams 
(Institute of Molecular, Cell and Systems Biology, University of Glasgow) in the 
same method described above. 
2.2.2.2 Lentiviral infection 
HPAECs were maintained in 6 cm dishes until reaching approximately 70% 
confluency. Polybrene (8 μg/ml)-containing DMEM was prepared and 1 ml was 
aliquoted in to sterile 1.5 ml tubes. The lentivirus was then thawed at room 
temperature and mixed via gentle tapping. Appropriate volume of virus particle 
was added to 1 ml polybrene-containing media and mixed by gentle pipetting 
with a 1000 µl pipette. Media was then aspirated from the cells and replaced 
with the virus/polybrene-containing DMEM. Cells were incubated overnight in 
the cell culture incubator before removal of media. Cells were then incubated 
in the cell culture incubator for a further 24 hours in 2 ml of fresh Endothelial 
Cell Growth Medium MV prior to any further treatments. 
Transduction efficiency was monitored via imaging of GFP expression in cells. 
HPAECs were seeded in Nunc™ Lab-Tek™ Chambered Coverglass at a 
density of 2x105 cells per chamber and left to incubate overnight. Cells were 
then infected with pLV(Exp)-EGFP:T2A:puro-EFIA>mcherry as described 
above prior to fixation via incubation in methanol for 10 minutes at -20⁰C. Cells 
were then washed with 500 µl ice-cold 0.1% v/v triton/PBS for 5 minutes prior 
to 2 X 5 minute washes in 500 µl PBS at room temperature. HPAECs were 
counterstained via 20 minutes incubation with 500 µl 1 µM Hoechst 33342 in 
PBS at room temperature prior to 3 X 5 minutes washes in 500 µl PBS at room 
temperature. Cells were fluorescently imaged to visualise GFP expression 
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using a Nikon ECLIPSE TE2000-E confocal microscope. Images were taken 
at 400x magnification with a large pinhole, a pixel dwell of 20 millisecond and 
an average of 4 using EZ-C1 3.90 software. For representative figures, an 
image was taken from each chamber and a 5 cm x 5 cm section of the image 
was cropped from the centre of the image using EZ-C1 3.90 freeviewer 
software. 
2.2.2.3 siRNA transfection 
HPAECs were maintained in 6 cm dishes until reaching approximately 70% 
confluency. siRNAs were stored at -20°C at 10 µM. Appropriate volumes of 
siRNA and 3 μl HiPerFect were added to Opti-MEM media to make 100 μl total 
volume of 0.2 – 2 µM siRNA and left to incubate at room temperature for 10 
minutes. A further 900 μl of OPTIMEM media was then added and mixed via 
pipetting before adding the mix to the cells. After 3 hours a further 1 ml of EGM-
2 media was added to the cell culture dish. Further treatments were then 
applied after 48 hours. 
2.2.2.4 Short hairpin (sh)RNA infection 
For silencing of SOCS3, HPAECs were maintained in 6 cm dishes until 
reaching 50 - 70% confluency. Polybrene (8 μg/ml)-containing DMEM was 
prepared and 1 ml was aliquoted in to sterile 1.5 ml tubes. pLV[shRNA]-
mCherry:T2A:Puro-U6>hSOCS3 and pLV[shRNA]-mCherry:T2A:Puro-
U6>Scramble shRNA lentivirus were thawed at room temperature and mixed 
via gentle tapping. A full summary of the shRNA vectors can be found in 
Appendix 1 and Appendix 2 respectively. Appropriate volume of virus particle 
was added to 1 ml polybrene-containing media and mixed via vortexing for no 
longer than 1 second. Media was then aspirated from the cells and replaced 
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with the shRNA/polybrene-containing DMEM. Cells were incubated overnight 
in the cell culture incubator before replacing the shRNA-containing media with 
Endothelial Cell Growth Medium MV. Cells were then maintained in the cell 
culture incubator for 5 - 7 days prior to any further treatments. 
To monitor shRNA infection, treated HPAECs were imaged for mCherry 
expression. Cells were seeded in Nunc™ Lab-Tek™ Chambered Coverglass 
at a density of 20,000 cells per chamber and left to incubate overnight. The 
lentivirus was then prepared at appropriate concentrations and applied to cells 
as previously described. Cells were incubated for 5 days prior to fixation via 
incubation in methanol for 10 minutes at -20⁰C. Cells were then washed with 
500 µl ice-cold 0.1% v/v triton/PBS for 5 minutes prior to two 5 minute washes 
in 500 µl PBS at room temperature. HPAECs were counterstained via 20 
minutes incubation with 500 µl 1µM Hoechst 33342 in PBS at room 
temperature prior to three 5 minutes washes in 500 µl PBS at room 
temperature. Cells were fluorescently imaged to visualise mCherry expression 
using a Nikon ECLIPSE TE2000-E confocal microscope. Images were taken 
at 400x magnification with a medium pinhole, a pixel dwell of 20 millisecond 
and an average of 4 using EZ-C1 3.90 software. For representative figures, an 
image was taken from each chamber and a 5cm x 5cm section of the image 





2.2.3 Protein analysis 
2.2.3.1 Immunoblot analysis 
Whole cell lysate preparation 
HPAECs and AS-M.5 cells were seeded and maintained in 6 cm dishes, except 
for siRNA and shRNA experiments where cells were maintained in 6-well 
plates. HPMECs were seeded and maintained in 6-well plates only. Post-
treatment, cell stimulations were stopped by transferring the cell dishes to an 
ice bath, discarding the media and washing monolayers twice with ice-cold 
PBS. Cells were then harvested in to 500 μl ice-cold PBS for 6-well plates or 
800 μl ice-cold PBS for 6 cm plates and centrifuged at 500 g for 5 minutes at 
4°C. A 200 μl pipette tip was used to remove all supernatant without disturbing 
the pellet and cells were lysed in 40 - 100 μl of RIPA+ (50 mM HEPES pH 7.4, 
150 mM sodium chloride, 1% (v/v) Triton x100, 0.5% (v/v) sodium 
deoxycholate, 0.1% (w/v) SDS, 10 mM sodium fluoride, 5 mM EDTA, 10 mM 
sodium phosphate, 0.1 mM PMSF, 10 μg/ml benzamidine, 10 μg/ml soybean 
trypsin inhibitor, 2% (w/v) EDTA-free complete protease inhibitor cocktail) and 
vortexed to mix for no longer than 2 seconds. When required, lysates were 
stored at this point at -80⁰C in 1.5 ml microcentrifuge tubes and thawed before 
analysis. Samples were rotated at 4°C for 30 minutes and centrifuged at 
20,000g for 15 minutes at 4°C to remove insoluble cellular debris. Without 
disturbing the pellet, the supernatant was transferred in to a fresh 





Determination of protein content 
Protein content was then determined via a bicinchoninic acid (BCA) assay. 2 - 
5 µl of the supernatant were added to the relevant wells on a 96-well plate and 
made up to a total volume of 10 µl with RIPA+ buffer (as previously described). 
A standard curve of protein concentrations (0 - 2 mg/ml) was prepared using 
appropriate volumes of 2 mg/ml BSA made up in RIPA+ buffer to a total volume 
of 10 µl. All assays were performed in duplicate.  
49 parts BCA reagent (1% (w/v) 4,4-dicarboxy-2,2-biquinoline disodium salt, 
2% (w/v) anhydrous sodium carbonate, 0.16% (w/v) sodium potassium 
tartrate, 0.4% (w/v) sodium hydroxide and 0.95% (w/v) anhydrous sodium 
bicarbonate) was mixed with 1 part 4% (w/v) copper (II) sulphate. 200 μl of this 
solution was added to each well and the colour change monitored by 
determining the absorbance at 560 nm Biorad iMARK microplate absorbance 
reader until the most concentrated standard dilution gave a reading of 700 - 
800. The absorbance of each supernatant was determined at 560 nm and the 
protein content calculated using the equation of the best fit straight line as 
calculated by the A560 values of the standard dilutions.  
SDS PAGE and transfer 
Samples were equalised for protein content (10 - 50 μg) based on the results 
obtained from the BCA assay and volumes equalised by adding the required 
amount of RIPA+ buffer. SDS-loading buffer (50 mM Tris pH 6.8 at room 
temperature, 10% (v/v) glycerol, 12% (w/v) SDS, 100 mM dithiothreitol, 0.2% 
(w/v) bromophenol blue) was added to denature cellular proteins. Samples 
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were then heated at 70⁰C for 30 seconds before being centrifuged for 30 
seconds to recover any condensation. 
8%, 10% or 12% (w/v) acrylamide resolving gels (Appendix 3) were prepared 
beforehand when possible and stored at 4°C. Samples were loaded on to the 
gel and separated via electrophoresis at 100-180 V in Tris-Glycine-SDS buffer 
(24.7 mM Tris, 0.19 M glycine). 
Fractionated proteins were then transferred electrophoretically to a 0.2 μm 
diameter Protran nitrocellulose membrane for 45 minutes at 400 mA in transfer 
buffer (24.7mM Tris, 0.19 M glycine and 20% (v/v) methanol). When 
transferring proteins greater than 200 kDa, transfer was performed for 90 
minutes at 400 mA in transfer buffer (as previously described). 
Immunoblotting 
To prevent non-specific antibody binding, membranes were incubated for 1 
hour with 5% (w/v) non-fat milk powder made up in TBST (Tris-buffered saline 
(TBS), pH 7.6 at room temperature, containing 0.1% (v/v) Tween 20) (TBST-
M) or 5% (w/v) BSA - TBST. Membranes were then incubated overnight with 
the appropriate primary antibody as described in Table 2.1 at 4⁰C on a rotator. 
Following incubation, membranes were washed for 3 x 10 minutes in 30 ml 
TBST and incubated for one hour on a rotator at room temperature with the 
appropriate secondary horseradish peroxidase (HRP)-conjugated antibody as 
described in Table 2.1. Membranes were then washed in 30 ml TBST for 3 X 
10 minutes before 1 minute incubation in Western Lightning® Plus, Enhanced 
Chemiluminescence Substrate or 1.5 minutes incubation in WESTAR 









Flag M2 Mouse 
Sigma/ 
Merck 
F3165 5% TBST-M 1:1000 
GAPDH Mouse Abcam ab8245 5% TBST-M 
1:10000 – 
1:20000 
GFP Sheep - - 5% TBST-M 1:1000 - 1:2000 
Nur77 Rabbit SCBT sc-990 5% TBST-M 1:200 – 1:500 
P(Tyr705)-
STAT3 
Rabbit CST 9131 
5% BSA - 
TBST 
1:200 -1:1000 
SOCS3 Goat SCBT sc-7009 5% TBST-M 1:100 – 1:500 
SOCS3 Rabbit Abcam ab16030 5% TBST-M 1:500 – 1:1000 
STAT3 Rabbit Abcam ab68153 5% TBST-M 1:500 - 1:1000 
Tubulin Mouse DSHB 12G10 5% TBST-M 
1:1000 – 
1:10000 
VEGFR2 Goat NB AF357-SP 5% TBST-M 1:1000 
VCAM1 Rabbit CST 12367 5% TBST-M 1:1000 
Table 2.1: Description of antibodies used in immunoblotting 
CST; Cell Signalling Technology, DSHB; Developmental Studies Hybridoma 
Bank, GAPDH; glyceraldehyde 3-phosphate dehydrogenase, NB; Novus 
Biologicals, SCBT; Santa Cruz Biotechnology, SOCS; suppressor of cytokine 
signalling, STAT; signal transducer and activator of transcription, TBST-M; 5% 
(w/v) non-fat milk powder in tris-buffered saline containing 0.1% (v/v) Tween 
20. AM1; vascular cell adhesion molecule 1, VEGFR2; vascular endothelial 
growth factor receptor 2. 
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using a Biorad ChemiDoc MP Imaging System. Immunoblots were quantified 
via densitometry performed using LI-COR Image Studio Lite Ver 5.2. The 
protein band of interest was then normalised to the loading control to correct 
for any loading errors and results were expressed as a % change from the 
vehicle control unless described otherwise. 
2.2.3.2 VEGF enzyme-linked immunosorbent assay (ELISA) 
HPAECs were maintained in 6-well plates until 80% confluency was reached, 
and then incubated in EGM-2 media containing no VEGF 2 hours prior to 
treatment to reduce background VEGF expression. Treatments were 
administered in 1 ml EGM-2 media containing no VEGF, a smaller volume was 
used to reduce dilution of VEGF protein. The experiment was attenuated via 
removal and storage of the media at -80⁰C. Analysis of VEGF protein in the 
media was performed using a Human VEGF-A Platinum ELISA according to 
the manufacturer’s instructions. Microwell strips were washed twice with 400 
µl wash buffer per well for 10 seconds with care being taken to thoroughly 
aspirate media between washes. Excess buffer was removed by gently 
tapping the microwell strips on absorbent paper towels. A human VEGF-A 
standard dilution was then prepared and 100 µl of each dilution was pipetted 
into the relevant wells. 50 µl or 100 µl of sample diluent was added to sample 
well or blank wells respectively prior to 50 µl of sample being added to 
appropriate sample wells. All samples and standards were performed in 
duplicate. The wells were then covered with an adhesive film and incubated at 
room temperature for 2 hours on a shaker (400 rpm). Biotin-conjugate was 
prepared via the addition of 60 - 120 µl Biotin-conjugate solution to 5.94 - 11.88 
ml 1X Assay Buffer depending on the number of microwell strips being used. 
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Microwell strips were then washed 6 X as previously described. 100 µl of 
Biotin-Conjugate was then added to each well before covering the wells with 
an adhesive cover and incubating for 1 hour as previously described. During 
incubation, Streptavidin-HRP was prepared via the addition of 60 - 120 µl 
Streptavidin-HRP solution to 5.94 - 11.88 ml 1X assay buffer depending on the 
number of microwell strips being used. Post-incubation, microwell strips were 
washed 6 X as previously described and 100 µl of Streptavidin-HRP was 
added to each well before covering the wells with an adhesive cover and 
incubating for 1 hour before washing the microwell strips 6 X as previously 
described. 100 µl of TNB Substrate Solution was then pipetted into all wells 
and the microwell strips incubated at room temperature for 30 minutes or until 
the highest standard developed a dark blue colour, with care being taken to 
not expose the microwell strips to intense light. The reaction was then 
quenched by adding 100 µl Stop Solution into each well. Absorbance of each 
well at 450 nm was then measured immediately using a NanoDrop ND-1000 
Spectrophotometer. 
2.2.4 Analysis of RNA 
2.2.4.1 Plasmid DNA preparation and quantification 
The DNA plasmid (Table 2.2) were purchased as lyophilised plasmid and re-
suspended in sterile water according to manufacturer’s instructions before 
storage at -20⁰C. Plasmids were amplified by transforming XL1-Blue E.coli via 
heat shock treatment. This involved adding 500 ng of DNA to 50 μl of thawed 
competent cells and incubating on ice for 30 minutes, then incubating at 42⁰C 
for 90 seconds in a water bath, immediately followed by incubation on ice for 






















Table 2.2: Description of DNA plasmids 
AR; antibiotic resistance: Amp; ampicillin, NECB; National Center for 
Biotechnology Information, SB; sino-biological, VEGF-T3; vascular 
endothelial growth factor transcript 3. 
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(w/v) yeast extract, 1% (w/v) NaCl) was then added to the cells and the 
suspension incubated in a 37⁰C shaker for 45 minutes. Cells were then 
centrifuged at 1000 g for 5 minutes after which the volume of media was 
reduced to the appropriate amount (1 ml/glycerol stock plus 100 µl/LB-agar 
plate). The cells were then re-suspended. To make glycerol stocks, 400 μl of 
autoclaved sterile 50% (v/v) glycerol was mixed with 1 ml of the resulting LB 
media and stored at -80⁰C. 100 μl of the remaining LB media was spread under 
aseptic conditions onto LB-agar plates supplemented with ampicillin (50 μg/ml) 
and incubated overnight at 37⁰C. If necessary, plates were then stored at 4⁰C 
until required, though no longer than 6 weeks. A starter culture was prepared 
by picking of a single colony from the agar plate and inoculating 5 ml in LB 
media with relevant selection antibiotic (Ampicillin (50 μg/ml)) in a 37⁰C shaker 
overnight. For a culture from glycerol stocks, 5 ml of LB media supplemented 
with the relevant antibiotic was inoculated with a stab of glycerol stock and 
incubated overnight in a 37⁰C shaker. 
Plasmid DNA was then extracted using the Promega Wizard Plus Miniprep 
DNA Purification System following the manufacturer’s instructions. The 
overnight culture was centrifuged for 5 minutes at 10,000g and the resulting 
pellet was thoroughly resuspended in 250 μl Cell Resuspension Solution. 250 
μl of Cell Lysis Solution was then added to the suspension which was inverted 
4 X to mix. 10 μl of Alkaline Protease Solution was added and mixed as 
previously described. To cease the reaction, 350 µl of Neutralizing Solution 
was added to each sample and mixed as previously described. The solution 
was then centrifuged at maximum speed for 10 minutes at room temperature 
which resulted in the production of a clear lysate. This was decanted into a 
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spin column which had previously been inserted in to a collection tube, which 
was centrifuged at maximum speed for 1 minute at room temperature. Wash 
Solution was then prepared by the addition of 35 ml 95% ethanol to the Column 
Wash Solution. 750 μl of Wash Solution was added to the spin tube prior to 
centrifugation at maximum speed for 1 minute at room temperature. This was 
then repeated with 250 μl of Wash Solution. The spin tube, still inserted in a 
collection tube, was then centrifuged at maximum speed for 2 minute at room 
temperature. The spin column was then transferred to a sterile 1.5 ml 
centrifuge tube and centrifuged at maximum speed for 1 minute at room 
temperature to remove any excess Wash Solution prior to being transferred in 
to a fresh sterile 1.5 ml centrifuge tube. 100 μl of nuclease-free water was 
added to spin column which was centrifuged at maximum speed for 1 minute 
at room temperature. The concentration of the resulting DNA was measured 
via UV absorbance at 260nm/280nm (A260/280) on a Thermo Scientific™ 
NanoDrop Lite Spectrophotometer. A260/280 values greater than 1.8 were 
considered suitable for analysis. Plasmid DNA was stored at -80⁰C. 
2.2.4.2 Restriction enzyme digestion 
Restriction enzyme digestion was performed according to the Promega 
Assembly of Restriction Enzymes Digestions protocol. All stages were 
performed on ice. 1 μg DNA was added to 2 μl of the appropriate 10X reaction 
buffer and 0.2 μl of acetylated BSA (10 μg/ul). The volume was made up to a 
total of 19.5 μl with sterile, deionized H2O which was mixed via pipetting. 0.5 
μl of restriction enzyme (10 u/μl) was then added before mixing gently with a 
pipette and centrifuged at 10,000g for 5 seconds before incubation at 37°C for 
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4 hours. Promega Blue/Orange 6x Loading Dye was then added to a final 
concentration of 1x and agarose gel analysis was performed. 
2.2.4.3 RNA purifcation 
HPAECs were seeded and maintained in 6 cm dishes until 80% confluent. 
Post-treatment RNA was isolated using a Qiagen RNeasy micro kit according 
to the manufacturer’s instructions. Medium was removed from the HPAECs 
which were then lysed directly into 600 µl Buffer RLT. The lysate suspension 
was transferred into a microcentrifuge tube and mixed using a 1000 µl pipette 
tip until no cell clumps were visible. The lysate was then passed 10 times 
through a 20-gauge needle (0.9 mm diameter) using a RNase-free syringe. 
500 - 600 µl (equal amount to the volume of lysate) 70% ethanol was then 
added to the lysate and mixed using a 1000 µl pipette tip. The lysate was then 
transferred to a RNeasy spin column placed in a 2 ml collection tube at a 
maximum of 700 µl at a time and centrifuged at 10,000g for 15 seconds at 
room temperature. The flow-through was discarded after each centrifugation. 
700 µl Buffer RW1 was then added to the spin column prior to centrifugation 
at 10,000g for 15 seconds at room temperature. The flow through was 
discarded and 350 µl Buffer WB1 was added to the spin column before 
centrifugation at 12,000g for 15 seconds at room temperature. To reduce the 
risk of DNA contamination a PureLink™ DNase Set was utilised. The spin 
column was then transferred to a fresh collection tube prior to the addition of 
80 µl DNase mix (8 µl DNase Buffer, 10 µl DNase, 62 µl RNase-free water) 
and incubated at room temperature for 15 minutes. RNA purification was then 
continued using the Qiagen RNeasy micro kit. 350 µl Buffer RW1 was then 
added to the spin column which was centrifuged at 12,000 g for 15 seconds at 
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room temperature prior to being transferred to a fresh collection tube. 500 µl 
Buffer RPE containing ethanol (made up as described in the manufacturer’s 
instructions) was added to the spin column. The spin column was centrifuged 
at 10,000g for 15 seconds at room temperature before a final wash with 500 
µl Buffer RPE and centrifugation at 10,000g for 2 minutes at room temperature. 
The spin column was then transferred into a fresh collection tube and 
centrifuged at top speed for 1 minute prior to transferring the spin column into 
a new collection tube. 40 µl RNase-free water was then added to the spin 
column which was centrifuged for at 10,000g for 1 minute at room temperature. 
The concentration of RNA was determined via UV absorbance at 260 nm 
(A260). The purity of RNA was calculated as a ratio of A260:A280, with a ratio 
of 2.0 indicating RNA purity. RNA was then made up to a concentration of 2 
µg/10µl in RNase-free water and stored at -80⁰C. 
Purified RNA was reverse transcribed using an Applied Biosystems high-
capacity cDNA reverse transcription kit according to the manufacturer’s 
instructions. 10 µl 2x reverse transcriptase mastermix (2 µl 10x RT buffer, 0.8 
µl 25x 100 Mm dNTP mix, 2 µl 10x RT random primer, 1 µl Multiscribe reverse 
transcriptase, 1 µl RNAse inhibitor, 3.2 µl nuclease-free water) was added to 
10 µl of 2 µg/10 µl RNA sample. Reverse treanscription was then performed 
in a Techne Progene thermal cycler at 25⁰C for 10 minutes, 37⁰C for 2 hours 
and then 85⁰C for 5 minutes to produce cDNA which was then made up to a 
concentration of 10 ng/ml in RNase-free water and stored at -80⁰C. When 
measuring SOCS3 mRNA this was repeated with all samples in the absence 
of Multiscribe reverse transcriptase to ensure no contaminating genomic DNA 
was present. When measuring VEGF mRNA the IL-6/sIL-6Rα sample was 
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always repeated in the absence of Multiscribe reverse transcriptase to ensure 
no contaminating genomic DNA was present. 
2.2.4.4 Polymerase chain reaction 
1 μl of cDNA (10 ng/μl) was added to a PCR mix consisting of 5 μl Pfu buffer, 
1 μl dNTP mix (10 mM), 1 μl sense primer (25 pmol/μl) (Table 2.3), 1 μl 
antisense primer (25 pmol/μl) (Table 2.3), 0.42 μl Pfu thermostable DNA 
polymerase and 40.58 μl nuclease-free water to make a total volume of 50 μl. 
PCR was then performed in a Techne Progene thermal cycler. VEGF primer 
sequences were taken from Medford et al. (2009) and checked using Clustal 
Omega multiple sequence alignment program. Initial denaturation was at 94⁰C 
for 2 minutes, followed by 35 cycles of denaturation at 94⁰C for 1 minutes, 
annealing at 43⁰C for 0.5 minutes and extension at 72⁰C for 3 minutes, 
followed by a final extension at 72⁰C for 5 minutes. The resulting PCR mix was 
stored at 4⁰C for short term use or -20⁰C for long term storage before analysis 
by agarose gel electrophoresis.  
2.2.4.5 Agarose gel electrophoresis 
 Agarose gels were prepared at either 1% (w/v), 1.5% (w/v) or 2% (w/v) 
agarose concentrations (Appendix 4) in 1X TAE buffer (40 mM Tris, 20 mM 
acetate, 1 mM EDTA, pH 8.6 at room temperature). SYBR safe was 
incorporated in to the agarose gel at a final concentration of 1X as per 
manufacturer’s instructions to enable visualisation of nucleic acids under UV 
illumination. 2 μl Promega Blue/Orange 6x Loading Dye was added to 10 μl 
PCR product which was mixed via pipetting and loaded onto the gel. Samples 












Table 2.3: Polymerase chain reaction primer sequences 
Vascular endothelial growth factor A (VEGF-A) 
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fractionation was visualised under UV light and captured using a Biorad 
ChemiDoc MP Imaging System. 
2.2.4.6 Real-time quantitative PCR 
1 μl of cDNA (10 ng/μl) was added to 10 μl of Taqman Universal Master MixII, 
no uracil-N-glycosylase (UNG), 1 μl of the relevant probe and 8 μl of RNase 
free H2O to make a total volume of 20 μl which was then added to wells on a 
96-well plate. The 96-well plate was then sealed with optical adhesive film and 
centrifuged for 30 seconds. Real-time quantitative (q)PCR was then carried 
out using Stepone software according to the manufacturer’s instructions.  The 
cycle conditions for real-time qPCR were 95°C for 15 minutes, followed by 40 
cycles of 95°C for 15 seconds, and 60°C for 1 minute.  All assays were 
performed in duplicate. RNase-free water was used as a negative control. 
Average CT values were calculated for each sample and normalised to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) which was used as a 
loading control. The amount of RNA was then calculated as a % of the 
maximum SOCS3 mRNA level. 
2.2.5 Analysis of cell permeability 
2.2.5.1 FITC-dextran in vitro vascular permeability assay 
Collagen-coated transwell inserts were seeded with HPAECs at a density of 
1x106 cells/well and placed inside a receiver well containing EGM-2. The cells 
were then incubated overnight in the cell culture incubator. The same plates 
were then seeded with a further 1x106 cells and incubated for a further 48 
hours to ensure monolayer confluency. EGM-2 media containing relevant 
treatments were then applied to the receiver wells and the cells left to incubate 
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for the appropriate time before removing treatment media from the wells. 75 µl 
of 250 mg/ml high molecular weight FITC-dextran diluted in EGM-2 medium 
was added to each transwell insert. 250 µl EGM-2 medium alone was added 
to the receiver well. Cells were incubated for 45 minute in the cell culture 
incubator before the incubation was terminated by removing the inserts from 
the receiver well. Whilst being careful to protect the receiver medium from light 
to prevent photobleaching, the receiver medium was thoroughly mixed and 
100 µl transferred to a 96-well opaque plate for fluorescence measurement at 
485 nm excitation/535 nm emission wavelengths on a GloMax® GM3000 
Luminescence Detection Plate Reader. All measurements were taken in 
duplicate with the mean value used for statistical analysis. 
2.2.5.2 Fluorescent imaging of VE-cadherin 
HPAECs were seeded on to 4-well Nunc™ Lab-Tek™ chambers at 1x105 cells 
and incubated for 2 - 3 days in the cell culture incubator to reach 100% 
confluency. Post-treatment HPAECs were fixed via incubating in absolute 
methanol at -20⁰C for 10 minutes immediately after completion of treatments. 
Cells were then washed with 500 µl ice- cold 0.1% v/v triton/PBS for 5 minutes 
prior to 2 5 minute washes in 500 µl PBS at room temperature. Cells were then 
blocked via incubation for 1 hour at room temperature in 1% (w/v) BSA, 2.96 
M glycine in PBST (PBS + 0.1% (v/v) Tween 20) before overnight incubation 
in 500 µl/well 2 μg/ml anti-VE Cadherin antibody in 1% (w/v) BSA in PBST at 
4⁰C. Cells were then washed with 500 µl PBS room temperature 3 X 5 minutes 
per wash before incubation in 4 μg/ml Alexa Fluor 568-conjugated goat anti-
rabbit IgG (H+L) cross-adsorbed secondary antibody, for 1 hour in the dark at 
room temperature. The secondary antibody was then removed, and the cells 
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washed with PBS at room temperature 3 X 5 minutes per wash prior to 20 
minutes incubation with 500 µl 1 µM Hoechst 33342 in PBS at room 
temperature. Cells were then washed for 3 X 5 minutes in 500 µl ice-cold PBS 
before either being immediately imaged or stored in the dark at 4⁰C in 500 µl 
PBS for no longer than 24 hours prior to imaging using a Nikon ECLIPSE 
TE2000-E confocal microscope. Images were taken at 400x magnification with 
a large pinhole, a pixel dwell of 20 millisecond and an average of 4 using EZ-
C1 3.90 software. 3 images were taken for each treatment, 1 from the left, 
centre and right of each chamber. For representative figures, a 5 cm x 5 cm 
section of the image was cropped from the centre of the image using EZ-C1 
3.90 freeviewer software. 
2.2.6 Analysis of cell membrane stability  
AS-M.5 WT and SOCS3 KO cells were seeded at a density of 6x104 – 1x105 
cells and incubated overnight prior to treatment with either EGM-2 medium or 
hypotonic EGM-2 medium (1 part EGM-2 medium:9 parts sterile H2O) 
containing SYTOX™ Green Nucleic Acid Stain (167 nM) and Wheat Germ 
Agglutinin (WGA), Alexa Fluor™ 594 Conjugate (1 µg/ml) for the appropriate 
before 2 X 5 minute washes in Hank’s balanced salt solution (HBSS). EGM-2 
medium was then added to the cells prior to immediate imaging on a Nikon 
ECLIPSE TE2000-E confocal microscope. Images were taken at 200x 
magnification with a medium pinhole, 8.64 millisecond pixel dwell and average 
of 2. Images were then exported in tif format for red and blue channels only to 
measure WGA fluorescence, and green channels only to measure SYTOX 
fluorescence, and analysed using ImageJ software. Average background 
density was calculated from three raw integrated density measurements. The 
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total raw integrated density was then measured and used to calculate the 
corrected total cell fluorescence (CTCF) via the following equation. 
CTCF = integrated density – (area of selected cell X mean fluorescence of 
background readings) 
The CTCF was calculated for all 3 images of each chamber and an average 
CTCF calculated. For each treatment, the CTCF value for SYTOX was then 
normalised against the CTCF value for WGA to correct for different cell density. 
2.2.7 Statistical Analysis 
All results were analysed by one-way analysis of variance followed by 
Bonferroni post-hoc test. Statistical analysis was performed using Graphpad 




3. Prostanoids induce SOCS3 protein expression in endothelial cells.  
3.1 Introduction  
PGI2 was first identified in the pulmonary arterioles where it inhibited platelet 
aggregation (Moncada et al. 1976). It was later determined that PGI2 was also 
able to induce vasodilation (Dusting et al. 1978), therefore making it a prime 
drug target in vascular disorders. Reduced PGI2 is characteristic of PAH 
(Section 1.3.4.1) and consequentially, prostanoid drugs which act by re-
establishing PGI2 signalling are currently used in the treatment of PAH (Del 
Pozo et al. 2017) (Section 1.6.1). 
Although treatment options for PAH are limited, the prostanoid epoprostenol 
has shown some success in improving survival rates (Sitbon et al. 2002) and 
other prostanoids, such as BPS and treprostinil, have shown to be beneficial 
in improving exercise capacity and QOL (Simonneau et al. 2002; Barst et al. 
2003).  
With the exception of elevating cAMP to stimulate PKA-induced vasodilation, 
the mechanisms by which prostanoid-activated pathways improve patient 
survival rates have not been fully determined. As previously mentioned 
(Section 1.5), cAMP also induces SOCS3, an inhibitor of IL-6 induced JAK-
STAT signalling (Sands et al. 2006; Yarwood et al. 2008), and there is growing 
evidence to support that IL-6 is a key factor in PAH development (Section 
1.4.2). 
To induce vasodilation, prostanoid drugs stimulate IP on SMCs, however the 
effects of prostanoids on ECs is yet to be fully investigated. Thus, to establish 
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if VECs respond to prostanoids and express SOCS3 protein, HPAECs were 
treated with BPS, treprostinil and the selexipag metabolite, ACT-333679. 
HPAECs were chosen as an ideal cell line as in vivo they are heavily involved 
in the vascular remodelling characteristic of PAH and, as HPAECs border the 
arterial lumen, they are ideally located as a potential drug target. SOCS3 
protein was measured to establish if prostanoids are capable of inducing 
SOCS3 expression in these cell types, as SOCS3 is a key negative regulator 
of IL-6 signalling activity (Section 1.4.3) (reviewed by Babon et al. 2014). 
3.2 Results 
3.2.1 Beraprost-mediated induction of SOCS3 
BPS is currently used for the treatment of PAH and has been discussed in 
Section 1.6.1. To investigate the effect of BPS on SOCS3 protein expression, 
HPAECs were treated with 10 μM BPS alongside 6 μM MG-132 at 0.5 hours, 
1, 2, 4 and 8 hours. Due to the high turnover of SOCS3 protein via proteasomal 
degradation (Siewert et al. 1999; Haan et al. 2003), treatment with the 
proteasome inhibitor MG-132 (6 μM) was used to inhibit the degradation of 
SOCS3 when measuring SOCS3 protein expression (Haan et al. 2003; Wiejak 
et al. 2013). As Fsk, which directly binds and activates AC isoforms (Seamon 
et al. 1981), has previously been shown to induce SOCS3 (Woolson et al. 
2009; Wiejak et al. 2013; Piao et al. 2014; Wiejak et al. 2019), Fsk (50 μM) in 
combination with MG-132 (6 μM) was used as a positive control for SOCS3 
induction. MG-132 (6 μM) alone was used as a negative control. Cells were 
then harvested and lysed as previously described (Section 2.2.3.1) before 
protein content was determined. Immunoblotting was carried out and the 
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membranes were probed for SOCS3. STAT3 used as a loading control for 
protein content. Nur77, which is the product of a gene upregulated by cAMP 
via a PKA/cAMP responsive element binding protein (CREB)-dependent 
mechanism independent of EPAC1 (Fass et al. 2003; Hamid et al. 2008; Martin 
et al. 2008; Martin et al. 2009), was used as a positive control to ensure cAMP-
mobilising drugs were active for experiments investigating cAMP-mediated 
changes in protein expression.  
Fsk alongside MG-143 produced a significant accumulation of SOCS3 and 
Nur77 after 4 hours of treatment. A time-dependent transient increase of 
SOCS3 protein expression occurred post-BPS treatment which was significant 
after 2 hours and 4 hours of treatment (Figure 3.1), whilst Nur77 protein 
expression was significantly increased after 2 hours only. Although increased 
at 1 and 8 hours after BPS treatment, expression of SOCS3 was not significant 
at these time points. As 2 hours of BPS treatment significantly increased 
SOCS3 protein expression, cells were treated for 2 hours with BPS for all 
future experiments unless stated otherwise. 
3.2.2 Treprostinil-mediated induction of SOCS3 
Treprostinil is currently approved worldwide for the treatment of PAH and has 
been discussed in Section 1.6.1. To investigate the effect of treprostinil on 
SOCS3 protein expression, HPAECs were treated with 10 μM treprostinil for 1 
hour, 2 and 4 hours alongside MG-132 (6 μM). 4 hours treatment with Fsk (50 
μM) alongside MG-132 (6 μM) was used as a positive control. 4 hours 

















Figure 3.1: Beraprost-mediated time-dependent induction of 
SOCS3 
HPAECS were treated with beraprost sodium salt (BPS) (10 μM) for 0.5 hours, 
1, 2, 4 and 8 hours in the presence of MG-132 (6 μM). 4 hour treatment with 
forskolin (Fsk) (50 μM) and MG-132 (6 μM) was used as a positive control. 4 
hour treatment with MG-132 (6 μM) only was used as a negative control. 
Whole cell lysates were equalised for protein content and resolved via SDS-
PAGE for immunoblotting with the indicated antibodies. Levels of SOCS3 and 
Nur77 were normalised and measured as a fold difference compared to 
treatment with MG-132 alone. * indicates p<0.05 versus MG-132 treatment 
only, ** indicates p<0.01. Quantification for n=4 experiments is shown.  
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Fsk significantly induced SOCS3 and Nur77 protein expression after 4 hours 
of treatment. Significant induction of SOCS3 was achieved after 1 hour, 2 and 
4 hours of treatment with treprostinil, with maximum induction occurring 2 
hours post-treatment (Figure 3.2). Significant induction of Nur77 protein was 
detectable after 2 and 4 hours of treatment. As a result, cells were treated with 
treprostinil for 2 hours in all future experiments unless indicated otherwise. 
3.2.3 Selexipag-mediated induction of SOCS3 
Selexipag, discussed in Section 1.6.1, if the first oral synthetic selective IP 
agonist developed (reviewed by Duggan et al. 2017). Selexipag is a pro-drug 
and is metabolised in vivo to ACT-333679 by carboxylesterase 1. As SOCS3 
induction experiments were performed on HPAECs in vitro, cells were treated 
with the active metabolite ACT-333679 instead of selexipag in all 
experiements. HPAECs were treated with 1 μM ACT-333679 for 1 hour, 2 and 
4 hours alongside MG-132 (6 μM). 4 hours of treatment with Fsk (50 μM) 
alongside MG-132 (6 μM) was used as a positive control. 4 hours of treatment 
with MG-132 (6 μM) alone was used as a negative control. Cells were 
harvested and lysed (Section 2.2.3.1) before protein content was determined 
and immunoblotting was carried out to assess SOCS3 and Nur77 induction, 
with STAT3 used as a loading control. 
Fsk significantly induced SOCS3 and Nur77 protein expression after 4 hours 
of treatment. Significant induction of SOCS3 was achieved only after 4 hours 
of ACT-333679 stimulation (Figure 3.3) while Nur77 was significantly induced 
after 2 and 4 hours of treatment (Figure 3.3).  Based on these resuls, cells 










Figure 3.2: Treprostinil-mediated induction of SOCS3 
HPAECS were treated with treprostinil (Trep) (10 μM) for 1 hour, 2 and 4 
hours in the presence of MG-132 (6 μM). 4 hour forskolin (Fsk) (50 μM) and 
MG-132 (6 μM) treatment was used as a positive control. MG-132 (6 μM) 
alone was used as a negative control. Whole cell lysates were then equalised 
for protein content and resolved via SDS-PAGE for immunoblotting with the 
indicated antibodies. Levels of SOCS3 and Nur77 were measured as a fold 
difference compared to treatment with MG-132 alone. * indicates p<0.05 
versus treatment with MG-132 alone, ** indicates p<0.01, *** indicates 














Figure 3.3: ACT-333679-mediated time-dependent induction of 
SOCS3 
HPAECS were treated with ACT-333679 (1 μM) for 1 hour, 2 and 4 hours in 
the presence of MG-132(6 μM). 4 hour forskolin (Fsk) (50 μM) and MG-132 (6 
μM) treatment was used as a positive control. 4 hour MG-132 (6 μM) alone 
was used as a negative control. Whole cell lysates were then equalised for 
protein content and resolved via SDS-PAGE for immunoblotting with the 
indicated antibodies. Levels of SOCS3 and Nur77 were measured as a fold 
difference compared to treatment with MG-132 alone. * indicates p<0.05 
versus treatment with MG-132 alone, ** indicates p<0.01. Quantification for 
n=4 experiments is shown.  
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3.2.4 Prostanoid induction of SOCS3 in human pulmonary microvascular 
endothelial cells. 
Vascular remodelling in PAH typically occurs in the small pulmonary arterioles 
and veins located in the lungs (reviewed by Tuder 2017). Thus HPMECs, 
which line the capillaries and venules within the lungs, are another key cell 
type involved in the vascular remodelling characteristic of PAH. To establish if 
HPMECs respond to prostanoids in the same manner as HPAECs, prostanoid 
induction of SOCS3 was measured in HPMECs. 
HPMECs were treated with BPS, treprostinil and ACT-333679 for the optimum 
time points as identified in time course experiments in HPAECs (Sections 3.2.1 
– 3.2.3). 4 hours of treatment with Fsk (50 μM) alongside MG-132 (6 μM) was 
used as a positive control. 4 hours of treatment with MG-132 (6 μM) alone was 
used as a negative control.  
Fsk significantly induced SOCS3 and Nur77 protein expression after 4 hours 
of treatment. Similar to the response seen in HPAECs, BPS, treprostinil and 
ACT-333679 significantly induced SOCS3 in HPMECs (Figure 3.4). Likewise, 
BPS and treprostinil significantly induced Nur77 expression after 2 hours of 
treatment in HPMECs. 4 hours treatment with ACT-33679 did not result in 





















Figure 3.4: Prostanoid-mediated induction of SOCS3 in human 
pulmonary microvascular endothelial cells 
HPMECS were treated with beraprost sodium salt (BPS) (10 μM) or treprostinil 
(Trep) (10 μM) for 2 hours, or the selexipag metabolite ACT-333679 (ACT) (1 
μM) for 4 hours in the presence of MG-132 (6 μM). 4 hour treatment with 
forskolin (Fsk) (50 μM) alongside MG-132 (6 μM) was used as a positive 
control. MG-132 (6 μM) alone was used as a negative control. Whole cell 
lysates were equalised for protein content and seperated via SDS-PAGE for 
immunoblotting with the indicated antibodies. Levels of SOCS3 and Nur77 
were measured as a fold difference compared to treatment with MG-132 alone. 
* indicates p<0.05 versus treatment with MG-132 alone, ** indicates p<0.01, 
**** indicates p<0.0001. Quantification for n=4 are shown. 
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3.2.5 Prostanoid-mediated induction of SOCS3 mRNA. 
To determine if the effects of prostanoids on SOCS3 protein expression were 
due an increase of SOCS3 mRNA, RT-qPCR was performed as previously 
described (Section 2.2.4.6) on RNA purified from BPS-treated HPAECs. 
HPAECs were treated with 10 μM BPS at 0 hours, 0.5, 1, 2 and 4 hours. 1 hour 
Fsk treatment was used as a positive control with vehicle as a negative control. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to normalise 
the results. The CT value of each treatment was then and expressed as a fold 
difference of the vehicle control.  
BPS triggered a rapid and significant increase in SOCS3 mRNA, detectable at 
the earliest time point (30 minutes) and sustained for 60 minutes. However the 
increase was transient as mRNA levels returned to basal levels after 2 hours 
and for at least 4 hours (Figure 3.5A). 
For previous experiments in which SOCS3 protein expression has been 
measured (Section 3.2.1 – 3.2.4), cells were treated with the proteasome 
inhibitor MG-132 in order to maximise detection of SOCS3.  To ensure the 
effect of MG132 was not due to any unanticipated effect on SOCS3 gene 
expression, cells were treated with BPS (10 μM) or Fsk (50 μM) for 1 hour in 
the presence and absence of MG-132 prior to harvesting cells. A vehicle 
treatment was used as a negative control. This has been shown as a bar graph 
for easier comparison between treatments with and without MG-132. The 
presence of MG-132 had no significant effect on SOCS3 mRNA levels either 
on its own or in combination with BPS or Fsk (Figure 3.5B). Thus, the effect of 














Figure 3.5: Prostanoid-mediated induction of SOCS3 gene 
expression 
A) HPAECs were treated with beraprost sodium (BPS) (10 μM) for 0 hours, 
0.5, 1, 2 and 4 hours. RNA was then purified for reverse transcription and 
analysis by real time – qPCR. GAPDH values were used to normalise the 
results. The CT value of each treatment was calculated and expressed as a 
fold difference compared to the vehicle control. *** indicates P<0.001 versus 
treatment with BPS for 0 hours. Quantification for n=4 is shown. B) HPAECS 
were treated with MG-132 (6 μM) alone for 1 hour and for 1 hour with either 
BPS (10 μM) or forskolin (Fsk) (50 μM) in the presence and absence of MG-
132 (6 μM). A vehicle (Veh) treatment was used as a negative control. RNA 
was then purified for reverse transcription and analysis by real time – qPCR. 
The level of SOCS3 mRNA was normalised to GAPDH concentrations and 
expressed as a percentage of the maximum SOCS3 mRNA expression level. 
** indicates p<0.01 versus SOCS3 mRNA levels post-vehicle treatment. 




independent of any effect on SOCS3 mRNA levels and consistent with 
stabilisation of SOCS3 protein. 
3.2.6 Identifying the signalling pathway in prostanoid induction of SOCS3 
As experiments have shown prostanoids to increase SOCS3 protein 
expression in relevant cell types, it is important to identify the key receptors 
and proteins involved.  
BPS is an IP agonist, whereas treprostinil has been shown to demonstrate 
affinity for IP and EP2 (Whittle et al, 2012), and selexipag is a highly selective, 
potent IP agonist (Kuwano et al., 2007). To investigate if treprostinil acts via 
EP2 in prostanoid induction of SOCS3, HPAECs were treated with prostanoids 
in the presence and absence of the EP2 selective antagonist PF-04418948 (10 
μM) (Forselles et al., 2011). Cells were treated with PF-04418948 30 minutes 
prior to treatment with either BPS, treprostinil of ACT-333679. Fsk (50 μM) 
treatment in the presence and absence of PF-04418948 (10 μM) was also 
performed. As Fsk is cell permeable and acts directly on AC, treatment with 
Fsk should not be affected by PF-04418948. Thus, it was used to ensure 
treatment with PF-04418948 had no effect on signalling downstream from AC. 
For easy comparison between protein expression induced by the drug in the 
presence and absence of PF-04418948, the results have been shown as 
expression by drug alone, set at 1, with the drug alongside PF-04418948 
expressed as fold difference to this. 
In none of the treatments did PF-04418948 inhibit prostanoid induction of 
SOCS3 or Nur77 when compared to treatment with the agonist alone (Figure 













Figure 3.6: The EP-2-selective antagonist PF-04418948 has no 
effect on prostanoid induction of SOCS3 
HPAECs were treated with beraprost sodium salt (BPS) (10 μM) for 2 hours, 
Treprostinil (Trep) (10 μM) for 2 hours, or ACT-333679 (ACT) (1 μM) for 4 
hours in the presence or absence of the EP-2 receptor antagonist PF-
04418948 (PF) (10 μM). 4 hour treatment with forskolin (Fsk) (50μM) in the 
presence and absence of PF was used to ensure there was no downstream 
effect of PF. All treatments were given alongside MG-132 (6 μM). Treatment 
with MG-132 (6 μM) or PF (10 μM) alone for 4 hours were used as negative 
controls. Cells were treated with PF-04418948 30 minutes prior to prostanoid 
treatment. Whole cell lysates were then equalised for protein content and 
resolved via SDS-PAGE for immunoblotting with the indicated antibodies. 
Levels of SOCS3 and Nur77 after PF-04418948 (10 μM) treatment were 
measured as a fold difference compared to treatment with the relevant agonist 
only (set at 1). Quantification for n=5 experiments is shown.  
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EP2 sufficiently to elevate cAMP and induce SOCS3 gene expression. As 
treprostinil shows greater affinity to EP2 than the other drugs measured, we 
would expect to see some reduction in treprostinil-mediated induction of 
SOCS3 in the presence of PF-04418948 and although it does appear less, 
statistical analysis showed this not to be significant.  
A large body of research has suggested that cAMP-mediated induction of 
SOCS3 occurs via a PKA-independent, EPAC1-dependent mechanism 
(Gasperini et al. 2002; Sands et al. 2006; Borland et al. 2009; Woolson et al. 
2009; Wiejak et al. 2019). However, whether prostanoid induction of SOCS3 
in HPAECs is via EPAC1 has not been investigated. To address this, SOCS3 
protein expression was measured after treatment with either EPAC or PKA 
activators alone or in combination.  
HPAECs were treated with the EPAC activator 8-CPT-2Me-cAMP sodium salt 
(8-CPT) (200 μM) or with PKA activator 6-Bnz-cAMP sodium salt (6-Bnz) (100 
μM) for 4 hours in the presence of MG-132 (6 μM). The combined stimulatory 
effects of treatment with 8-CPT (200 μM) and 6-Bnz (100 μM) alongside MG-
132 (6 μM) was also investigated (Figure 3.7A). Cells were treated with Fsk 
(10 μM) alone or in the presence of the PKA inhibitor myrPKI14-22 amide (PKI) 
(1 μM) to determine the role of PKA in Fsk induction of SOCS3 in HPAECs. 
PKI was administered 30 minutes prior to Fsk treatment. Treatment with MG-
132 (6 μM) alone and PKI (1 μM) alone were used as negative controls. 
Neither the EPAC activator (8-CPT) or PKA activator (6-Bnz) alone or in 
combination significantly induced SOCS3 under conditions in which significant 
















Figure 3.7: Induction of SOCS3 by forskolin in HPAECs does not 
require EPAC or PKA  
A) HPAECS were treated for 4 hours with 8-CPT-2Me-cAMP (8-CPT) (200 
μM), 6-Bnz-cAMP sodium salt (6-Bnz) (100 μM), or both in the presence of 
MG-132 (6 μM). 4 hour treatment with forskolin (Fsk) (50 μM) with MG-132 (6 
μM) was used as a positive control. Treatment with Fsk in the presence of MG-
132 (6 μM) and myristoylated PKI 14-22 amide (PKI) (1 μM) was used to 
measure the effect of PKA. PKI was administered 30 minutes prior to Fsk 
treatment. MG-132 (6 μM) only and PKI (1 μM) only treatments were used as 
negative controls. Whole cell lysates were then equalised for protein content 
and resolved via SDS-PAGE for immunoblotting with Nur77 and SOCS3. 
Immunoblotting with STAT3 was used for a loading control. The concentration 
of SOCS3 and Nur77 was measured as a fold difference compared to MG-132 
only treatment. Quantification for n=4 has been shown. * indicates p<0.05 
versus treatment with MG-132 alone, ** indicates p<0.01, *** indicates 
p<0.001, # indicates p<0.05 versus treatment with Fsk. B) HPAECs were 
treated with 8-CPT (200 μM) for 5 minutes, 15 and 30 minutes prior to fixing in 
methanol as previously described. A 30 minute vehicle treatment was used as 
a positive control. Fixed cells were stained with VE-cadherin (red) and nuclear 
stain Hoescht 33342 (blue) prior to confocal imaging. These data are 
representative of n=2 experiments which produced similar results. 
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findings (Sands et al. 2006; Yarwood et al. 2008; Wiejak et al. 2019), 
pharmacological inhibition of PKA had no effect on Fsk-mediated induction of 
SOCS3, but significantly reduced induction of PKA/CREB target gene product 
Nur77, thereby demonstrating that PKI effectively inhibited PKA under our 
experimental conditions but that this had no impact on SOCS3 expression. 
Together these data suggest that prostanoid induction of SOCS3 cannot be 
recapitulated by activation of EPAC and PKA.  
EPAC is known to increases VE-cadherin localisation to cell junctions 
(Fukuhara et al. 2005; Kooistra et al. 2005), thus to ensure the EPAC activator 
was active, the effect of 8-CPT (200μM) on localising VE-cadherin expression 
to cell junctions was assessed by confocal imaging. Cell junction expression 
of VE-cadherin was increased after 15 and 30 minute treatments with 8-CPT 
suggesting that it is active under these conditions (Figure 3.7B). 
3.3 Discussion 
Treatment with both BPS and treprostinil resulted in time-dependent induction 
of SOCS3 in HPAECS that was significant after 2 hours (Figures 3.1 and 3.2). 
ACT-333679, the pro-drug of a recently developed synthetic analog, also 
increased SOCS3 expression after 4 hours of treatment (Figure 3.3). Results 
were similar in HPMECs, ECs isolated from different microvessles involved in 
the vascular remodelling characteristic of PAH, in which both prostanoids and 
ACT-333679 induced SOCS3 after the same treatment time (Figure 3.4). In 
HPAECs, data derived from RT-qPCR demonstrated that this is due to a robust 
but transient prostanoid-mediated increase in SOCS3 mRNA (Figure 3.5). 
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Previous studies have shown cAMP mobilising drugs, in this case a PGE2 
agonist, to increase SOCS3 transcription in THP-1 cells (Cheon et al. 2006). 
Thus, it is probable BPS is working in the same manner as opposed to altering 
SOCS3 RNA degradation or turnover. To confirm this, actinomycin D, a 
transcriptional inhibitor, could be incorporated into future experiments as 
described by Cheon et al. (2006). Additionally, a reporter gene assay in which 
HPAECs are transfected with constructs in which the expression of luciferase 
is under control of the human SOCS3 promoter would allow measurement of 
SOCS3 gene transcription via luciferase activity. This method has previously 
been used in HUVECs to determine a role for the AP1 transcription factor in 
forskolin/rolipram and 8-pCPT, but not 6-Bnz, mediated increase in SOCS3 
promoter activity (Wiejak et al. 2014). 
As prostanoids stimulate the production of cAMP via activation of AC (Boskey 
et al. 1996) this is most likely due to cAMP-mediated induction of SOCS3. In 
the case of BPS and treprostinil, these experiments supported this hypothesis, 
as protein expression of Nur77, a highly responsive PKA activated gene and 
a measure of cAMP activity (Hamid et al. 2008), was also increased post-
treatment (Figures 3.1 and 3.2). With regards to ACT-333679, although still 
significantly increased compared to the negative control, Nur77 protein 
expression was comparably less than the level of induction observed with 
either BPS or treprostinil. In contrast to the other prostanoid drugs, ACT-
333679 did not significantly induce Nur77 protein expression in HPMECs 
compared to basal levels.  
This could be due to prostanoids activating a range of different prostaglandin, 
and other, receptors, whereas ACT-333679 is highly selective for IP (Kuwano 
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et al., 2007). Treprostinil in particular appears to show a high affinity to EP2 
(3.6 nM compared to 1172 nM for ilaprost) (Whittle et al. 2012) and recent 
research in HPASMCs has shown that the anti-proliferative effects of 
treprostinil, but not ACT-333679, are due to activation of EP2 (Patel et al. 2018) 
as opposed to IP which is the primary receptor for beraprost and ACT. In 
addition, treprostinil has been shown to exerts its anti-proliferative effects in 
PASMCs isolated from MCT-rat models and in human lung fibroblasts via 
PPAR, although reports disagree on whether this via PPARβ or PPARγ (Ali et 
al. 2006; Lai et al. 2009). This may suggest a tissue specific PPAR response 
to treprostinil. 
To determine if treprostinil is acting via EP2 receptors, we used an EP2 
antagonist (PF-04418948) to assess its role in prostanoid-mediated induction 
of SOCS3 in HPAECs. Results suggest EP2 is not required for SOCS3 
induction by either BPS, treprostinil or ACT-333679 (Figure 3.6). However, no 
positive control was included to ensure the EP2 antagonist was active, thus 
further experimentation is required to ensure the EP2 selective antagonist is 
active in the conditions used. For instance, determining the effect of PF-
04418948 on (R)-Butaprost-mediated induction of Nur77 under the same 
conditions (PF-04418948 (10 μM) treatment 30 minute prior to treatment with 
(R)-Butaprost in HPAECs). (R)-Butaprost (Abcam; Cat. No. Ab144476), is a 
selective EP2 antagonist. If PF-04418948 is found to be active under these 
conditions, a dose-concentration course and time course of PF-04418948 
inhibition of (R)-Butaprost-induced Nur77 expression could be utilised to 
determine the optimal conditions for PF-04418948 antagonism in HPAECs 
prior to repeating the experiment. Additionally, the use of an IP-selective 
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antagonist such as Ro 1138452 hydrochloride (Bley et al., 2006) would provide 
further information regarding the role of the IP in BPS, treprostinil, and ACT-
333679-mediated SOCS3 and Nur77 induction.  
As well as prostanoids acting on different receptor subtypes, there may also 
be cell-specific differences in the receptors expressed. RT-PCR could be 
performed to identify the different prostaglandin receptor subtypes expressed 
in HPAECs and HPMECs, and to investigate the balance of prostaglandin 
receptors versus non- prostaglandin receptors activated by prostanoids such 
as PPARs.  
Combined, these experiments would build a picture of the different receptor 
subtypes being activated in a cell-specific manner. Identifying the primary 
prostanoid receptors responsible for the induction of SOCS3 would not only 
provide a new mechanism of action for existing prostanoid use in PAH 
treatment but potentially provide new therapeutic targets for the future 
development of drugs aimed at reducing the pulmonary vascular inflammation 
involved in disease progression. Establishing the predominant signalling 
pathway utilised by prostanoids is important for this aim.  
As previously mentioned, it is well established that prostanoids modulate 
cAMP activity depending on the prostanoid receptor subtype they activate 
(Boskey et al. 1996; Tsuboi et al. 2002). Research suggests cAMP induction 
of SOCS3 has been shown to occur via EPAC1 in COS1 cells (Borland et al. 
2009), HUVECs (Yarwood et al. 2008), and human aortic endothelial cells 
(Babon et al. 2008). Additionally, in HUVECs, the EPAC agonist I942 was 
shown to suppress IL-6/sIL-6Rα induced JAK/STAT signalling and 
134 
 
consequential expression of inflammatory genes such as ICAM1 and VCAM1 
(Wiejak et al. 2019), potentially via SOCS3 induction . However our results did 
not support this hypothesis. Instead they showed that EPAC activation via 
treatment with 8-CPT, a selective EPAC1 activator, alone had no effect on 
SOCS3 protein expression (Figure 3.7). 8-CPT did however increase VE-
cadherin staining at cell junctions, consistent with published findings 
(Fukuhara et al. 2005; Kooistra et al. 2005), proving that the drug was active 
at the concentration used. An alternative method to measure the role of EPAC1 
in prostanoid induction of SOCS3 would be to utilise EPAC1 agonists and 
antagonists. 
The EPAC1 agonist, N-(2,4-dimethylbenzenesulfonyl)-2-(naphthalen-2-
yloxy)acetamide (I942) (MolPort; Cat. No. 868145-09-9), has been shown to 
induce SOCS3 in HUVECs which was attenuated via treatment with the EPAC 
inhibitor ESI-09 (Tocris; Cat. No. 4773)  (Wiejak et al. 2019). EPAC1 siRNA 
was also utilised in this experiment and blocked I942-mediated induction of 
SOCS3 (Wiejak et al. 2019). However, this has not been investigated in 
HPAECs. 
Interestingly, PKA activators appear to trigger a small increase in SOCS3 
expression but this did not reach significance (Figure 3.7). In addition, a PKA 
inhibitor had no effect on Fsk induction of SOCS3 but did significantly reduce 
Fsk induction of Nur77. This supports existing data that PKA is not involved in 
cAMP-mediated induction of SOCS3 (Woolson et al. 2009; Wiejak et al. 2019). 
Interestingly, in human breast cancer cells the PKA inhibitor H89 was found to 
inhibit PGE2-mediated upregulation of SOCS3 mRNA (Barclay et al. 2007), 
and in HUVECs H89 was found to partially inhibit Fsk/rolipram-mediated 
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induction of SOCS3 (Wiejak et al. 2019), suggesting that PKA and EPAC may 
both be required for optimal SOCS3 induction. Contradictory to this, treatment 
with PKA and EPAC activiators together did not significantly increase SOCS3 
induction in HPAECs (Figure 3.7).  
Further optimisation of 8-CPT and 6-Bnz treatment via dose-concentration and 
time courses are required to ensure the appropriate concentration and 
treatment times are being used for maximum SOCS3 accumulation. 
Additionally, whether cAMP is crucial for prostanoid and selexipag induction of 
SOCS3 in HPAECs needs to be established in case there is an alternative 
signalling mechanism occurring which is yet to be identified. CRISPR/Cas9  
technology has been used to produce AC deficient HEK293 cells that 
demonstrated a significant reduction in the Fsk-stimulated cAMP response 
(Soto-Velasquez et al. 2018). Utilising this model in VECs would be ideal to 
measure a role for cAMP in prostanoid-mediated stimulation of SOCS3 
expression in the context of this research. 
As discussed, it has been suggested that treprostinil can mediate its anti-
proliferative effects via PPAR (Ali et al. 2006; Lai et al. 2009). Numerous 
PPARγ antagonists are available (Tocris, Cat. #1326, Cat. # 2022 and Cat. # 
2301) that could be administed to HPAECs prior to measuring treprostinil-
induced SOCS3 expression to determine the impact of PPARs. Lung-specific 
PPARβ-deficient mice have previously been utilised to determine an anti-
proliferative role for treprostinil mediated via PPARs (Ali et al. 2006). Similar 




To conclude, these experiments confirm that the BPS, treprostinil, and ACT-
333679, the biologically active metabolite of pro-drug selexipag, do induce 
SOCS3 protein expression as a result of increased SOCS3 gene transcription. 
However, further work is required to establish the key proteins and receptors 
involved. 
4. Prostanoids attenuate IL-6 trans-signalling  
4.1 Introduction 
As prostanoids induce the expression of SOCS3 protein in HPAECs and 
HPMECs (Chapter 3), and SOCS3 negatively regulates IL-6 trans-signalling 
(Schmitz et al. 2000) (Section 1.4.3), it could be hypothesised that prostanoids 
are able to limit IL-6 trans-signalling and pro-inflammatory effects. With the 
exception of a minority of cells, IL-6 binds to cleaved sIL-6Rα extracellularly 
prior to binding to membrane bound gp-130 to initiate IL-6 trans-signalling via 
JAK/STAT activation (Section 1.4.1). Consequently, IL-6 induced tyrosine 705 
phosphorylation of STAT3 can be used as a measure of IL-6 signalling activity. 
IL-6 signalling initiates the transcription of numerous pro-angiogenic and pro-
survival factors such as adhesion molecules and VEGF which are associated 
with PAH progression (Section 1.4.1). Thus, prostanoid inhibition of IL-6 trans-
signalling may contribute to the therapeutic properties of prostanoids and 






4.2.1 Lentiviral expression of SOCS3 inhibits IL-6/sIL-6Rα induced 
tyrosine 705 phosphorylation of STAT3 in HPAECs 
To initially determine if SOCS3 inhibits IL-6 trans-signalling activity in HPAECs, 
lentiviral SOCS3 gene delivery was utilised to determine the effect of 
increasing SOCS3 expression. SOCS3 has a half-life of 40 – 120 minutes 
depending on the cell type (Siewert et al. 1999; Fletcher et al. 2010; Munro 
2016b), and is barely detectable at basal concentrations even in the presence 
of a proteasome inhibitor (Figures 3.1 – 3.4, 3.6, 3.7). Treatment with a SOCS3 
lentivirus results in constitutive SOCS3 activity that allows us to measure the 
effect of SOCS3 on IL-6/sIL-6Rα signalling activity without any additional 
stimulation. Tyrosine 705 phosphorylation of STAT3 was considered 
representative of IL-6 trans-signalling activity. To ensure the effects were not 
a consequence of treatment with lentivirus, HPAECs were treated in parallel 
with a GFP-expressing lentivirus. This also allowed confirmation of lentivirus 
transduction via fluorescence microscopy. 
HPAECs at 70% confluency were treated with either Flag-SOCS3 lentivirus or 
GFP lentivirus at a concentration of 1x106 TU/μl and 2x106 TU/μl respectively 
for 5 days as previously described (Section 2.2.2.2). Transduction of cells by 
lentivirus was monitored via fluorescence microscopy as previously described 
(Section 2.2.2.2). Cells were then harvested and lysed for SDS-PAGE and 
immunoblotting to determine Flag-SOCS3 and GFP protein expression. 
STAT3 was used as a control to ensure equivalent loading.  
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Treatment with Flag-SOCS3 lentivirus alone was sufficient to cause SOCS3 
protein expression, whilst GFP lentivirus alone was sufficient to cause GFP 
protein expression (Figure 4.1A). Fluorescence imaging indicated high 
transduction rates for the GFP lentivirus at the concentration used with all cells 
in the image taken also expressing GFP (Figure 4.1B), however the rates were 
not calculated. 
Although the action of IL-6 alone was not measured in HPAECs, treatment with 
IL-6 alone in other cells such as leucocytes is not sufficient to elicit tyrosine 
705 phosphorylation of JAK/STAT (Romano et al. 1997). Thus, when 
measuring the effects of IL-6 induced signalling in HPAECs, cells were treated 
with an IL-6/sIL-6R complex made up at least 30 minutes and no more than 
two weeks prior to treatment to represent trans-signalling conditions. To 
measure the effect of Flag-SOCS3 expression on IL-6/sIL-6Rα signalling, 
HPAECs were treated with either GFP or Flag-SOCS3 lentivirus as previously 
described prior to 30 minute treatment with IL-6/sIL-6Rα. Cells were harvested 
and lysed as previously described (Section 2.2.3.1) prior to SDS-PAGE and 
immunoblotting for Flag-SOCS3 and GFP. 
In the absence of IL-6/sIL-6R treatment, there is no tyrosine 705 
phosphorylation in either GFP- or Flag-SOCS3-expressing cells. IL-6 trans-
signalling resulted in significant tyrosine 705 phosphorylation in GFP-
expressing HPAECs, which was significantly reduced after treatment with 
Flag-SOCS3 lentivirus (Figure 4.1C). However, Flag-SOCS3 was not sufficient 
to reduce tyrosine 705 phosphorylation to basal (no IL-6/sIL-6Rα treatment) 
levels (Figure 4.1C). This supports our hypothesis that increasing SOCS3 in 












Figure 4.1: Lentiviral expression of SOCS3 inhibits IL-6/sIL-6Rα induced 
tyrosine 705 phosphorylation of STAT3 in HPAECs 
A) HPAECs were treated with either Flag-SOCS3 lentivirus or green 
fluorescent protein (GFP) lentivirus for 24 hours as described in Section 
2.2.2.2. Cells were then incubated in fresh media for 2 – 5 days before 
harvesting. Whole cell lysates were equalised for protein content and 
fractionated via SDS-PAGE for immunoblotting with anti-GFP and Flag-
antibodies. Total STAT3 was used as a protein loading control. B) 
Fluorescence images taken 5 days post-infection with GFP lentivirus (GFP-
expressing cells = green). Cells were fixed with methanol for 10 minutes at -
20°C and then incubated at room temperature with the nuclear stain Hoechst 
33342 (blue) for 20 minutes prior to imaging. C) HPAECs were treated with 
either Flag-SOCS3 or GFP lentiviruses for 24 hours prior to incubation in fresh 
media for 2 – 5 days before harvesting. Cells were treated with IL-6 (5 ng/ml) 
and sIL-6Rα (25 ng/ml) (IL-6/sIL-6Rα) 30 minute prior to harvest. Whole cell 
lysates were then equalised for protein content and fractionated via SDS-
PAGE for immunoblotting with antibodies against GFP, Flag M2 and Tyr705 
P-STAT3. The concentration of P-STAT3 was compared to maximum P-
STAT3 expression, set as 100. Immunoblotting with STAT3 was used for a 
loading control. *** indicates p<0.0001 compared to GFP + IL-6/sIL-6Rα. ### 
indicates p<0.0001 compared to Flag-SOCS3. Quantification for n=3 
experiments have been shown.   
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4.2.2 Prostanoid mediated inhibition of IL-6/sIL-6Rα induced tyrosine 705 
phosphorylation of STAT3 in HPAECs 
As lentiviral delivery of the SOCS3 gene significantly inhibited IL-6/sIL-6Rα 
induced phosphorylation of STAT3 at tyrosine 705 in HPAECs and prostanoids 
induced SOCS3 expression in HPAECs (Section 3.2.1 – 3.2.2), the effects of 
BPS and treprostinil on IL-6 trans-signalling activity were then measured. 
HPAECs were serum starved for 2 hours before being treated for 4 hours with 
Fsk (50 μM), BPS (10 μM) or treprostinil (10 μM). Treatment with IL-6/sIL-6Rα 
occurred 30 minutes prior to cell lysis. Treatment with Fsk (50 μM), BPS (10 
μM) and treprostinil (10 μM) in the absence of IL-6/sIL-6Rα were used as 
negative controls. 
As ACT-333679, the pro-drug of selexipag, also induced SOCS3 (Section 
3.2.3), the experiment was repeated with treatment of ACT-333679. Again, 
cells were serum starved for 2 hours before being treated for 4 hours with Fsk 
(50 μM) or ACT-333679 (1 μM) in the presence or absence of IL-6/sIL-6Rα 
which was administered 30 minutes prior to cell lysis. Consistent with previous 
findings (Sands et al. 2006; Wiejak et al. 2019), 4 hours of treatment with Fsk 
significantly inhibited IL-6/sIL-6Rα-mediated STAT3 phosphorylation at 
tyrosine 705 (Figure 4.2). Treatment with BPS (Figure 4.2A), treprostinil 
(Figure 4.2A) and ACT-333679 (Figure 4.2B) for 4 hours also significantly 












Figure 4.2: Prostanoids inhibit IL-6/sIL-6Rα-induced tyrosine 705 
phosphorylation of STAT3 in HPAECs 
A) HPAECs were serum starved for 2 hours before treatment for 4 hours with 
beraprost sodium salt (BPS) (10 μM), treprostinil (Trep) (10 μM) or forskolin 
(Fsk) (50 μM) which was used as a positive control, with and without the 
presence of IL-6 (5 ng/ml) and sIL-6Rα (25 ng/ml) (IL-6/sIL-6Rα) for 30 
minutes prior to harvest. Whole cell lysates were then equalised for protein 
content and fractionated via SDS-PAGE for immunoblotting with antibodies 
against Tyr705-phosphorylated STAT3 (P-STAT3) and total STAT3 which was 
used as a loading control. Levels of P-STAT3 were measured as a percentage 
of IL-6/sIL-6Rα treatment alone (set at 100%). * indicates p<0.05 compared to 
IL-6/sIL-6Rα treatment alone, ** indicates p<0.01. Quantification for n=4 
experiments is shown. B) HPAECs were serum starved for 2 hours before 
treatment for 4 hours with ACT-333679 (1 μM) or Fsk (50 μM) which was used 
as a positive control, with and without the presence of IL-6/sIL-6Rα. Cells were 
treated with IL-6/sIL-6Rα 30 minutes prior to harvest. Whole cell lysates were 
then equalised for protein content and fractionated via SDS-PAGE for 
immunoblotting with P-STAT3 and total STAT3 which was used as a loading 
control. Levels of P-STAT3 were measured as a percentage compared to IL-
6/sIL-6Rα treatment alone (set at 100%). *** indicates p<0.001 versus IL-6/sIL-




4.2.3 Prostanoid-mediated inhibition of IL-6 trans-signalling is dependent 
on SOCS3 
In HPAECs, BPS, treprostinil and selexipag metabolite ACT-333679 increase 
SOCS3 expression (Section 3.2, Figures 3.1 - 3.3) and attenuate IL-6/sIL-6Rα 
induced phosphorylation of STAT3 (Figure 4.2), however whether SOCS3 
induction and IL-6 inhibition are linked is unclear. Thus, it was important to 
determine if prostanoid-mediated limitation of IL-6 trans-signalling activity was 
dependent on SOCS3. To test this we utilised AS-M.5 cells, an established 
immortalised human endothelial cell model (Krump-Konvalinkova et al. 2003), 
and a SOCS3 KO AS-M.5 line generated in house using CRISPR/Cas9 
technology (Williams et al. 2018).  
Initially, WT and SOCS3 KO AS-M.5 cells were stimulated with BPS or 
treprostinil for 2 hours in the presence of proteasome inhibitor MG-132 to 
prevent SOCS3 degradation. MG-132 alone was used as a negative control 
and treatment with Fsk for four hours in the presence of MG-132 was used as 
a positive control. In WT AS-M.5 cells, Fsk treatment produced a significant 
induction of SOCS3 protein. 2 hours of stimulation with either BPS or 
treprostinil also significantly induced SOCS3 protein expression (Figure 4.3). 
However, treating AS-M.5 SOCS3 KO cells under the same conditions did not 
results in SOCS3 expression. In contrast, the cAMP-inducible gene product 
Nur77 was significantly induced by Fsk, BPS and treprostinil in WT and 
SOCS3 KO cells (Figure 4.3), demonstrating a positive response to the drugs 










Figure 4.3: Prostanoid mediated induction of SOCS3 in AS-M.5 WT and 
AS-M.5 SOCS3 KO cells 
Cells were treated with beraprost (BPS) (10 μM) or treprostinil (Trep) (10 μM) 
for two hours in the presence of MG-132 (6 μM). Fsk (50 μM) + MG-132 (6 
μM) was used a positive control for SOCS3 induction. Treatment with MG-132 
(6 μM) alone was used as a negative control. Whole cell lysates were then 
equalised for protein content and fractionated via SDS-PAGE for 
immunoblotting with antibodies against Nur77, SOCS3 and STAT3 (protein 
loading control). Levels of SOCS3 and Nur77 were measured as a fold 
difference compared to treatment with MG-132 only, set at 1. * indicates 
P<0.05 compared to treatment with MG-132 alone, ** indicates p<0.001, *** 




As SOCS3 KO AS-M.5 cells were shown to not express SOCS3 (Figure 4.3), 
these cells were used to assess any role for SOCS3 in prostanoid inhibition of 
IL-6 mediated tyrosine 705 phosphorylation of STAT3. Cells were serum 
starved for two hours before being treated for 4 hours with Fsk (50 μM), or 2 
hours with BPS (10 μM) or treprostinil (10 μM) in the presence or absence of 
IL-6/sIL-6Rα which was administered 30 minutes prior to harvesting the cells. 
This experiment was performed in AS-M.5 WT and AS-M.5 SOCS3 KO cells 
in parallel. 
Fsk significantly reduced the phosphorylation of STAT3 caused by treatment 
with IL-6/sIL-Rα in WT but not SOCS3 KO AS-M.5 cells (Figure 4.4). BPS and 
treprostinil also significantly reduced IL-6/sIL-Rα-mediated tyrosine 705 
STAT3 phosphorylation in AS-M.5 WT but not SOCS3 KO AS-M.5 cells. This 
demonstrates prostanoid inhibition of IL-6 trans-signalling was in part due to 
the inhibitory effects of SOCS3. In addition, unlike WT AS-M.5 cells, SOCS3 
KO AS-M.5 cells displayed a pronounced basal phosphorylation of STAT3 that 
could be seen in the absence of IL-6/sIL-6Rα stimulation and which, in the 
case of Fsk showed no significance difference compared to IL-6/sIL-Rα-
mediated tyrosine 705 STAT3 phosphorylation (Figure 4.4). Although still 
pronounced, there was a significant difference between tyrosine 705 STAT3 
phosphorylation in the vehicle, BPS and treprostinil treatment and maximum 










Figure 4.4: Prostanoid mediated inhibition of phosphorylation of total-
STAT3 at tyrosine 795 in AS-M.5 WT cells and AS-M.5 SOCS3 KO cells 
Cells were serum starved for 2 hours before 2 hours of treatment with 
beraprost sodium salt (BPS) (10 μM), treprostinil (Trep) (10 μM) or forskolin 
(Fsk) (50 μM), which was used as a positive control, in the presence and 
absence of IL-6 (5 ng/ml) and sIL-6Rα (25 ng/ml) (IL-6/sIL-6Rα) which was 
applied 30 minutes prior to harvest. Whole cell lysates were then equalised for 
protein content and fractionated via SDS-PAGE for immunoblotting with 
phospho-STAT3 and total STAT3. Immunoblotting with Nur77 was performed 
to show elevation of cAMP. The concentration of P-STAT3 was measured as 
a difference compared to IL-6/sIL-6Rα treatment only, set at 100%. * indicates 
p<0.05 compared to treatment with IL-6/sIL-6Rα alone, ** indicates p<0.01, *** 
indicates P<0.001. Quantification for n=4 experiments has been shown.  
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4.2.4 Gene silencing of SOCS3 in HPAECs 
In AS-M.5 cells, BPS and treprostinil significantly limit IL-6/sIL-6Rα mediated 
STAT3 phosphorylation at tyrosine 705; however this was not the case in 
SOCS3 KO AS-M.5 cells (Figure 4.4). This suggests BPS and treprostinil- 
mediated inhibition of IL-6 trans-signalling in AS-M.5 cells is due in part to the 
induction of SOCS3. Although these cell types are representative of 
endothelial cells, it was necessary to test this in HPAECs as they are involved 
in the pathogenesis and vascular remodelling characteristic of PAH (Masri et 
al. 2007; reviewed by Ranchoux et al. 2018).  
To achieve this, Flexitube GeneSolution siRNA, purchased from Qiagen and 
prepared by colleagues from the University of Glasgow, was utilised to silence 
SOCS3 gene expression in HPAECs as previously described (Section 
2.2.2.3). Flexitube GeneSolution siRNA was chosen as it includes siRNA for 4 
genes, in this case 4 different SOCS3 variants (SOCS3-1, -4, -6, and SOCS3-
7). Control siRNA and HiPerFect only treatments were used as negative 
controls. HPAECs were treated for 4 hours with Fsk (50 μM) in the presence 
of MG-132 (6 μM). Treatment with MG-132 (6 μM) alone was used as a 
negative control while Fsk (50 μM) and MG-132 (6 μM) in the absence of 
siRNA was used a positive control for SOCS3 induction. Cells were harvested 
and lysed as previously described before protein content was determined and 
immunoblotting for SOCS3 performed. 
SOCS3 protein expression was undetectable after MG-132 only treatment, 
while 4 hours treatment with Fsk and MG-132 triggered a significant 
accumulation of SOCS3 protein (Figure 4.5A). This was not affected by 
treatment with negative control siRNA or HiPerFect. 48 hours of incubation 
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with 100 nM of SOCS3 siRNAs 1, 4, 6, and 7 was not sufficient to attenuate 
Fsk-induced SOCS3 induction compared to SOCS3 expression post-
treatment with negative control siRNA (Figure 4.5A).  
To ensure the siRNA was active, fresh Flexitube GeneSolution SOCS3 siRNA 
was purchased and prepared prior to repeating the experiment. As treatment 
with MG-132 alone had not resulted in SOCS3 protein expression in any 
condition previously (Figure 4.5A), just one MG-132 only negative control 
treatment was performed. Again, SOCS3 accumulation induced by Fsk in the 
presence of MG-132 was not attenuated by 48 hours of incubation with SOCS3 
siRNA 1, 4, 6, and 7 compared with negative control siRNA and HiPerFect 
treated HPAECs (Figure 4.5B). 
An attempt to optimise the formation of transfection complexes and overall cell 
transfection was performed by increasing the volume of HiPerFect as 
recommended by the supplier. The experiment was repeated exactly as 
previously described (Section 2.2.2.3) but with 12 μl HiPerFect and 78 μl Opti-
MEM media. However, SOCS3 protein expression was the same as seen in 
previous experiments with a significant induction by Fsk which was not limited 
by 48 hours of incubation with SOCS3 siRNA 1, 4, 6, and 7 compared to 
treatment with negative control siRNA and HiPerFect (Figure 4.5C). 
As siRNA transfection was not successful in silencing SOCS3 gene induction 
under the conditions used, lentivirus-mediated shRNA delivery was utilised as 
an alternative strategy. Lentiviruses containing pLV[shRNA]-
mCherry:T2A:Puro- U6>hSOCS3 (SOCS3) and pLV[shRNA]-












Figure 4.5: SOCS3 siRNA is not sufficient to silence SOCS3 gene 
expression in HPAECs 
A) HPAECs were maintained in 6 cm dishes until reaching 70% confluency. 
SOCS3-1, 4, 6 and 7 siRNA (100 nM) were prepared individually in 3 μl 
HiPerFect and 87 μl Opti-MEM media and incubated at room temperature for 
10 minutes prior to mixing with 900 μl Optim-MEM. HPAECs were incubated 
in the siRNA-containing media for 48 hours prior to 4 hours treatment with 
forskolin (Fsk) (50 μM) in the presence of MG-132 (6 μM) or with MG-132 
alone. Treatment with Fsk (50 μM) + MG-132 (6 μM) in the absence of siRNA 
was used as a positive control for SOCS3 induction. Treatment with control 
siRNA (100 nM) and HiPerFect only were used as siRNA negative controls. 
Whole cell lysates were then equalised for protein content and fractionated via 
SDS-PAGE for immunoblotting with SOCS3 and STAT3 antibodies. 
Experiment completed to n=1. B) Experiment completed as above but just one 
treatment with MG-132 (6 μM) alone was used as a negative control. 
Experiment completed to n=1. C) HPAECs were maintained in 6cm dishes 
until reaching 70% confluency. SOCS3 siRNA-1, 4, 6 and SOCS3 siRNA-7 
(100 nM) were prepared individually in 12 μl HiPerFect and 78 μl Opti-MEM 
media and incubated at room temperature for 10 minutes prior to mixing with 
900 μl Optim-MEM. The experiment was completed as previously described. 




were prepared and lentiviral concentration determined as previously described 
(Section 2.2). shRNA-containing media was prepared at concentrations 
ranging from 9.37x104 TU/µl to 1.872x106 TU/µl and applied to cells overnight. 
Cells were then maintained in fresh EGM-2 media for 5 days prior to 4 hours 
treatment with Fsk (50 μM) in the presence of MG-132 (6 μM). Treatment with 
MG-132 (6 μM) alone and Fsk (50 μM) in the presence of MG-132 (6 μM) in 
the absence of lentiviral treatment were used as negative and positive controls 
of SOCS3 induction respectively. Treatment with Fsk (50 μM) and MG-132 (6 
μM) in the absence of shRNA but presence of polybrene (8 μg/ml) was also 
performed to ensure any effects on SOCS3 expression were not a result of 
polybrene treatment. Cells were harvested and lysed as previously described 
prior to SDS-PAGE and immunoblotting for SOCS3 (Section 2.2.3.1). 
Immunoblotting with STAT3 was used as a loading control.  
SOCS3 protein was expressed 4 hours after treatment with Fsk and MG-132 
in the absence of lentiviral treatment and in the polybrene only control, but not 
after treatment with MG-132 only (Figure 4.6A). None of the lentivirus 
concentrations were successful in reducing SOCS3 protein expression 
compared to SOCS3 expression in the polybrene only treatment (Figure 4.6A). 
As numerous resources advised lower cell densities can enhance shRNA 
infection (Qiagen 2014; Aznan et al. 2018; ThermoFisherSCIENTIFIC 2019), 
an attempt to optimise SOCS3 gene silencing by lentiviral delivery of SOCS3 
shRNA was performed by treating HPAECs at 40% confluency as opposed to 
70% confluency. Cells were incubated for 6 days post-infection but otherwise 
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experimental details remained the same as described above. SOCS3 protein 
was expressed in all conditions (Figure 4.6B) including the negative control 
treatment (MG-132 only) so it is difficult to draw conclusions from this particular 
experiment. 
To determine if HPAECs were being successfully infected with the virus, the 
experiment was repeated as previously described with lentiviral treatment 
administered when the cells reached 70% confluency. Lentivirus-treated cells 
were then maintained in puromycin (2 µg/ml)-containing EGM-2 post-
treatment. In this experiment, cells were incubated for 10 days post-lentiviral 
treatment. This was because cells which had not been infected by the lentivirus 
necrosed after treatment with puromycin-containing EGM-2, thus a longer 
incubation period was required for the puromycin-resistant cells to reach 
confluency adequate for cell harvest. For one treatment, cells which had not 
been treated with lentivirus were also treated with puromycin (2 µg/ml)-
containing EGM-2 containing media to ensure the antibiotic sufficiently killed 
non-transfected kills. After 24 hours of incubation, the majority of cells had died 
and detached from the flask, thus the cell count was not high enough to 
continue incubating these cells.  
SOCS3 was not expressed 4 hours post-treatment with MG-132 alone but was 
expressed after treatment with Fsk and MG-132 in the absence of shRNA and 
the presence of polybrene only (Figure 4.6C). Although the shRNA-treated 
cells had demonstrated antibiotic resistance as a result of transfection, 











Figure 4.6: Lentiviral delivery of SOCS3 shRNA is not sufficient to silence 
SOCS3 gene expression 
A) HPAECs were seeded in 6 cm dishes and grown to 70% confluency prior 











 TU/μl. SOCS3 shRNA 
lentivirus was prepared in polybrene (PB) (8 μg/ml) containing DMEM. Cells 
were then maintained in endothelial cell growth medium (ECGM) for 4 days 
prior to 4 hours of treatment with Fsk (50 μM) in the presence of MG-132 (6 
μM). Treatment with Fsk (50 μM) in the presence of MG-132 (6 μM) for 4 hours 
without lentiviral treatment was used as a positive control. Treatment with MG-
132 (6 μM) alone without lentiviral treatment was used as a negative control. 
Incubation with PB (8 μg/ml) in the absence of lentiviral treatment was also 
performed. Cells were harvested and whole cell lysates were equalised for 
protein content and fractionated via SDS-PAGE for immunoblotting with 
SOCS3. Immunoblotting with STAT3 was used for a loading control. 
Experiment performed to n=1. B) The experiment was performed as described 
above apart from HPAECs were treated with SOCS3 shRNA at 40% 
confluency. Experiment performed to n=1. C) The experiment was performed 
as described above apart from the ECGM media was supplemented with 
puromycin (2 µg/ml) and cells were incubated for 10 days post-shRNA 




To further establish if the shRNA lentivirus was successfully infecting HPAECs, 
cells were imaged for mCherry expression. Cells were seeded in Nunc™ Lab-
Tek™ Chambered Coverglass at a density of 2x104 cells per chamber and left 
to incubate overnight. The lentivirus was then prepared at the same 
concentrations used for the previous experiments (9.37x104 TU/μl, 1.87x105, 
4.68x105, 9.36x105, 1.404x106 and 1.872x106 TU/μl) and applied to cells as 
previously described. As a negative control, HPAECs were maintained in fresh 
EGM-2 in the absence of lentiviral treatment. Cells were incubated for 5 days 
and then prepared for imaging of mCherry as previously described (Section 
2.2.2.4) 
There was no mCherry expressed in the absence of lentiviral treatment. 
SOCS3 shRNA lentiviral treatment at 9.37x104 TU/μl, 1.87x105, 4.68x105, and 
1.872x106 TU/μl also produced no mCherry expression (Figure 4.7A). 
Lentivirus concentrations of 9.36x105 TU/μl and 1.404x106 TU/μl did result in 
mCherry expression (Figure 4.7A) suggesting these concentrations are 
suitable for successful transfection of HPAECs. The average percentage of 
infected cells was calculated as described (Section 2.2.2.4) to generate 
infection efficiency data. A shRNA concentration of 1.404x106 TU/μl resulted 
in 98.6% infection efficiency, compared to 72.6% for 9.36x105 TU/μl of 
lentivirus (Figure 4.7B). 
4.3 Discussion 
Treatment with a SOCS3-containing lentivirus is sufficient to cause SOCS3 



















Figure 4.7: Lentiviral delivery of SOCS3 shRNA in HPAECs results in 
mCherry expression at 9.36x105 and 1.40x106 TU/μl 
A) HPAECs were seeded in Nunc™ Lab-Tek™ Chambered Coverglass at a 
density of 2x104 cells per chamber and left to incubate overnight prior to 











 TU/μl. Lentiviral media was 
replaced with fresh endothelial cell growth media after 24 hours and incubated 
for 5 days prior to fixing in methanol. Cells incubated in the absence of 
lentivirus were used as a negative control. Cells were counterstained with 
Hoechst 33342 (1 µM) (blue) prior to imaging for mCherry expression (red). 
Experiment completed to n=1. B) Infection counts for cells treated with 
lentivirus concentrations of 9.36x105 TU/μl and 1.404x106 TU/μl. 
161 
 
6Rα mediated tyrosine 705 phosphorylation of STAT3 (Figure 4.1b). This 
supports other research that has shown SOCS3 to limit IL-6 trans-signalling 
activity (reviewed by Babon et al. 2014) and is relevant to the hypothesis 
because IL-6 is a key inflammatory mediator in the progression of PAH 
(Section 1.4.2) (Savale et al. 2009; Steiner et al. 2009; Maston et al. 2018; 
Tamura et al. 2018). Prostanoids are currently used in the treatment of PAH 
(O'Connell et al. 2016) and, in the case of BPS, treprostinil and the selexipag 
metabolite ACT-333679, also induce SOCS3 protein expression in cells 
involved in the pathogenesis of PAH (Chapter 3, Figures 3.1 and 3.4). Thus, 
this may indicate a novel therapeutic mechanism which has yet to be explored. 
To address this, the ability of BPS or treprostinil to limit IL-6/sIL-6Rα mediated 
tyrosine 705 phosphorylation of SOCS3 in HPAECs was measured and shown 
to be significant in HPAECs and WT AS-M.5 cells (Figures 4.2, 4.3 and 4.4). 
However, neither BPS nor treprostinil significantly limited IL-6 trans-signalling 
activity in AS-M.5 SOCS3 KO cells (Figure 4.3). As Nur77 was significantly 
induced by all treatments in both cell types (Figure 4.2), knockdown of SOCS3 
must be a result of SOCS3 gene knockout and not an indirect effect of SOCS3 
KO on cAMP signalling. Consequently, impaired inhibition of IL-6-mediated 
phosphorylation of STAT3 by BPS and treprostinil in AS-M.5 SOCS3 KO cells 
must also be due to SOCS3 gene knockout and not an indirect effect of SOCS3 
KO on cAMP signalling. 
Although not significant, there is a slight decrease in tyrosine 705 STAT3 
phosphorylation post-treatment with forskolin, BPS and treprostinil in AS-M.5 
SOCS3 KO cells. This reduction may be due to the effects of other inhibitory 
pathways. For instance, JAK/STAT signalling is also inhibited by PTPs such 
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as SHP2. SHP2 contains an SH2 domain (Hof et al. 1998) like that seen in 
SOCS3, thus it is able to bind to the phosphorylated tyrosine 759 residue of 
gp130 (Section 1.4.1). In the absence of SOCS3, and therefore with less 
competition for binding, it is reasonable to believe SHP2, which is ubiquitously 
expressed, will bind to tyrosine 759 to mediate JAK/STAT signalling. Research 
has shown PTP to regulate endothelial barrier function in human lung 
microvascular ECs and interact with VE-cadherin (Sui et al. 2005). 
Dysfunctional endothelial barrier function is associated with both IL-6 trans-
signalling activity (Alsaffar et al. 2018) and PAH (reviewed by Ranchoux et al. 
2018). In HPAECs, PTP mRNA has been shown to be expressed (Sui et al. 
2005), but the effects of PTP in limiting IL-6 activity in these cells has not been 
investigated. However, the effect of PTPs on IL-6/sIL-6Rα activity has been 
determined in other cell types. For instance, in T-cells, IL-6/sIL-6Rα-induced 
STAT3 phosphorylation was suppressed by overexpression of T-cell-PTP 
(Yamamoto et al. 2002), and in HUVECS, PTP-MEG2 knockdown resulted in 
increased IL-6 signalling and activity, as measured by VEGF signalling (Hao 
et al. 2012). 
Research has indicated crosstalk between cAMP and PTPs. In Jurkat T-cells, 
cAMP-mediated PKA regulates ERK1,2 signalling via phosphorylation of 
haematopoietic (He)PTP at serine 23 (Saxena et al. 1999). Additionally, in 
macrophages, cAMP-mediated PKA activates SHP2 to trigger apoptosis and 
protects against Bordetella adenylate cyclase toxin (Cerny et al. 2015; Ahmad 
et al. 2016). Interactions between cAMP and PTPs in vascular cells are not 
well understood, but this may be a potential route of cAMP-mediated inhibition 
of IL-6 activity. PTP inhibitors, such as the SHP2/SHP1 potent inhibitor NSC 
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87877 (Tocris; Cat. No. 2613), could be utilised in future experiments to 
determine the extent of PTP inhibition of IL-6-mediated phosphorylation of 
STAT3. 
Another unexpected finding was that phosphorylation of STAT3 occurred in 
the absence of stimulation by IL-6/sIL-6Rα in AS-M.5 SOCS3 KO cells (Figure 
4.4). Endo et al. (1997) suggested there was constitutive inhibition of JAK by 
SOCS proteins and the presence of constitutively expressed SOCS3 has been 
found in other experiments performed by the Palmer lab (currently 
unpublished), which supports potential constitutive SOCS3 inhibition of 
JAK/STAT signalling.  
Current SOCS3 antibodies available are not sensitive enough to detect low 
levels of expression. Towards the end of this project, a more sensitive 
chemiluminescent substrate (WESTAR SUPERNOVA horseradish peroxidase 
(HRP) detection, Cyanogen; Cat. No. XLS3) was utilised. This may explain 
why the SOCS3 band in MG-132 only treatments is more pronounced in later 
experiments (Figure 4.6) compared to immunoblots in earlier experiments 
(Chapter 3), although the use of WESTAR SUPERNOVA HRP detection 
substrate also resulted in the speckled dots apparent on some figures. To 
ensure sensitivity and linearity of protein detection by the WESTAR 
SUPERNOVA HRP, detection of protein samples over a range of 
concentrations (0 ng/µl, 10, 20, 30, 40 ng/µl) was measured by utilising protein 
samples from previously lysed cells treated with Fsk. SDS-PAGE and 
immunoblotting for STAT3, SOCS3 and Nur77 was then completed which 
showed the WESTAR SUPERNOVA HRP detection substrate detected small 
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changes in protein content, including SOCS3, over a range of concentrations 
in a linear manner (Figure 4.8).  
Utilising other sensitive methods of protein detection may give some 
clarification on the presence of constitutive SOCS3 protein. SOCS3 ELISA kits 
(MyBioSource, Inc.; Cat. No. MBS703435) are now commercially available 
and claim to detect very low protein levels. Alternatively, the use of 
immunofluorescence antibodies in immunocytochemistry or flow cytometric 
analysis of HPAECs may help determine if constitutive SOCS3 protein is 
present in ECs. 
To further explore a role for SOCS3 in prostanoid treatment of PAH, 
techniques were utilised to silence SOCS3 expression in HPAECs. Neither 
shRNA nor siRNA were successful in reducing Fsk-induced SOCS3 protein 
expression (Figure2 4.4 and 4.6). The effect of shRNA and siRNA on SOCS3 
RNA levels were not determined but should be considered in the future as 
qPCR will enable greater sensitivity than western blotting alone. One potential 
reason for unsuccessful silencing of SOCS3 protein is that the experiments 
were not optimised for successful transfection of the RNA into the cells. For 
siRNA, an increased amount of HiPerFect was used to try and improve siRNA 
transfection. However, a range of HiPerFect concentrations alongside altering 
variables such as cell confluency and treatment time was not tested due to 
time limits.  
With regards to shRNA experiments, the confluency of the cells at the time of 
lentiviral treatment was reduced to enable greater transduction efficiency. 











Figure 4.8 Sensitivity and linearity of WESTAR SUPERNOVA HRP 
detection substrate 
A) Increasing concentrations of protein from cells previously treated with 
forskolin (Fsk) (10 µM) and lysed were separated via SDS-PAGE for 
immunoblot analysis with SOCS3, Nur77 and STAT3 as previously described 
(Section 2.2.3.2). B) Densitometry values for SOCS3, Nur77 and STAT3 
acquired using LICOR Image Studio Lite software were plotted on a graph 
against protein concentration to measure linearity of protein detection. 
Experiment completed to n=1. 
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Further measures to determine if cells were being successfully infected by the 
lentivirus such as treatment with puromycin-containing media (Figure 4.6C) 
suggested HPAECs were demonstrating puromycin-resistance as a result of 
lentivirus infection but not SOCS3 knockdown. Similarly, fluorescent images of 
cells taken 5 days post-treatment with shRNA lentivirus demonstrate mCherry 
expression (Figure 4.7). These results suggest HPAECs are being 
successfully infected by the lentivirus, but that the lentivirus is not sufficient to 
silence SOCS3 gene expression. Alternatively, the process of lentiviral 
infection may be initiating an immune response, thus increasing SOCS3 
production to a greater extent than it is silencing it. 
As attempts to silence SOCS3 gene expression via siRNA and shRNA in 
HPAECs were unsuccessful, alternative methods to measure the role of 
SOCS3 in prostanoid mediated inhibition of IL-6 trans-signalling should be 
utilised in the future. HPAEC SOCS3 KO cells could potentially be developed 
using CRISPR (Gilbert et al. 2013) or transcription activator-like effector 
nucleases (TALEN) technology (Sun and Zhao 2013). However, genome 
engineering techniques such as these may also not be successful in HPAECs 
due to them being primary cells and having a limited passage capacity.  
Mutagenesis of HPAECs may provide a different approach. SU/Hx animal 
models with a gp130YF knock in mutation at tyrosine 759, essentially 
preventing the attenuation of JAK-mediated gp130 phosphorylation which 
would normally result from SOCS3 or SHP2 binding to gp130, have been 
utilised previously to measure the impact of STAT3 hyper-activation (Atsumi 
et al. 2002; Tsuji et al. 2009). In animal models, mice carrying this mutation  
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experienced greater RVSP after hypoxia compared to healthy mice 
(unpublished data provided by Professor Tim Palmer, University of Hull). 
Creating the same mutation in HPAECs or utilising lung ECs isolated from WT 
and gp130YF knock in mice would provide an alternative method to attenuate 
SOCS3 inhibition of JAK/STAT signalling. 
Alternatively, lentiviral delivery of mutated SOCS3 in vitro that results in loss 
of function to either the SH2 or KIR domain of SOCS3 have previously been 
shown to enhance JAK/STAT signalling. KIR single point mutations (L22D and 
F25A) have previously been found to attenuate the ability of SOCS3 to inhibit 
cytokine signalling as measured by breast tumour kinase-mediated STAT3 
phosphorylation (Gao et al. 2012). In HEK 293 cells transiently transfected with 
SOCS F136L, a F136L mutation within the SH2 domain of SOCS3 causing 
loss-of-function, resulted in increased erythropoietin/JAK2 mediated cell 
growth (Suessmuth et al. 2009). Whether HPAECs could withstand such 
mutations and their effect on SOCS3 inhibition of IL-6/sIL-6Rα induced 
JAK/STAT signalling are yet to be investigated. 
To conclude, prostanoids significantly limit IL-6/sIL-6Rα signalling activity in 
HPAECs and WT but not in SOCS3 KO AS-M.5 cells, suggesting the effects 
of prostanoids may be mediated by SOCS3. However, further work to 
knockdown SOCS3 expression in HPAECs is required before we can 
conclusively demonstrate this in ECs relevant to PAH.  
Although immunoblotting has shown the reduction in IL-6/sIL-6Rα-induced 
tyrosine 705 phosphorylation of STAT3 by prostanoids in HPAECs to be 
significant, it is unclear as to whether this would be sufficient to have 
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therapeutic affects in PAH. Thus, the impact of BPS, treprostinil and ACT-
333679 on IL-6/sIL-6Rα-mediated gene transcription and cell barrier function 
was determined. 
5. Prostanoids limit functional effects of IL-6 trans-signalling 
5.1 Introduction 
As previously discussed, IL-6 trans-signalling is associated with the 
proliferation, migration and survival of ECs, as well as impacting EC 
permeability enabling inflammatory and pro-growth factors to access the 
underlying PASMCs (Section 1.4.2). Affected ECs and SMCs contribute to the 
vascular remodelling and characteristic plexiform lesions associated with PAH. 
To be therapeutically beneficial, drugs would need to prevent or potentially 
reverse these IL-6-mediated effects. BPS, treprostinil and ACT-333679 limited 
IL-6 trans-signalling in HPAECs, which are involved in PAH vascular 
remodelling, measured via tyrosine 705 phosphorylation of STAT3 (Figure 
4.2). The following experiments aim to determine if prostanoid inhibition of IL-
6 trans-signalling activity is sufficient to reduce functional effects of IL-6/sIL-
6Rα in HPAECs. 
5.2 Results   
5.2.1 Prostanoids limit IL-6/sIL-6Rα-induced cell permeability 
IL-6/sIL-6Rα, but not IL-6 alone, compromised EC barrier function in ovarian 
ECs according to the redistribution of actin filaments (Wei et al. 2013), and IL-
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6-/- KO mice were protected from mechanical ventilation and hydrochloric acid -
induced alveolar-capillary permeability (Gurkan et al. 2011). Endothelial 
permeability enables the movement of inflammatory factors and GF through 
the EC monolayer where they can stimulate SMCs resulting in a pro-
inflammatory, proliferative phenotype that contributes to the development of 
PAH (Section 1.3.1). As increased cell permeability contributes to PAH 
progression, the effect of prostanoids on IL-6/sIL-6Rα induced cell permeability 
in confluent HPAECs was measured via a FITC-dextran cell permeability 
assay (Anderl et al. 2012). 
Transwell collagen coated inserts were seeded with 1x106 cells. This was 
repeated after 24 hours to ensure confluency of the cell monolayer. Cells were 
treated 72 hours after the initial seeding for 2 hours with BPS (10 μM). Fsk (50 
μM) treatment for 4 hours was used as a positive control of IL-6/sIL-6Rα 
inhibition (Figure 4.2). 4 hours of vehicle treatment was used as a negative 
control. Cells were then treated with IL-6/sIL-6Rα for 24 hours prior to the 
assay being performed as previously described (Section 2.2.5.1).  
In the absence of IL-6/sIL-6Rα, Fsk and BPS had no significant effect on cell 
permeability compared to the vehicle (Figure 5.1). In contrast, IL-6/sIL-6Rα 
treatment significantly increased cell permeability, which was attenuated by 
treatment with either BPS or Fsk (Figure 5.1). Treating with high 
concentrations of IL-6 (100 ng/ml) to mimic overexpression of IL-6 reduced 
VE-cadherin expression local to cellular junctions (Kayakabe et al. 2012), and 
treating IL-6/sIL-6Rα signalling in HUVECs resulted in increased cell 
permeability and reduced VE-cadherin expression at cellular junctions (Lo et 










Figure 5.1: Prostanoids limit IL-6/sIL-6Rα induced HPAEC permeability 
Confluent HPAECs were treated for 2 hours with beraprost sodium salt (BPS) 
(10 μM), or for 4 hours with forskolin (Fsk) (50 μM), which was used as a 
positive control, in the presence and absence of IL-6 (5 ng/ml) and sIL-6Rα 
(25 ng/ml) (IL-6/sIL-6Rα) which was added 24 hours prior to treatment with 
FITC-dextran as described in the Materials and Methods. Cells were incubated 
with FITC-dextran for 45 minutes before fluorescence readings were taken 
from the receiver media. Results were calculated as the percentage difference 
of fluorescence compared to treatment with IL-6/sIL-6Rα alone. * indicates 
P<0.05, which was considered significant. *** indicates <0.0001. 
Quantification for n=4 experiments has been shown.  
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VE-cadherin in confluent monolayers of HPAECs as an alternative measure of 
IL-6/sIL-6Rα-induced cell permeability. 
HPAECs were seeded on to 4-well Nunc™ Lab-Tek™ chambers as described 
in Section 2.2.5.2. Cells were then treated with or without Fsk (50 µM) for 4 
hours prior to treatment with or without IL-6/sIL-6Rα. Cells were then prepared, 
and images taken as previously described (Section 2.2.5.2). Prominent VE-
cadherin staining was evident at cellular junctions in the vehicle treatment 
(Figure 5.2A). Post-treatment with IL-6/sIL-6Rα there was a loss of localised 
VE-cadherin which was partially rescued by treatment with Fsk (Figure 5.2A). 
Interestingly, Fsk alone disrupted VE-cadherin localisation.  
Numerous attempts to complete this experiment were made, however only the 
one example shown in Figure 5.2A was of good enough quality to interpret. 
Details of the fixation, staining and imaging protocols used for the different 
attempts are described in the below schematic (Figure 5.2B). A representative 
image of vehicle treated cells has been used for all optimisation conditions for 
comparison. The initial experiment showed no VE-cadherin localisation at 
cellular junctions in any treatment. As VE-cadherin expression at cellular 
junctions increases with increased monolayer confluency (Ferreri et al. 2008), 
this may be result from a lack of cell confluency so increased the initial cell 
density. Also, as fixation via methanol permeates the cell membrane (Jamur 
and Oliver 2010), the 0.1% v/v triton/PBS wash was removed. The final change 
was magnification used, with images taken at 400x magnification as opposed 
to 800x (Figure 5.2B, opt. 1). However, as the staining of these cells appeared 





















Figure 5.2: VE-cadherin staining of HPAECs post-treatment with IL-6/sIL-
6Rα and forskolin 
A) Cells were treated for 4 hours with Forskolin (Fsk) (50 μM) in the presence 
and absence of IL-6 (5 ng/ml) and sIL-6Rα (25 ng/ml) (IL-6/sIL-6Rα) which 
was applied 24 hours prior to fixing cells. A vehicle (Veh) control was also 
performed. Cells were prepared for imaging as described (Section 2.2.5.2) and 
then visualised at 800x magnification using a Nikon ECLIPSE TE2000-E 
confocal microscope. Images were retained using EZ-C1 3.90 software. B) 
Cell seeding, staining and imaging details of all experiments completed to 




was reincorporated in future experiments to increase cell permeability (Jamur 
and Oliver 2010). To reduce background staining, the concentration of Alexa 
Fluor 568-conjugated goat anti-rabbit IgG (H+L) and Hoescht 33342 was 
reduced to 1 μg/ml and 0.5 µM respectively. In addition, a larger volume of 
PBS (0.5 ml) was used for washing steps to ensure efficient washing of cells 
between incubation with antibodies and Hoechst 33342. In addition, 
magnification was increased back up to 800x (Figure 5.2B, opt. 2). This 
resulted in good quality images that clearly demonstrated VE-cadherin 
expression at cellular junctions. 2 further repeats (Figure 5.2B, opt. 3 and opt. 
4) of the method used in optimisation 2 were completed but images were taken 
at 400x magnification. For optimisation 4 conditions, wash volumes were 
further increased to 1 ml. Neither opt. 3 nor opt. 4 resulted in better quality 
images than those seen in opt. 2.  
As BPS, treprostinil and ACT-333679 limited IL-6/sIL-6Rα-induced STAT3 
tyrosine 705 phosphorylation to a similar degree as Fsk (Figure 4.2), further 
experiments were performed to determine if BPS could also prevent IL-6 trans-
signalling-mediated loss of localised VE-cadherin. HPAECs were prepared as 
described above prior to pre-treatment with or without BPS (10 μM) for 3 hours 
in the presence or absence of IL-6/sIL-6Rα treatment for a further 24 hours. 
Treatment with Fsk (50 μM) with or without IL-6/sIL-6Rα was also included. 
Treatment with LPS (1 μg/ml) was included as a positive control stimulus to 
induce loss of VE-cadherin from the cell surface (Flemming et al. 2015; Zheng 
et al. 2018). A vehicle control was also completed. Cells were prepared for 
fluorescence microscopy as previously described (Section 2.2.5.2). Confocal 
images were taken in which VE-cadherin localisation appears similar in post-
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vehicle, LPS only and IL-6/sIL-6Rα only treatments but increased with 
treatment of Fsk in the presence of IL-6/sIL-6Rα (Figure 5.3). In contrast to the 
previous experiment (Figure 5.2A), treatment with Fsk alone increased VE-
cadherin localisation to the cellular junctions, as did treatment with BPS alone 
(Figure 5.3). Although attempts were taken to optimise imaging of VE-cadherin 
expression (Figure 5.2B), the images displayed in the figure were the best 
quality acquired. Unfortunately, due to images being too blurry to identify 
individual cells and VE-cadherin expression around the whole of the cells, 
imageJ analysis or manual cell counting was not possible thus statistical 
analysis has not been performed and only visual interpretation of the figures 
shown has been described. 
5.2.3 The effects of prostanoids on IL-6 stimulated gene and protein 
expression 
As discussed, IL-6 induces genes that promote PAH pathogenesis (Section 
1.4.1), including those for cell adhesion molecules. A recent study in HUVECs 
found IL-6 induced both ICAM1 and VCAM1 after 48 hours of stimulation 
(Wiejak et al. 2019). This is interesting as increased serum soluble-ICAM1 
levels correlate with increased mPAP, systolic PAP and diastolic pulmonary 
arterial pressure (Sungprem et al. 2009) and has been suggested as a possible 
biomarker for PAH (Pendergrass et al. 2010; Oguz et al. 2014), and 
upregulation of plasma VCAM1 levels is associated with vascular diseases 
including PAH (Pendergrass et al. 2010; Agassandian et al. 2015). Therefore, 
IL-6/sIL-6Rα induction of adhesion molecules may be one mechanism in which 






Figure 5.3 VE-cadherin staining of HPAECs post-treatment with IL-6/sIL-
6Rα and beraprost sodium salt 
HPAECs were treated for 2 hours with beraprost sodium salt (BPS) (10 μM) in 
the presence and absence of IL-6 (5 ng/ml) and sIL-6Rα (25 ng/ml) (IL-6/sIL-
6Rα) which was applied for 24 hours. 4 hours of treatment with forskolin (Fsk) 
(50 μM) was used as a positive control, treatment with lipopolysaccharide 
(LPS) (1 μg/ml) for 24 hours was used as a negative control. Cells were 
prepared for imaging as described (Section 2.2.5.2) and then visualised at 
400x magnification using a Nikon ECLIPSE TE2000-E confocal microscope. 
Images were retained using EZ-C1 3.90 software. Experiment was completed 
to n=5. Representative images have been shown. 
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To test this, HPAECs were treated with or without IL-6/sIL-6Rα for up to 24 
hours. Cells were then harvested and lysed prior to analysis by SDS-PAGE 
and immunoblotting for VCAM1 and STAT3.  The 16-hour IL-6/sIL-6Rα 
treatment was harvested at a different time to the other treatments, thus a 
separate 16-hour control was performed. VCAM1 expression is not increased 
after 16 hours treatment with IL-6/sIL-6Rα in comparison to the 16-hour vehicle 
control (Figure 5.4A). All other treatments were harvested at the same time as 
the 24-hour vehicle control. LPS was used as a positive control of VCAM1 
expression (Lin et al. 2007; Sawa et al. 2008), but was not sufficient to induce 
VCAM1 after 24 hours treatment in HPAECs in comparison to the 24-hour 
vehicle control (Figure 5.4A). Similarly, none of the IL-6/sIL-6Rα treatments 
influenced VCAM1 expression compared to the vehicle control (Figure 5.4A). 
This could be indicative of high basal VCAM1 expression in HPAECs, making 
it difficult to detect further VCAM1 induction.  
As IL-6/sIL-6Rα induction of VCAM1 was not successful, IL-6/sIL-6Rα 
induction of ICAM1 was considered. Although treatment with LPS did result in 
more pronounced ICAM1 expression after 24 hour, IL-6/sIL-6Rα induction of 
ICAM1 in human saphenous vein (HSV)ECs also showed high basal levels of 
ICAM1 protein which were not affected by treatment with IL-6/sIL-6Rα (Figure 
5.4B) (unpublished data provided by Dr J.J.L.Williams, University of Glasgow). 
As it was crucial to identify an IL-6/sIL-6Rα-induced gene in HPAECs, 
VEGFR2 induction was investigated. IL-6 is also known to promote 
angiogenesis via upregulation of VEGF (Cohen et al. 1996; Wei et al. 2003b; 















Figure 5.4: IL-6/sIL-6Rα has no effect on ICAM1 or VCAM1 protein 
expression in HSVECs and HPAECs respectively 
A) HPAECS were treated with IL-6 (5 ng/ml) + sIL-6Rα (25 ng/ml) for 0.5 hours, 
1, 2, 4, 8, and 24 hours. A vehicle (Veh) control was performed as a negative 
control and cells were treated with lipopolysaccharide (LPS) (1 μg/ml) for 24 
hours as a positive control. A 16-hour treatment with IL-6 (5 ng/ml) + sIL-6Rα 
(25 ng/ml) was performed in parallel alongside a 16-hour Veh control. Whole 
cell lysates were then equalised for protein content and fractionated via SDS-
PAGE for immunoblotting with VCAM1. Immunoblotting with STAT3 was used 
for a loading control. Experiment performed to n=1. B) HSVECS were treated 
with IL-6/sIL-6Rα for 0 hours, 0.5, 2, 4, 8 and 24 hours. 4 hour treatment with 
forskolin (Fsk) (50 μM) was used as a negative control. Treatment with LPS (1 
μg/ml) for 8 hours and 24 hours was used as a positive control. Whole cell 
lysates were then equalised for protein content and fractionated via SDS-
PAGE for immunoblotting with ICAM1. Immunoblotting with tubulin (TUB) was 
used for a loading control. Experiment performed to n=1. This data was 




receptor in VECs (Millauer et al. 1993; Quinn et al. 1993; Shalaby et al. 1995) 
and VEGFR mRNA and protein is elevated in ECs of plexiform lesions isolated 
from PAH patients (Tuder et al. 2001). 
As it is crucial for VEGF signalling, which is also increased in PAH and 
associated with EC dysregulation and vascular remodelling (Section 1.3.2) 
(Partovian et al. 1998; Papaioannou et al. 2009), it is likely a key factor in PAH 
development. Thus, as an alternative to adhesion molecules, IL-6/sIL-6α 
stimulation of VEGFR2 protein expression was determined in HPAECs. 
HPAECs were treated with or without IL-6/sIL-6Rα for up to 24 hours. LPS has 
previously been shown to upregulate VEGF/VEGFR2 signalling in Th1 and 
Th17 cells (Kim et al. 2010), and as LPS has previously been used as a pro-
inflammatory control in these experiments, 24 hours of treatment with LPS was 
used as a positive control. Cells were harvested and lysed as previously 
described before protein content was determined. Immunoblotting was carried 
out and the membranes were probed for VEGFR2 and STAT3. VEGFR2 
protein was present in unstimulated HPAECs and its levels were not increased 
at any time point post-IL-6/sIL-6Rα treatment (Figure 5.5A).  
As high basal levels of VEGFR2 were potentially hiding any IL-6/sIL-6Rα-
mediated induction of VEGFR2 protein expression, efforts were made to 
reduce basal protein expression in order to maximise detection of any IL-6/sIL-
6Rα-mediated induction. Initially, HPAECs were incubated in EGM-2 or M199 
at a range of serum concentrations for up to 24 hours prior to harvesting for 
lysis and analysis by SDS-PAGE and immunoblotting for VEGFR2 and STAT3 
as previously described. However, basal VEGFR2 levels were not reduced in 
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any condition tested when compared to incubation in normal EGM-2 (Figure 
5.5B). 
As serum levels did not impact basal VEGFR2 protein expression, but cAMP-
modulating agents have been shown to reduce IL-6 mediated inflammatory 
protein expression, the effect of BPS on basal VEGFR2 was measured. 
Samples from a previous experiment in which HPAECs were treated with or 
without BPS (10 µM) for up to 8 hours were utilised (Section 3.1). As this 
experiment had initially been completed to determine BPS-mediated SOCS3 
induction, cells had also been treated with MG-132. Thus, MG-132 alone was 
used as a negative control. 4 hours of treatment with Fsk in the presence of 
MG-132 was used a positive control. Like previous experiments, basal 
VEGFR2 protein was detectable in lysates in the negative control treatment 
(MG-132 only). As BPS induction of VEGFR2 protein expression was only 
measured for n=1 experiments it cannot be used to draw conclusions. 
However, treatment with BPS appeared to trigger a transient increase in 
VEGFR2 expression after 0.5 hours, 1 and 2 hours of treatment returning to 
basal levels 4 hours post-BPS treatment (Figure 5.5C) which is supported by 
published research.  
BPS has previously been shown to stimulate transcription of the VEGF gene 
after 2 hours and VEGF mRNA is still elevated 24 hours post-treatment with 
BPS in C2/2 cells, a progenitor cell of the peripheral airway epithelium, and rat 
aortic SMC (Atsuta et al. 2009). As 2 hours was the earliest time treatment 
measured, whether gene induction occurs earlier than this is unknown. As 
VEGF and VEGFR2 protein expression is initially induced in a parallel manner 










Figure 5.5: IL-6/sIL-6Rα has no effect on VEGFR2 protein expression 
A) HPAECS were treated with IL-6 (5 ng/ml) + sIL-6Rα (25 ng/ml) for 0.5 hours, 
1, 2, 4, 8, and 24 hours. A vehicle (Veh) control was performed as a negative 
control and cells were treated with lipopolysaccharide (LPS) (1 μg/ml) for 24 
hours as a positive inflammatory control. A 16-hour treatment with IL-6 (5 
ng/ml) + sIL-6Rα (25 ng/ml) was performed in parallel alongside a 16 hour 
vehicle (Veh) control. Whole cell lysates were then equalised for protein 
content and fractionated via SDS-PAGE for immunoblotting with VEGFR2. 
Immunoblotting with STAT3 was used for a loading control. Experiment 
performed to n=1. B) HPAECs were incubated in either 1% FBS EGM-2, 1% 
FBS M199 or serum free (SF) M199 for 2 hours, 4, 8, or 24 hours. 24 hours 
incubation in fresh 2% FBS EGM-2 was used as a control. Whole cell lysates 
were then equalised for protein content and fractionated via SDS-PAGE for 
immunoblotting with VEGFR2. Immunoblotting with STAT3 was used for a 
loading control. Experiment performed to n=1. C) HPAECS were treated with 
beraprost sodium salt (BPS) (10 μM) for 0.5 hours, 1, 2, 4 and 8 hours in the 
presence of MG-132 (6 μM). 4 hour treatment with forskolin (Fsk) (50 μM) with 
MG-132 (6μM) was used as a positive control. MG-132 (6 μM) only was used 
as a negative control. Whole cell lysates were then equalised for protein 
content and fractionated via SDS-PAGE for immunoblotting with VEGFR2. 
Immunoblotting with GAPDH was used for a loading control. Experiment 
performed to n=1. 
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timeframe to VEGF which would be consistent with the increase in VEGFR2 
expression seen 0.5 hours, 1 and 2 hours post-treatment with BPS (Figure 
5.5C).  
As IL-6/sIL-6Rα did not stimulate protein expression of ICAM1, VCAM1 or 
VEGFR2, we investigated the effect of IL-6/sIL-6Rα on RNA levels of the 
STAT3-regulated gene VEGF (Niu et al. 2002; Wei et al. 2003a; Chen et al. 
2008).  VEGF is increased in the lung tissue of chronic hypoxia and MCT 
induced lung injury in animal models (Burke et al., 2009, Cho et al., 2009). 
Additionally, VEGF levels correlate with increased systolic pressure in the 
pulmonary artery (Papaioannou et al., 2009). 
A human VEGFA transcript variant 3 (VEGFA-T3) DNA plasmid (Figure 5.6A) 
that included a 630 bp VEGFA sequence (Chapter 2, Table 4), and an 
ampicillin resistant gene, supplied by Sino Biological was expanded in 
transformed XL1-Blue E.coli and prepared (Section 2.2.4.1). Restriction 
enzyme digests (Section 2.2.4.2) were performed to verify the plasmid. The 
restrictions enzymes Xba1 and Kpn1 were utilised as these cleaved the 
plasmid at unique sites that in combination were predicted to generate two 
DNA products of approximately 0.75 kbp and 5.5 kbp. Cleavage with either 
Xba1 and Kpn1 individually was predicted to result in a DNA product of 6.2 kbp 
consistent with the predicted size of VEGFA-T3 cDNA. These were confirmed 
in digests using three of the resulting cDNA preparations and monitored via 
1.5% (w/v) agarose gel electrophoresis. The resulting DNA bands were 
consistent with the estimated results. When Xba1 and Kpn1 are used in 
combination there is band visible between 3 and 10 kbps, and a smaller band 
at 0.75 kbp (Figure 5.6B). When only one restriction enzyme is utilised there 
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is a visible band between 3 and 10 kbps which is indicative of a DNA product 
slightly larger than that seen when Xba1 and Kpn1 are used in combination 
(Figure 5.6B). A lower agarose gel % may have enabled more accurate 
identification of kbp size for the larger DNA products, however higher agarose 
concentrations were used to allow for separation of smaller DNA products at 
the 500 bp region. DNA products are consistent between all three of the 
colonies isolated (Figure 5.6B). 
As restriction enzyme and agarose gel analysis demonstrated successful 
expansion and preparation of the VEGFA-T3 plasmid DNA, it was 
subsequently used to optimise PCR conditions required for amplification and 
detection of endogenous VEGF mRNA in RT-PCRs from HPAECs. PCR was 
performed as described (Section 2.2.4.4) using plasmid cDNA from each of 
the three colonies. Reactions were analysed via 2% (w/v) agarose gel 
electrophoresis. The main PCR product for all colonies was a single band at 
approximately the 300 bp (Figure 5.6C). Interestingly, this is more consistent 
with VEGFA exon 2 (367 bp) or exon 7 (313 bp) than the total transcript size 
(Zhang et al. 2016a). Nevertheless, this was used as a positive control for RT-
PCR analysis of VEGFA expression when measuring IL-6/sIL-6Rα-mediated 
induction of VEGF RNA in HPAECs. 
HPAECs were treated with IL-6/sIL-6Rα for up to 48 hours before RNA was 
purified and reverse transcribed as previously described (Section 2.2.4.4). As 
cells treated with IL-6/sIL-6Rα for 16 hours were harvested prior to the other 
treatments, a separate 16 hour vehicle control was also performed. Reaction 
products were analysed via agarose gel electrophoresis (Section 2.2.4.5) 











Figure 5.6: Human VEGFA-transcript variant 3 
A) VEGFA-T3 plasmid map, provided by supplier. B) VEGFA-T3 plasmid 
DNA was extracted from three VEGFA-T3 colonies using the Promega 
Wizard Plus Miniprep DNA Purification System according to manufacturer’s 
instructions. A restriction enzyme digest was then performed with Xba1 and 
Kpn1 restriction enzymes on DNA isolated from each colony prior to 1.5% 
agarose gel analysis. DNA fractionation was monitored under UV light and 
captured using a Biorad ChemiDoc MP Imaging System. C) VEGF-T3 
plasmid DNA was analysed via 2% agarose gel electrophoresis. DNA 
migration was monitored under UV light and captured using a Biorad 














Figure 5.7: IL-6/sIL-6Rα induces VEGF gene expression 
A) HPAECS were treated with IL-6 (5 ng/ml) + sIL-6Rα (25 ng/ml) for 2 hours, 4, 8, 16, 
24, and 48 hours. A vehicle (Veh) control was performed as a negative control. RNA 
was then purified from cell lysates and reverse transcribed to form cDNA (10 ng/ml). 
A no reverse transcriptase (RT) was performed at this point. Resulting cDNA was 
amplified via a PCR and separated via 2% agarose gel electrophoresis as described 
(Sections 2.2.4.4 – 2.2.4.5). VEGF-T3 plasmid cDNA was used as a positive control. 
DNA fractionation was monitored under UV light and captured using a Biorad 
ChemiDoc MP imaging system. B) HPAECS were treated with IL-6 (5 ng/ml) + sIL-6Rα 
(25 ng/ml) for 1 hour, 2, 4, 6 and 8 hours. A Veh control was performed as a negative 
control. RNA was then purified from cell lysates and reverse transcribed to form cDNA 
(10 ng/ml). A no RT was performed at this point. Resulting cDNA was amplified via a 
PCR and separated via 2% agarose gel electrophoresis as described (Sections 2.2.4.4 
– 2.2.4.5). VEGF-T3 plasmid cDNA was used as a positive control. DNA migration was 
monitored under UV light and captured using a Biorad ChemiDoc MP imaging system. 
191 
 
negative control sample, incubated without reverse transcriptase, was also 
included to assess contamination with genomic DNA. VEGFA RNA was 
present 2 hours post-IL-6/sIL6Rα treatment and this was sustained for at least 
the last time point examined (48 hours). One band is visible between 300 and 
400 bps which is consistent with the VEGF-T3 plasmid and VEGFA isoform 2. 
A slightly smaller DNA product consistent with VEGFA isoform 7 is also visible. 
Bands representative of two smaller DNA products are also visible consistent 
with VEGF isoforms described by Harper and Bates (2008). 
 As the initial time-point was too late to identify the earliest treatment time 
required to induce VEGF RNA expression, the experiment was repeated over 
a shorter time frame. HPAECs were treated with IL-6/sIL-6Rα for up to 8 hours 
prior to undergoing RNA purification, reverse transcription and PCR in the 
same manner as previously described (Sections 2.2.4.4 and Sections 2.2.4.5). 
Agarose gel analysis showed VEGF RNA to be present 4 hours post-IL-
6/sIL6Rα treatment and this was sustained after 8 hours (Figure 5.7B). Along 
with the longer time course, this suggests VEGF RNA is induced in HPAECs 
within 4 hours of treatment with IL-6/sIL-6Rα. 
As the PCR results suggested IL-6 induced VEGF gene expression, a VEGF-
A ELISA was performed as previously described (Section 2.2.3.2) to determine 
if this resulted in any detectable change in IL-6 mediated VEGF protein 
expression and, if so, was this limited by prostanoid treatment. Initially, a 
VEGF-A ELISA was performed with increasing concentrations of VEGF-A 
standard (supplied by manufacturer) to produce a standard curve of VEGF-A 
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concentration versus absorbance (Figure 5.8A). HPAECs were then treated 
with BPS (10 μM) for 2 hours prior to 24 hours treatment with IL-6/sIL-6Rα. 
Treatment with BPS alone and IL-6/sIL-6Rα alone was also measured and a 
vehicle control was performed. The VEGF protein content of the treated 
medium was then determined by ELISA performed according to the 
manufacturer’s instructions (Section 2.2.3.2). Levels of detectable VEGF-A 
protein were at the lower limit of the sensitivity of the assay as determined by 
the low absorbance (and thus low concentration) of detectable VEGF-A in all 
conditions; however, the data is included for information (Figure 5.8B). 
5.3 Discussion 
As previously mentioned, BPS, treprostinil and ACT-333679 significantly 
inhibited IL-6 trans-signalling activity in HPAECs (Figure 4.2). However, for this 
to have therapeutic benefit, it must be sufficient to limit the functional effects of 
IL-6 trans-signalling that contribute to PAH progression. 
The prostanoid BPS significantly protected HPAECs from the increased cell 
permeability resulting from treatment with IL-6/sIL-6Rα (Figure 5.1). As an 
increase in cell permeability is associated with EC dysfunction which has been 
associated with PAH progression and suggested as a potential therapeutic 
target (reviewed by Ranchoux et al. 2018), this suggests BPS may be 
beneficial for this particular effect of IL-6/sIL-6Rα. To provide more conclusive 
appear to increase VE-cadherin localisation at cellular junctions when 
compared to treatment with IL-6/sIL-6Rα alone. Interestingly, research 
















Figure 5.8: VEGF-A protein is undetectable via ELISA 
A) VEGF-A standard curve produced by preparing VEGF-A standard 
dilutions and analysing via an enzyme-linked immunosorbent assay 
(ELISA) as described in the manufacturer’s instructions. The absorbance of 
known VEGF-A concentrations were measured immediately upon 
completion of the ELISA using a Thermo Scientific™ NanoDrop 1000 
Spectrophotometer and plotted on a graph using GraphPad Prism software. 
B) HPAECs were treated with BPS (10 μM) for 2 hours prior to 24 hour 
treatment with IL-6 (5 ng/ml) + sIL-6Rα (25 ng/ml) (IL-6/sIL-6Rα). The 
experiment was attenuated via removal and storage of the media. A vehicle 
control and treatment with IL-6/sIL-6Rα alone was also performed. The 
concentration of VEGF protein in the sample media was then determined 
via an ELISA performed according to the manufacturer’s protocol. The 
absorbance of each sample was measured using a Thermo Scientific™ 
NanoDrop 1000 Spectrophotometer and compared to the VEGF-A standard 




a loss of VE-cadherin local to cellular junctions but reports this is a direct 
consequence of IL-6/sIL-6Rα signalling, not a result of increased permeability 
(Alsaffar et al. 2018). Thus, VE-cadherin may not be an accurate measure of 
IL-6/sIL-6Rα induced cell permeability. 
IL-6 trans-signalling has many other functional affects that would contribute to 
the vascular remodelling characteristic of PAH and should be measured in 
HPAECs. For instance, IL-6/sIL-6Rα has been shown to stimulate cell 
migration, cell proliferation, and angiogenesis (Yao et al. 2006; Liu et al. 2017), 
IL-6/sIL-6Rα induced migration of HPAECs could easily be measured via 
established cell migration assays such as scratch wound assays (reviewed by 
Justus et al. 2014). Similarly, IL-6/sIL-6Rα induced HPAEC proliferation could 
be measured via BrdU incorporation assays (Gallagher et al. 2007). Treating 
cells with IL-6/sIL-6Rα in the presence and absence of a prostanoid drug, as 
performed in Figure 5.1, would determine the effect of IL-6 alone, and the 
ability of prostanoids to limit this effect. 
To study the effect of IL-6/sIL-6Rα on angiogenesis endothelial tube formation 
assays (Ponce 2009; DeCicco-Skinner et al. 2014) could be utilised. However, 
to gain a more realistic perspective a co-culture system would be better. Many 
co-culture systems that utilise fibroblasts to form a matrix which supports 
endothelial cell tube formation have been developed (Richards and Mellor 
2016). Ideally, the incorporation of HPASMCs into such systems would allow 
for a more representative environment of that local to PAH pathology.  
The key genes induced by IL-6/sIL-6Rα that mediate pro-inflammatory effects 
have already been identified and include adhesion molecules (Kuppner et al. 
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1990; Kvale et al. 1992). IL-6 induction of ICAM-1 and VCAM-1 protein 
induction was measured in HPAECs and in all cases levels of protein in 
untreated cells were the same as in treated cells (Figure 5.4), suggesting high 
basal levels of these proteins. It could be that the process of maintaining and 
passaging these cells is sufficient to induce an inflammatory response. IL-
6/sIL-6Rα has been shown to induce ICAM1 and VCAM1 after 48 hours of 
treatment, and VCAM1 (Wiejak et al. 2019), which is a longer time period than 
used for these experiments in HPAECs. Thus, a longer time course may be 
beneficial. Also, in both experiments there appeared to be high basal levels of 
ICAM1 and VCAM1. In the future, serum-starving cells prior to stimulating with 
IL-6/sIL-6Rα may reduce basal expression of adhesion molecules, although 
this did not have an effect on VEGFR2 expression in the same cell type (Figure 
5.5B). Alternatively, measuring mRNA levels via PCR or promoter activity via 
luciferase reporter assays may indicate if IL-6/sIL-6Rα induces VCAM1/ICAM1 
gene transcription. High basal-levels of adhesion molecules may also be 
specific to ECs, thus measuring IL-6/sIL-6Rα-induction of ICAM1 and VCAM1 
in other cells involved in PAH pathology, such as PASMCs, may also be 
valuable. 
Research has shown that in gastric carcinoma and human cervical cancer 
C33A cells IL-6 induces angiogenesis by upregulating VEGF (Wei et al. 2003b; 
Huang et al. 2004). Similarly to adhesion molecules, VEGFR2 protein was 
found to be expressed in HPAECs in the absence of IL-6/sIL-6Rα stimulation 
and this was not altered with treatment of IL-6/sIL-6Rα. Treatment with BPS, 
however, stimulated VEGFR2 expression. This has been found previously with 
VEGF in rat aortic SMCs where BPS increased VEGF mRNA through a 
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PKA/CREB-dependent mechanism (Atsuta et al. 2009). In HPAECs, IL-6/sIL-
6Rα appeared to stimulate VEGF-A transcription 2 - 48 hours post-treatment 
(Figure 5.7) but VEGF protein expression, measured by an ELISA, did not 
increase in line with this (Figure 5.7). Measuring the impact of BPS or other 
prostanoids on the IL-6-mediated increase in VEGF mRNA may offer an 
alternative to measuring the effect on protein levels. However, as BPS has 
also been shown to induce VEGF, treatment alongside a PKI may be required. 
Alternatively, the EPAC1 agonist I942 which has been shown to induce 
SOCS3 and limit IL-6 induction of adhesion molecules (Wiejak et al. 2019) 
could be utilised to determine the impact of SOCS3 without having to control 
for PKA activation. 
Measuring the impact of prostanoids on the aforementioned effects of IL-6 
would result in a greater understanding on the potential therapeutic 
mechanism of prostanoids, as well as potentially highlighting new therapeutic 
targets within the IL-6 trans-signalling pathway. 
6 Potential role of SOCS3 in cell membrane integrity. 
6.1 Introduction 
The primary aims of this PhD research have revolved around the anti-
inflammatory role of SOCS3; however potential other roles of SOCS3 may 
have a therapeutic benefit in PAH. SOCS3 has been shown to interact with 
cavin-1 via the proline (P), glutamic acid (E), serine (S), and threonine (T) 
(PEST) motif of the SH2 domain of SOCS3 and multiple regions of cavin-1 
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(Williams et al. 2018). As discussed (Section 1.3.3.2), cavin-1 interacts with 
CAV1 to stabilise caveolae at the plasma membrane (Liu et al. 2008), and 
caveolae have been shown to have a mechanoprotective function in 
endothelial cells, including preventing membrane rupture in response to 
increased cardiac output (Cheng et al. 2015). 
Cavin-1 and SOCS3 appear to interact in a mutually beneficial mechanism 
where SOCS3 enhances cavin-1 stability and thus caveolae stability, but 
cavin-1 is also required for cAMP-mediated SOCS3 inhibition of IL-6 signalling 
and SOCS3 localisation to the plasma membrane (Williams et al. 2018). 
Evidence for this has been found in human myoblasts expressing CAV3 
mutations. CAV3 codes for Cavin-3, a muscle cell-specific cavin homologue. 
Loss of cavin-3 resulted in a loss of caveolae at the plasma membrane and 
caused hyperactivation of IL-6 signalling determined via confocal microscopy 
of immunofluorescent pSTAT3 and pSTAT3 nuclear translocation which was 
rescued via transduction with Cavin-3-GFP (Dewulf et al. 2019), although 
whether this involved SOCS3 was not investigated. 
As caveolae have numerous functions including mechanoprotection (Sinha et 
al. 2011) and plasma membrane signalling (Sowa et al. 2001), caveolae 
dysfunction is associated with numerous diseases including muscular 
dystrophies (Hayashi et al. 2009), cancer (Moon et al. 2014), and 
cardiovascular disease including PAH. Several heterozygous mutations in 
CAV1, including 474delA, 473delC, F160X, and 479_480delTT, have been 
identified in PAH patients (Austin et al. 2012; Garg et al. 2015). In addition, 
fibroblasts from PAH patients were found to have reduced co-localisation of 
cavin-1 with caveolin-1 and decreased stability of the caveolin-1 complexes 
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necessary for caveolae formation (Han et al. 2016). Thus, SOCS3 regulation 
of cavin-1 stability and maintenance of cellular caveolae may provide an 
alternative mechanism by which SOCS3 mediates its potential therapeutic 
benefits in PAH. 
6.2 Results 
6.2.1 Membrane stability in AS-M.5 WT cells compared to AS-M.5 SOCS3 
KO cells 
AS-M.5 WT and AS-M.5 SOCS3 KO cells were utilised to investigate the role 
of SOCS3 in cell membrane stability. AS-M.5 WT and AS-M.5 SOCS3 KO cells 
were seeded in Nunc™ Lab-Tek™ chambers at 4x104 – 6 x104 cells/chamber 
and 8x104– 1x105 cells/chamber respectively to achieve a high cell density and 
incubated for 48 hours until confluent. AS-M SOCS3 KO cells were seeded at 
a higher seeding density as they demonstrated lower levels of attachment to 
the cell culture flask and a slower growth rate.  
Initial experiments to determine the optimum staining protocol were completed. 
Cells were treated with hypotonic EGM-2 medium (1 part EGM-2 medium:9 
parts sterile H2O) for 10 minutes. The use of hypotonic solutions to induce 
cellular swelling, causing the plasma membrane to stretch is an established 
model of plasma membrane mechanical stress (Pietuch et al. 2013; 
Yamamoto and Ando 2015; Tachikawa et al. 2017). Cells incubated in fresh 
EGM-2 medium for 10 minutes were used as a vehicle control. Post-treatment, 
cells were fixed via a 10 minute incubation in ice-cold methanol at -20°C prior 
to 3 x 5 minute washes with PBS at room temperature. Cells were then treated 
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with SYTOX (167 nM) for 10 minutes at room temperature before staining with 
1 µM Hoechst 33342 in PBS at room temperature prior to being visualised via 
fluorescence microscopy. As SYTOX is non-cell permeable, it will only stain 
the nucleic acid of ruptured cells. If SOCS3 is necessary for cell membrane 
stability, AS-M.5 SOCS3 KO cells should be more vulnerable to membrane 
rupture as a result of incubation in hypotonic media and will show greater 
SYTOX staining.  
Cells prepared in the manner described showed SYTOX staining of all the 
vehicle control cells and after 10 minutes of hypotonic treatment in both cell 
types (Figure 6.1A), suggesting either methanol fixation of the cells was 
damaging the cell membrane, or potentially that Hoechst 33342 was 
transporting residue SYTOX into the cell. The experiment was repeated with 
the following changes; cells were fixed in 4% formaldehyde via incubation at 
room temperature for 10 minutes and cells were stained with WGA (1 µg/ml) 
via incubation at room temperature for 20 minutes as an alternative to Hoechst 
33342. Again, both cell types demonstrated SYTOX staining in all cells in the 
vehicle control sample and those that had been treated with hypotonic media 
(Figure 6.1B). Thus, in future experiments cells were stained during the 
treatment process and imaged immediately to avoid fixing the cells. 
Preliminary experiments also identified the risk of fluorescence bleed-through 
from the green SYTOX stain when imaging the red WGA stain when scanning 
the images with both lasers at the same time. This is evident from the nuclei 
staining seen in the WGA images as WGA should not stain nucleic acid, and 
the colour of the merged image. To prevent this in further experiments, images 












Figure 6.1: Representative images of AS-M.5 WT vs AS-M.5 SOCS3 KO 
from preliminary hypotonic experiments 
A) AS-M.5 WT and AS-M.5 SOCS3 KO Cells were incubated in hypotonic 
EGM-2 medium (1 part EGM-2 medium:9 parts sterile H2O) for 10 minutes 
prior to immediate fixing in methanol. Cells incubated in fresh EGM-2 medium 
for 10 minutes were used as a vehicle (Veh) control. Cells were then stained 
with SYTOX™ Green Nucleic Acid Stain (SYTOX) (167 nM) and Hoechst 
33342 (1 µM) prior to imaging with a Nikon ECLIPSE TE2000-E confocal 
microscope. B) AS-M.5 WT and AS-M.5 SOCS3 KO cells were incubated in 
hypotonic EGM-2 medium (1 part EGM-2 medium:9 parts sterile H2O) for 10 
minutes prior to immediate fixing in 4% paraformaldehyde. Cells incubated in 
fresh EGM-2 medium for 10 minutes were used as a Veh control. Cells were 
then stained with SYTOX (167 nM) and WGA (1 µg/ml) prior to imaging with a 
Nikon ECLIPSE TE2000-E confocal microscope. 
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These changes were incorporated into the final protocol (Section 2.2.6) which 
was used for the experiments described below. 
AS-M.5 WT and AS-M.5 SOCS3 KO cells were seeded in Labtek chambers at 
4x104 – 6x104 cells and 8x104 – 1x105 cells respectively. Cells were then 
treated with hypotonic EGM-2 medium (1 part EGM-2 medium:9 parts sterile 
H2O) containing SYTOX (167 nM) and WGA (1 µg/ml) for 2 minutes, 4 and 10 
minutes prior to 2 X 5 minute washes with HBSS. Cells were then immediately 
imaged via fluorescence microscopy. The amount of SYTOX DNA staining 
was measured as previously described (Section 2.6) and compared to 
minimum SYTOX expression. Cells incubated in fresh EGM-2 medium 
containing SYTOX and WGA for 10 minutes were used as a vehicle control 
and were prepared in parallel to the cells treated with hypotonic media. 
SYTOX expression was the same for both cell types in the vehicle control 
(Figure 6.2). The staining seen in these conditions were caused by factors 
other than hypotonic media such as toxicity of the stains, thus, this level of 
staining should not be attributed to cell membrane vulnerability in any 
conditions. SYTOX expression in AS-M.5 WT was consistent with that seen in 
the vehicle treatment for the 2 minute, 4 minute and 10 minute treatment times 
(Figure 6.2). In the AS-M.5 SOCS3 KO cells, SYTOX expression after 2 
minutes and 4 minutes incubation in hypotonic media are comparable to that 
seen in the vehicle control but there appears to be greater SYTOX staining 
after 10 minutes treatment with hypotonic media compared to the other 
treatment times (Figure 6.2). Statistical analysis did not show this to be 
significant, most likely due to the relatively large standard error of the mean 























Figure 6.2: SYTOX DNA staining in AS-M.5 WT vs AS-M.5 SOCS3 KO 
post-short hypotonic treatments 
AS-M.5 WT and AS-M.5 SOCS3 KO cells were incubated in hypotonic EGM-
2 medium (1 part EGM-2 medium:9 parts sterile H2O) containing SYTOX™ 
Green Nucleic Acid Stain (SYTOX) (167 nM) and Wheat Germ Agglutinin, 
Alexa Fluor™ 594 Conjugate (WGA) (1 µg/ml)  for  2 minutes, 4 or 10 minutes. 
Cells incubated in fresh EGM-2 medium containing SYTOX and WGA for 10 
minutes were used as a vehicle (Veh) control. Cells were then washed twice 
for 5 minute washes in HBSS, incubated in fresh EGM-2 medium and imaged 
immediately using a Nikon ECLIPSE TE2000-E confocal microscope. Analysis 
of the images was completed using ImageJ software. Quantification for n=5 
experiments has been shown. 
207 
 
is approaching the maximum time SOCS3 KO cells can withstand treatment 
with hypotonic media but has not exceeded that time, thus there is variability 
in the number of ruptured cells.  
To test this, the experiment was repeated as described previously but cells 
were treated in hypotonic media for longer times of 15 and 30 minutes. Cells 
incubated in fresh EGM-2 medium containing SYTOX and WGA for 30 minutes 
were used as a vehicle control. Similar to the shorter time course, SYTOX 
expression was the same for both cell types in the vehicle control (Figure 6.3) 
and this level of staining should not be attributed to cell membrane vulnerability 
in any condition. AS-M.5 WT cells demonstrated similar levels of SYTOX 
staining after 15 and 30 minutes of treatment time. SYTOX staining in AS-M.5 
SOCS3 KO cells appeared to increase between each time point (Figure 6.3), 
however statistical analysis did not show this to be significant. 
6.3 Discussion 
For both the short and long hypotonic treatment time course, AS-M.5 WT cells 
show similar levels of SYTOX treatment for all conditions whereas AS-M.5 
SOCS3 KO cells appear to show increased SYTOX expression but statistical 
analysis shows this is not significant. In the short time course (Figure 6.2), 
large SEM values for SYTOX staining in AS-M.5 SOCS3 KO cells results 
suggested the experiment could be better optimised. An attempt to do this by 
increasing the treatment time also resulted in relatively large SEM values at 
the 15 minute and 30 minute treatment time points for both cell types. This 










Figure 6.3: SYTOX DNA staining in AS-M.5 WT vs AS-M.5 SOCS3 KO 
post-hypotonic treatment 
AS-M.5 WT and AS-M.5 SOCS3 KO Cells were incubated in hypotonic EGM-
2 medium (1 part EGM-2 medium:9 parts sterile H2O) containing SYTOX™ 
Green Nucleic Acid Stain (SYTOX) (167 nM) and Wheat Germ Agglutinin, 
Alexa Fluor™ 594 Conjugate (WGA) (1 µg/ml) for 15 or 30 minutes. Cells 
incubated in fresh EGM-2 medium containing SYTOX and WGA for 30 minutes 
were used as a vehicle (Veh) control. Cells were then washed twice for 5 
minute washes in HBSS, incubated in fresh EGM-2 medium and imaged 
immediately using a Nikon ECLIPSE TE2000-E confocal microscope. Analysis 
of the images was completed using ImageJ software. Quantification for n=5 
experiments has been shown. 
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time points, or potential other factors may have a greater influence during 
longer treatment times than during a short exposure to hypotonic media. The 
effect of increasing passage number and increased cell seeding density were 
correlated against % SYTOX expression compared to the vehicle treatment 
after 30 minutes of treatment for n=5 experiments. AS-M.5 WT cells 
demonstrate a low negative correlation between SYTOX staining and 
increased passage number (r2 value = -0.3372) and a low positive correlation 
between SYTOX staining and seeding density (r2 = 0.3528) (Figure 6.4). On 
the other hand, AS-M.5 SOCS3 KO cells appear to be much more affected by 
these parameters with a strong positive correlation between SYTOX staining 
and increased passage number (r2 value = 0.8352) and a negative correlation 
between SYTOX staining and seeding density (r2 = - 0.0.6218) (Figure 6.4) 
suggesting they are less vulnerable to membrane damage at lower passages 
and higher confluency. However, as we are looking at % changes of SYTOX 
compared to the vehicle control, correlation analysis does not identify if the 
effect of passage number and seeding density occurs in the hypotonic-media 
treated cells, the vehicle controls or both. It also shouldn’t be used as 
conclusive evidence of an effect but could be considered for future 
experiments. 
Another noteworthy comparison between the AS-M.5 WT and SOCS3 KO cells 
are the morphological changes that occur post-hypotonic treatment that can 
be seen in WGA stained cells. For the short time course, the appearance of 
the AS-M.5 WT cells remains the same in all conditions however AS-M.5 
SOCS3 KO cells appear larger after 10 minutes treatment when compared to 















Figure 6.4: Correlation analysis for SYTOX expression compared to 
passage number and seeding density in AS-M.5 WT and AS-M.5 SOCS3 
KO cells 
A) Correlation analysis for SYTOX expression after 30 minutes of treatment 
with hypotonic media for n=5 experiments compared to passage number and 
seeding density of AS-M.5 WT cells. B) Correlation analysis for SYTOX 
expression after 30 minutes of treatment with hypotonic media for n=5 
experiments compared to passage number and seeding density of AS-M.5 
SOCS3 KO cells. 
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support the theory that AS-M.5 SOCS3 KO cells have a reduced plasma 
membrane stability as they are more vulnerable to hypotonic media passing 
through the membrane and thus become more turgid prior to rupturing. For the 
longer time course, an increase in size is more apparent in both cell types after 
15 minutes of treatment with hypotonic media compared to the vehicle control 
cells. After 30 minutes of treatment, both cell types appear larger but the AS-
M.5 SOCS3 KO cells also display a more bulbous appearance (Figure 6.3), 
which again suggests their membranes are less able to protect from the 
osmotic influx of hypotonic media. Morphological changes in the cells has not 
been analysed but should be considered in future experiments.  
Cells that are more prone to rupture may also be more likely to detach from 
the culture chamber, especially post-rupture. Thus, SYTOX-stained cells may 
be lost during the washing process and thus not included in the final SYTOX 
counts. This would skew the total cell:SYTOX ratio in favour of the more robust 
cells. To investigate any potential effect total viable cell counts could be taken 
prior to hypotonic treatment and immediately after. Minimising the number of 
cells lost as a result of the counting process would be crucial to ensure a 
reduction in cell number is a result of hypotonic treatment and not a result of 
the counting process. 
As AS-M.5 WT cells do demonstrate a faster growth rate and tend to form a 
more confluent monolayer than their SOCS3 KO counterparts, a co-culture 
system could potentially be utilised to remove any differences caused as a 
result of cell confluency. Individual cell types could be labelled using cell 
tracker dyes such as CellTracker™ Red CMTPX Dye (Invitrogen, Cat. # 
C34552) (Yeow et al. 2017) prior to seeding Nunc™ Lab-Tek™ chambers with 
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an equal amount of both cells and performing the experiment as previously 
described. As AS-M.5 WT and AS-M.5 SOCS3 KO cells could then be easily 
distinguished in the resulting fluorescent images, it will be possible to measure 
SYTOX uptake in the individual cell types in the same chamber under identical 
conditions.  
In vitro techniques to mechanically stretch cells have previously been used to 
measure the role of caveolae plasma membrane integrity, with FITC 
movement into the cell cytoplasm being used as a measure of cell membrane 
damage (Cheng et al. 2015; Yeow et al. 2017). This type of experiment could 
be replicated in AS-M.5 WT and AS-M.5 SOCS3 KO to measure if SOCS3 KO 
cells were more vulnerable to membrane rupture as a result of mechanical 
stretching. 
If the plasma membrane of AS-M.5 SOCS3 KO cells was found to be less 
stable than in the AS-M.5 WT cells the next step would be to determine if 
expressing SOCS3 in SOCS3 KO cells, potentially via lentiviral delivery of 
SOCS3 or by treatment with prostanoids, would be sufficient to rescue plasma 
membrane integrity in AS-M.5 SOCS3 KO cells. 
These experiments have investigated the role of SOCS3 in mechanoprotection 
as this is intrinsically linked to plasma membrane integrity and there is a body 
of research highlighting the role of EC permeability in PAH (Zhou et al. 2016; 
Ranchoux et al. 2018; Zhou et al. 2018). Further work is required to fully 
establish the interaction of SOCS3 and cavin-1/CAV1 and determine if this role 
of SOCS3 would have any therapeutic potential for PAH. Caveolae has 
numerous other functions, for instance regulation of signalling molecules and 
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intracellular trafficking (reviewed by Kovtun et al. 2015), which if lost or 
dysregulated could potentially be detrimental in PAH. Thus, it is not just the 
role of SOCS3 in mechanoprotection that should be considered. 
7. Final Discussion  
Current treatment of PAH is aimed at relieving the symptoms of PAH, not 
targeting the cause (Section 1.6). As a result, there is no cure for PAH and no 
recent improvements regarding survival rates. In addition, treatment is 
associated with many side effects such as flushing, nausea, and headaches 
(Lau et al. 2017), as well the complications of complex administration 
procedures (Sitbon et al. 2002; Kumar et al. 2016). Thus, there is a need for 
novel therapeutic options that target the pathological changes which occur in 
PAH prior to and following the onset of the disease, whilst also improving a 
patient’s QOL and survival rates.  
Although prostacyclins were discovered in 1976 (Moncada et al. 1976), and 
the first prostanoid clinically approved for PAH treatment was epoprostenol in 
the US in 1995 for its vasodilatory effects, relatively little consideration has 
been given to other potential effects of prostanoids which could be exploited. 
This is surprising considering the prostanoid epoprostenol is the only drug to 
have shown a capacity to improve survival rates (Sitbon et al. 2002). Thus, this 
research has addressed this gap in the literature and highlighted a novel 
alternative mechanism activated by prostanoids that could provide therapeutic 
benefits to the patient by reducing the inflammatory component of PAH. 
However, it would appear the system is much more complex that the original 
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hypothesis suggested (Section 1.7), with potential other interactions between 
prostanoids and IL-6 signalling involved, as highlighted in Figure 7.1. 
7.1 Inducing SOCS3 for the treatment of PAH and other diseases 
The prostanoids BPS and treprostinil, and ACT-333679, the active metabolite 
of the IP agonist selexipag, induced SOCS3 in HPAECs and HPMECs in vitro 
(Chapter 3). These cell types were investigated as they are affected by the 
vascular remodelling and inflammation typical of PAH. Although the exact 
signalling pathway is yet to be established, attempts to define the pathway with 
EPAC and PKA agonists were unsuccessful (Figure 3.7), this does provide a 
potential mechanism activated by prostanoids which has not been explored 
with regards to PAH. Prostanoids were also shown to limit IL-6 trans-signalling 
potentially via SOCS3, although further experiments to determine a role for 
SOCS3 utilising siRNA and shRNA knock-down of SOCS3 were not 
successful (Figures 4.5 and 4.6). In conclusion, the hypothesis was correct in 
that prostanoids have the capacity to both induce SOCS3 and inhibit IL-6/sIL-
6Rα signalling, however the exact mechanisms involved are yet to be 
confirmed (Figure 7.1).  
None the less, as the function of SOCS3 is becoming better understood, its 
potential therapeutic benefit is being explored for a number of inflammatory 
diseases in which IL-6 signalling and STAT3 hyperactivation are key factors 
including multiple sclerosis, cancers, rheumatoid arthritis, and diabetes 
(Mahony et al. 2016; Durham et al. 2019). Elevated IL-6 signalling activity has 
also been associated with PAH (Hashimoto-Kataoka et al. 2015; Jasiewicz et 
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al. 2015; Matura et al. 2015; Fang et al. 2017; Maston et al. 2018; Tamura et 
al. 2018), however attempts to minimise the effects of IL-6 with SOCS3-based 
therapies have yet to be investigated. There are challenges involved in 
SOCS3-based therapies, namely its short-half life and a body of research that 
shows SOCS3 may be detrimental in a number of illnesses. 
7.1.1 Increasing the stability of SOCS3 
SOCS3 has a half-life of 40 - 120 minutes depending on the cell type (Siewert 
et al. 1999; Fletcher et al. 2010). Numerous mechanisms for the regulation and 
degradation of SOCS3 have been identified. Key tyrosine residues (tyrosine204 
and tyrosine221) have been identified within the SOCS3 box region of SOCS3 
which when phosphorylated make SOCS3 a target for proteasomal 
degradation (Haan et al. 2003). SOCS3 Y204F,Y221F phosphorylation-
deficient COS-7 cells, prepared via transfection with a Y204F,Y221F SOCS3 
plasmid, demonstrated a half-life of 4 - 8 hours compared to the 2 hour half-
life of WT cells (Haan et al. 2003), although densitometry analysis was not 
performed in these experiments so it is difficult to establish if there is a 
significant change in SOCS3 expression. Also, the proteasome inhibitor MG-
132 protects SOCS3 from degradation (Haan et al. 2003; Liu et al. 2003) 
suggesting the role of proteasomal degradation is substantial. 
SOCS3 also contains a PEST domain, a common amino acid sequence found 
in proteins with a short half-life, within its SH2 domain which acts a proteolytic 
target (Rogers et al. 1986; Yasukawa et al. 2003). Deletion of the PEST 
domain in HEK 293T cells increases the stability of SOCS3 (Babon et al. 









Figure 7.1: Ongoing hypothesis highlighting prostanoid-mediated 
signalling pathways that may PAH pathogenesis. 
The original hypothesis (grey) (Figure 1.9) plus addition signalling pathways 
to be considered in the context of prostanoid-inhibition of IL-6 trans-signalling 
activity and PAH. Prostanoids limited IL-6 activity in part due to SOCS3 but 
there is also a potential SOCS3-independent mechanism (purple). 
Prostanoids induced SOCS3 but this appeared to be via a currently unknown 
PKA/EPAC-independent mechanism (orange). Mobilisation of cAMP activates 
PKA which also interacts with Notch and ERK (red and blue respectively). 
Prostanoid activation of PPARγ (green). cAMP; cyclic adenosine 
monophosphate, EPAC1; exchange protein directly activated by cAMP 1, 
ERK; extracellular signal–regulated kinase, gp130; glycoprotein-130, ICAM1; 
intracellular adhesion molecule 1, IL-6; interleukin 6, IP; prostaglandin I2 
receptor, JAK; janus kinase, KIR; kinase inhibitory region, PKA; protein kinase 
A (cAMP dependent protein kinase), PPAR; peroxisome proliferator-activated 
receptor, SOCS3; suppressor of cytokine signalling 3, sIL-6Rα; soluble IL-6 
receptor α, STAT3; signal transducer and activator of transcription 3, VEGF; 





deleting the SOCS box, without affecting the structure or ability of SOCS3 to 
inhibit STAT activity. Regulation of SOCS3 via ubiquitination of the N-terminal 
region of SOCS3 has also been evidenced. An N-terminal truncated form of 
SOCS3, created by alternative translation initiation as a result of endoplasmic 
reticulum stress, was found to be more stable than WT (Sasaki et al. 2003). A 
lysine residue at position 6 (Lys6) which was lost in the truncated SOCS3 was 
identified as a key ubiquitination site (Sasaki et al. 2003). Additional key lysine 
residues in SOCS3 have since been identified that recruit E3 ubiquitin ligases 
resulting in the rapid ubiquitination of SOCS3 and also of gp130 and JAK2 
(Kershaw et al. 2014; Munro 2016a). A SOCS3 mutant in which lysine was 
mutated to arginine at positions 6, 23, 28, 40, 85, 91, 122, 173 (lys-less 
SOCS3) was shown to have increased stability compared to WT SOCS3 whilst 
still maintaining proper function as measured by SOCS3 ability to inhibit 
erythropoietin-induced STAT3 tyrosine 705 phosphorylation and to interact 
with E3 ligase components (Munro 2016a). 
Thus, ubiquitination is another key factor in SOCS3 stability, providing an 
additional mechanism to exploit to improve the short half-life of SOCS3. The 
relevant E3 ligase for SOCS3 has yet to identified, however doing so would 
provide a potential target to improve SOCS3 stability. Small molecule inhibitors 
have been used to inhibit E3 ligases previously. For instance, thalidomide, 
used to treat multiple myeloma (Singhal et al. 1999; Mercurio et al. 2017) binds 
and inhibits the E3 ligase cereblon (Ito et al. 2010; Liu et al. 2015). Also, drugs 
targeting mouse double minute 2 homolog (the E3 ligase responsible for p53 
degradation) are in early phase clinical trials for cancers, e.g. AMG232 (Sun 
et al. 2014). 
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Thus, there are numerous mechanisms that could be targeted to increase the 
stability of SOCS3. However, some research suggests increasing SOCS3 
expression may also have detrimental effects. 
7.1.2 SOCS3 in disease 
Another challenge associated with increasing SOCS3 for therapeutic purposes 
is SOCS3 expression seems to have conflicting roles in the progression of 
some diseases. For instance, in atherosclerosis SOCS3 induced by IL-10 
initiates EC apoptosis, thus preventing EC dysfunction (Yin et al. 2013). 
However, in the same disease, overexpression of SOCS3 in T-cells appears 
to contribute to vascular inflammation and the development of atherosclerotic 
plaques (Taleb et al. 2009).  
Similarly, there is evidence to support both protective and causative roles for 
SOCS3 in diabetes. SOCS3 is overexpressed in the skeletal muscle of obese 
humans and as SOCS3 inhibits insulin signal transduction in the liver 
(Sachithanandan et al. 2010) and in adipose tissue (Emanuelli et al. 2001; Shi 
et al. 2004; Ueki et al. 2004), this provided rationale to examine the potential 
impact of SOCS3 on insulin in skeletal muscle. Skeletal muscle-specific 
SOCS3 knockout (SOCS3 MKO) in mice resulted in normal muscle 
development, body mass, and energy homeostasis but when fed a high fat 
diet, SOCS3 MKO mice were protected from insulin resistance compared to 
WT mice, even though both mice types experienced a similar increase in 
weight gain (Jorgensen et al. 2013). This was due to increased skeletal muscle 
insulin receptor substrate 1 expression and enhanced Akt phosphorylation 
post-insulin treatment in the SOCS MKO compared to the WT mice (Jorgensen 
et al. 2013), although how SOCS3 attenuated this was not specified. SOCS3 
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MKO mice also demonstrated a higher glucose tolerance than their WT 
counterparts. No difference in activity levels, food intake or oxygen utilisation 
were found, but SOCS MKO mice exhibited a higher respiratory exchange ratio 
which the authors attributed to greater carbohydrate oxidation as a result of 
increased insulin sensitivity and metabolic flexibility (Jorgensen et al. 2013). 
On the other hand, the anti-inflammatory effects of SOCS3 appear to reduce 
the dysfunction caused by diabetes in animal models. SOCS1 and SOCS3 
expression was increased in the renal cortex of streptozotocin (STZ)-induced 
diabetic rats and in human immortalised proximal tubule epithelial cells from 
normal adult human kidney and glomerular mesangial cells under 
hyperglycemic conditions (Ortiz-Munoz et al. 2010). SOCS3 adenovirus 
injection into STZ diabetic rats resulted in reduced inflammation, measured by 
ICAM, RANTES and MCP-1 protein expression, and reduced fibrosis, 
measured via TGF-β and collagen IV expression, compared to WT and control-
adenovirus groups (Ortiz-Munoz et al. 2010).  
In other diseases such as cancer and obesity, SOCS3 has been shown to 
either directly or indirectly enable disease progression. Although IL-6 signalling 
is considered key for the growth and metastasis of many cancers (reviewed by 
Kumari et al. 2016), and limiting IL-6 signalling is a key mechanismfor 
approved cancer drugs and those currently being developed (Angevin et al. 
2014; Dijkgraaf et al. 2015), SOCS3 has also been shown to promote cancer 
development. In prostate cancer, downregulating SOCS3 causes prostate 
cancer cell death via the activation of apoptotic pathways, suggesting SOCS3 
protects prostate cancer cells (Puhr et al. 2009), and in cutaneous T-cell 
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lymphoma, SOCS3 protected cells from growth inhibition caused by IFN-γ 
treatment (Brender et al. 2005).  
Leptin, a key regulator of energy homeostasis, acts via JAK/STAT signalling 
and is therefore negatively regulated by SOCS3. As a result, downregulating 
SOCS3 via a heterozygous SOCS3 KO mutation has been shown to protect 
against diet-induced obesity in mice (Howard et al. 2004). Neural cell-specific 
SOCS3 KO mice also demonstrated enhanced leptin-induced hypothalamic 
STAT3 tyrosine 705 phosphorylation, lower food intake and overall reduced 
diet–induced obesity (Mori et al. 2004). As a result, dysregulated energy 
homeostasis and obesity should be considered as potential side effects of any 
SOCS3-based therapeutic. 
Collectively, this suggests a complex role for SOCS3 in disease where its 
inhibition of JAK/STAT signalling results in enabling disease progression in 
some cases, but inhibiting it in others. Therefore, the specificity and selectivity 
of any SOCS3-based therapeutics developed for PAH or any other disease 
should be carefully considered to avoid potential outcomes such as obesity 
and increased vulnerability to cancer and atherosclerosis. 
In addition, the impact of novel SOCS3 interactions has not been considered. 
For instance, a link between SOCS3 and Cavin-1 stability and function has 
recently been identified (Williams et al. 2018), however the potential impact of 
this in endothelial permeability and if it could protect against the development 
of PAH has yet to be established. Attempts to identify a role for SOCS3 in 
endothelial cell membrane stability were unsuccessful (Chapter 6). Further 
optimisation and experiments are required to conclusively measure the impact 
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of SOCS3 on EC membrane stability. However, this does support there are 
roles of SOCS3 yet to be characterised and fully understood.  
Our research demonstrates a novel mechanism in which BPS, treprostinil and 
ACT-333679 induce SOCS3 expression in HPAECs, HPMECs and the 
established EC model, AS-M.5 cells (Krump-Konvalinkova et al. 2003) 
(Chapter 3), as well as limit IL-6 signalling as measured via tyrosine 705 
STAT3 phosphorylation in HPAECs and AS-M.5 cells, and cell permeability 
studies in HPAECs (Chapter 4). Experiments in AS-M.5 SOCS3 KO cells 
suggests prostanoid inhibition of IL-6 signalling is due in part to the induction 
of SOCS3 (Figure 4.4). Although further experiments are required to fully 
clarify this, these results do support that increasing SOCS3 expression, for 
instance via prostanoid treatment, is sufficient to reduce IL-6 trans-signalling 
activity. This may prove to be therapeutically beneficial in diseases such as 
PAH where the pro-inflammatory effects of IL-6 are a key component of 
disease progression (Section 1.4.2).  
Like SOCS3, prostanoids can also impact numerous other signalling pathways 
and these should be considered prior to any changes made in prostanoid 
treatment of PAH, or other diseases. 
7.2 The wider impact of prostanoid treatment 
The primary aim of prostanoid treatment for PAH is the activation of the GPCR 
IP resulting in the stimulation of cAMP-mediated PKA activity to induce 
vasodilation via PKA regulation of K+ channels (Haynes et al. 1992; reviewed 
by Clapp and Gurung 2015). However, activation of cAMP has a much broader 
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function than just vasodilation. This thesis has considered a potential anti-
inflammatory role of cAMP via the induction of SOCS3 which binds to gp130 
and inhibits further activation of IL-6/sIL-6Rα signalling. However, cAMP also 
interacts with the IL-6 signalling pathway via the Ras/Raf/ERK axis, a 
downstream mediator of IL-6. 
7.2.1 cAMP activation and ERK 1/2 
Initial research identified cAMP-mediated induction of PKA to limit 
Ras/Raf/ERK signalling. In oocyte extracts prepared from Xenopus laevis, 
incubation with PKA inhibited MAPK activity whereas PKI treatment alone was 
sufficient to enhance MAPK signalling (VanRenterghem et al. 1994). This was 
shown to be via PKA phosphorylation of the Raf1 serine 249 residue(Dhillon 
et al. 2002), which is required for Raf1 activity (King et al. 1998). Finally, cAMP-
mediated signalling independent of EPAC1 has also been shown to regulate 
IL-6 activity via inhibition of Ras/Raf/ERK signalling pathway (Woolson et al. 
2009). 
However, other research shows cAMP to activate ERK1/2. Fsk was shown to 
increase ERK activation in mice cortical neurones which was mediated via 
Fsk-induction of PKA (Ambrosini et al. 2000), although the effects of PKA 
inhibition were not investigated. In human melanocytes, Fsk-mediated cAMP 
activated ERK1/2 signalling via Ras mediated activation of B-raf in a PKA- and 
EPAC-independent manner (Busca et al. 2000). Interestingly, ras was not 
shown to be involved in cAMP activation of ERK in NIH/3T3 fibroblasts 
suggesting this is a melanocyte-specific mechanism (Busca et al. 2000), 
supporting that cAMP regulation of ERK1/2 activity is cell-specific.  
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This suggests a complex system in which cAMP can either limit or stimulate 
ERK1/2 signalling, depending on the cell type and Raf proteins involved, to 
regulate cell behaviour (reviewed by Dumaz and Marais 2005) (Figure 7.1). 
This ought to be further explored in vascular cells as it may provide an 
alternative signalling mechanism in which prostanoid activation of cAMP limits 
IL-6 signalling. In addition to modulating ERK activity, cAMP-mediated PKA 
acts on numerous other signalling pathways which may be important in PAH, 
including NOTCH. 
7.2.2 PKA activation and Notch 
cAMP and PKA have been shown to enhance Notch signalling in monocytes 
and C6 glioma cells (Angulo-Rojo et al. 2013; Larabee et al. 2013). Notch1 is 
increased in the lungs of PAH patients, HPAECs maintained in hypoxic 
conditions, and in SU/Hx rat models of PAH compared to WT rats (Dabral et 
al. 2016). In HPAECs, Notch1 was found to increase cell proliferation and 
inhibit apoptosis via downregulation of p21 and upregulation of Bcl-2 and 
Survivin respectively, whilst siRNA-mediated knockdown of Notch1 protected 
cells from hypoxia-induced proliferation (Dabral et al. 2016). In SU/Hx rats, 
treating with AMG2008827, a Notch inhibitor that prevents proteolytic cleavage 
of Notch into the active Notch intracellular domain (NICD) by selectively 
targeting γ-secretase, reduced RVSP and RH hypertrophy (Dabral et al. 2016). 
In addition, two Notch3 missense mutations (c.2519 G>A p.G840E, c.2698 
A>C p.T900P) which are associated with increased cell proliferation and 
viability have been identified in child PAH patients (Chida et al. 2014). 
Collectively, this suggests Notch enables PAH progression.  
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Notch also enhances IL-6 induced JAK/STAT signalling. In breast cancer cells, 
increased Notch was associated with increased IL-6 mRNA and protein 
expression, as well as increased JAK/STAT activation measured by tyrosine 
705 STAT3 phosphorylation and levels of the JAK/STAT target gene Bcl-xL 
(Jin et al. 2013). Notch, increased by either NICD transfection or increasing 
cell density, was also found to upregulate IL-6 gene transcription in NIH/3T3 
cells resulting in IL-6-mediated cell apoptosis via cleavage of caspase 3 
(Matsuno et al. 2018). The authors suggested that Notch/IL-6 hyperactivity 
may contribute to apoptotic resistance via the development of dysfunction 
apoptosis-resistant cells (Matsuno et al. 2018). Apoptotic resistance in EC and 
SMCs is characteristic of PAH (Masri et al. 2007; Courboulin et al. 2011). 
Activation of EP3 in HUVECs prmoteded Notch-induced angiogenesis and 
tube formation via the down-regulation of PKA (Chen et al. 2017) but in ECs 
isolated from the retinas of mice or in HUVECs, PKA did not appear to mediate 
Notch activity at all (Nedvetsky et al. 2016). This suggests a complex, cell-
specific cAMP/PKA/Notch axis exists which should be considered further due 
to the potentially detrimental effect that mobilising cAMP may have as a result 
of enhanced PKA/Notch and Notch/IL-6 signalling (Figure 7.1). Treatment with 
Notch inhibitors is being considered for the treatment of cancer but so far 
clinical trials have had mixed success (Pant et al. 2016; Wu et al. 2017) 
(Clinical trial identifier; NCT01122901), should be considered to limit IL-6-
mediated inflammation and angiogenesis. 
Interestingly, prostanoids are not specific to IP and the activation of cAMP, and 
therefore cAMP effector proteins such as PKA and EPAC, but also activate 
PPARs (Bishop-Bailey and Hla 1999). 
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7.2.3 Prostanoid activation of PPARγ receptors 
Anti-proliferative effects of treprostinil on human IPAH PASMCs were 
observed in IP knockout cells, and were unaffected by IP antagonists, but were 
inhibited by GW9662, a PPARγ antagonist, in human IPAH PASMCs (Falcetti 
et al. 2010). In addition, SMC specific knockdown of PPARγ in mice resulted 
in spontaneous muscularisation of the distal pulmonary arteries causing 
increased RVSP and RV hypertrophy (Hansmann et al. 2008). This provides 
evidence of an alternative prostanoid target that may also mediate the 
therapeutic effects of prostanoids in PAH. Reinforcing this is research showing 
activation of PPARγ in rats protected them from MCT-induced PASMC 
proliferation and pulmonary vascular remodelling (Zhang et al. 2014), and from 
RV dysfunction (Xu et al. 2017).  
Controversially, PPARγ receptors are upregulated in the SMC layer of small 
pulmonary arteries from child IPAH patients compared to those from control 
child small pulmonary arteries (Falcetti et al. 2010), though this may be a 
protective response. Thus, activation of PPARγ appears to protect against the 
vascular changes characteristic of PAH (Figure 7.1). Interestingly, PPARβ/δ 
activation had opposing effects, causing VEGF-mediated EC proliferation and 
endothelial tube formation (Piqueras et al. 2007). Although prostanoids are not 
known to activate this receptor type in VECs, if the role of PPARγ is to be 
exploited for PAH in the future, the specificity of the agonists used will need to 
be considered. 
To summarise, the wider impact of prostanoids in the context of PAH is mostly 
unknown. This research has aimed to increase our knowledge of prostanoid 
inhibition of IL-6/sIL-6Rα via cAMP-mediated SOCS3, but researching 
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prostanoid stimulation of ERK, Notch and PPARγ signalling in VECs may be 
worthwhile to better understand how to improve the therapeutic efficacy of 
prostanoids. Similarly, identifying the most efficient means of reducing IL-6 
signalling in PAH will result in more effective treatment. 
7.3 Limiting IL-6 signalling activity in PAH  
Research supports that IL-6 is a key factor is the development of PAH 
(Jasiewicz et al. 2015; Huang et al. 2016; Fang et al. 2017; Maston et al. 2018; 
Tamura et al. 2018) (Section 1.4.2), yet IL-6 signalling is still not targeted in 
the treatment of PAH. Drugs that target IL-6 have been approved for 
autoimmune diseases such as rheumatoid arthritis (Woodrick and Ruderman 
2010; Hashizume et al. 2015), and demonstrate effectiveness in clinical 
remission and increased QOL, with infections and hypersensitivity reactions 
noted as the most frequent adverse effects (Oton et al. 2018). As previously 
mentioned (Section 1.6.2.2), there has been one promisingcase of PAH where 
tocilizumab was administered in addition conventional PAH therapy (Arita et 
al. 2010). This supports the potential of larger re-purposing studies to test the 
efficacy of tociluzimab and other anti-IL-6 therapies such as siltuximab in the 
treatment of PAH. Similarly, JAK inhibitors such as tofacitinib and baracitinib, 
which are used in the treatment of inflammatory diseases including rheumatoid 
arthritis and ulcerative colitis (Gaudino et al. 2017; Bonovas et al. 2018; Wragg 




It is also of note that treatment with prostanoids and non-prostanoid IP 
antagonists such as selexipag is currently advised when patients are in WHO 
functional class III and worse (Galie et al. 2015). At this more developed stage, 
the impact of reducing IL-6 signalling will be limited, and it may be too late to 
attenuate further disease progression. Chapter 5 showed that prostanoids 
protect HPAECs from IL-6 induced cell permeability (Figure 5.1), and other 
groups have shown activation of cAMP and cAMP effector proteins such as 
EPAC to limit the expression of IL-6 induced inflammatory gene expression in 
HUVECs (Wiejak et al. 2019). In addition, animal models show silencing of IL-
6 or gp130 protects against PAH progression by reducing inflammatory cell 
infiltration and vascular remodelling (Savale et al. 2009; Huang et al. 2016), 
although these studies are limited as IL-6 knockdown occurs prior to PAH 
development so they do not measure the impact of limiting IL-6 post-PAH 
diagnosis. However, due to IL-6 being an established contributor to the 
pathological changes characteristic of PAH and the evidence which supports 
prostanoids ability to reduce IL-6 signalling, we propose reducing the WHO 
functional class at which prostanoids are currently prescribed in the aim of 
preventing further disease progression resulting from IL-6 signalling activity. 
8. Future work 
With regards to further research, these experiments have investigated the 
effect of prostanoids on healthy vascular cells only. Therefore, the response of 
PAH tissue to prostanoids and IL-6/sIL-6Rα stimulation/inhibition should also 
be investigated, especially as differences in receptor levels have been 
identified between control and PAH cells (Falcetti et al. 2010; Patel et al. 2018). 
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In addition, research has shown only some inflammatory cells and hepatocytes 
to express mbIL-6Rα (Hirata et al. 1989; Rojkind et al. 1995; Wang and Fuller 
1995). As a result these experiments the response of HPAECs to IL-6/sIL-6Rα, 
but not the response to IL-6 alone. Interestingly, PASMCs isolated from PAH 
patients and animal models of PAH demonstrate an increased expression of 
mbIL-6Rα (Tamura et al. 2018), suggesting both IL-6 classic signalling and IL-
6 trans-signalling may be occurring in PAH. As the HPAECs used in these 
experiments are not isolated from PAH patients, an assumption has been 
made that they will only respond to IL-6 trans-signalling. However, to confirm 
this, the response to IL-6 only in the cell types utilised in these experiments 
should be measured. Additionally, RT-PCR could be utilised to compare the 
ratio of mbIL-6Rα vs sIL-6Rα, as well as the ratio of different prostaglandin 
receptors and PPARs, in control HPAECs and PAH-HPAECs. This would 
provide a better informed judgement regarding the best therapeutic signalling 
pathways to target, and whether the focus should be on targeting IL-6 classic- 
or trans-signalling, or investigating the balance between them both. 
Once therapeutic targets have been identified, for instance increasing SOCS3, 
animal models of PAH could be utilised to test any therapeutic benefit. Tamura 
et al. (2018) demonstrated success utilising a curative model in which MCT-
rat models of PAH were treated with the IL-6/sIL-6Rα antagonist ERBF one-
week post-MCT injection. Treatment with ERBF in this manner resulted in 
reduced mPAP, PVR, RV hypertrophy and cardiac output compared to the 
control group at comparable levels to beginning treatment with ERBF at the 
same time as injecting with MCT (Tamura et al. 2018). Similarly, in Su/Hx 
models of PAH, starting treatment with ERBF five weeks post-SU5416 
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injection significantly reduced STAT3 activation, decreased MCL-1 protein 
expression and increased apoptosis, measured via TUNEL staining, compared 
to control mice to a similar extent as initiating treatment alongside SU5416 
treatment and hypoxia exposure (Tamura et al. 2018). This provides a model 
for measuring the curative effect of prostanoids on key factors, such as IL-6 
activity, in animal models of PAH.  As Chapter 4 showed prostanoid inhibition 
of IL-6 signalling to be due in part to SOCS3 (Figure 4.4), it would be interesting 
to determine the curative impact of SOCS3 overexpression in animal models 
of PAH. Adeno-associated virus treatment to introduce SOCS3, or a cre/lox 
system to mutate key ubiquitination sites of SOCS3 resulting in increased 
SOCS3 stability, could be administered to the animal post-initiation of PAH, or 
in animals with lung-specific overexpression of IL-6 as these have previously 
been shown to develop plexiform lesions comparable to those characteristic of 
PAH (Steiner et al. 2009). 
The exact mechanism of prostanoid-mediated induction of SOCS3 in HPAECs 
is still to be determined. Thus, further experiments to determine the role of 
EPAC, PKC and ERK, as these have previously been shown crucial for cAMP-
mediated induction of SOCS3 in HUVECs and COS-7 cells (Yarwood et al. 
2008; Borland et al. 2009), would be explored. Additionally, SOCS3-
independent regulation of IL-6 signalling activity would be explored, for 
instance the potential role of a prostanoid/PPARγ signalling axis and a 
prostanoid/PKA/notch signalling axis. 
Other roles of SOCS3 within VECs would also be explored in the context of 
PAH, and other vascular disease. The SOCS3/cavin interaction (Williams et 
al. 2018) is one such role that could potentially be exploited to increase the 
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ability of VECs to withstand higher levels of stress. Utilising AS-M.5 SOCS3 
KO to investigate a potential role for SOCS3 in membrane stability (Chapter 6) 
is a starting point for this line of research. Further optimisation of the technique 
used has been discussion in Section 6.3, however other models of cellular 
stress, such as modelling blood flow, could be utilised. Cavin1 proteins are 
also required for other caveolae functions such as transcytosis, signal 
transduction and lipid homeostasis (reviewed by Cheng and Nichols 2016), all 
of which are necessary for proper EC function. Thus, as SOCS3 stabilises 
cavin-1, the effect of SOCS3 on caveolae functions other than 
mechanoprotection should be explored. 
To summarise, future experiments would focus on defining the key elements 
involved in prostanoid induction of SOCS3, as well as the wider implications of 
prostanoid treatment such as PPARγ activation and potential PKA/IL-6 
interactions (Figure 1.7). In addition, the receptor profiles of VECs involved in 
PAH need to be confirmed to identify which signalling pathways will be best to 
target. Other effects of SOCS3 expression, for instance on caveolae function, 
should also be investigated. Combined, these experiments will highlight 
potential drug targets which could be further explored using the curative model 
of PAH in animal models previously described. 
8.1 Future perspectives  
PAH is currently a debilitating disease with no cure, thus novel treatments are 
required that target the pathological changes responsible for the disease. This 
research has started to address that gap in the literature and identified a novel 
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mechanism for the beneficial effects of prostanoid treatment for PAH in which 
IL-6/sIL-6Rα signalling activity is inhibited. As research has shown IL-6 
induced inflammation and vascular remodelling enables PAH progression 
(Section 1.4.2), a study to determine the effect of treating with prostanoids at 
an earlier functional class, potentially alongside clinically approved IL-6 
inhibitors, may prove to have an immediate impact. However, research should 
continue to improve the specificity, selectivity and safety of prostacyclin-based 
therapies to improve patient QOL. For instance, the introduction of new drug 
delivery systems that allow for sustained release of PGI2, or relevant 
analogues, that specifically target the damaged pulmonary vasculature 
(Ishihara et al. 2015; Segura-Ibarra et al. 2018) are encouraging and could 
lead to a novel method of prostanoid drug delivery which minimises the 
adverse effects and reduced QOL associated with current prostanoid 
treatments. Clinically approved PPARγ agonists such as thiazolidinediones, 
currently used in the treatment of type 2 diabetes (Vijay et al. 2009; Gupta et 
al. 2012), could also be repurposed as a PAH therapy as there is evidence to 
support enhancing PPARγ signalling would be beneficial (Section 7.2). 
Based on current research that proposes increasing SOCS3 expression or 
stability as a novel method of combatting disease (reviewed by Mahony et al. 
2016; reviewed by Durham et al. 2019) and the results of these experiments, 
i.e. a role for SOCS3 in prostanoid-mediated inhibition of IL-6 signalling and 
function, SOCS3-based therapies will be beneficial to diseases with a large 
inflammatory component, such as PAH. Thus, expanding this research will be 
of interest to other groups aiming to stabilise SOCS3 (Section 7.1) to identify 
and develop more effective treatments for a range of diseases. Although, as 
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there is a potential risk when increasing SOCS3 expression (Section 7.1.2), 
the specificity of SOCS3-based therapies will need to be carefully considered. 
To summarise, this research has identified a novel mechanism of prostanoid 
inhibition of IL-6 trans-signalling. These findings, in addition to future research 
identifying the most promising drug targets and developing new drug delivery 
systems, will form a bulk of research that enables the establishment of novel 
PAH therapies that address the limitations of current available PAH treatment. 
By targeting the underlying pathological causes of the disease, novel treatment 
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Vector ID VB180808-1176mwy 
Vector Name pLV[shRNA]-mCherry:T2A:Puro-U6>hSOCS3[shRNA#1] 
Date Created (Pacific 
Time) 
2018-08-08 
Vector Size 8338 bp 
Vector Type Mammalian shRNA Knockdown Lentiviral Vector 
Inserted shRNA hSOCS3[shRNA#1] 
Target Sequence CCACCTGGACTCCTATGAGAA 
Inserted Marker mCherry:T2A:Puro 
Plasmid Copy Number High 
Antibiotic Resistance Ampicillin 









(bp) Type Description Application notes 






































binding site that 
allows Rev-
dependent nuclear 










nuclear import of 
HIV-1 cDNA 






Human U6 small 
nuclear 1 promoter 
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of small RNAs. 
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Validation by Restriction Enzyme Digestion 
Restriction 
Enzymes 
Cutting Sites DNA Fragments (bp) 
XhoI 2200 8338 
ApaLI 2854, 4409, 6369, 7615 1555, 1960, 1246, 3577 
ApaLI+XhoI 2200, 2854, 4409, 6369, 
7615 





10.2 Appendix 2: Vector summary for pLV[shRNA]-mCherry/Puro-
U6>Scramble_shRNA 
Vector Summary 
Vector ID VB151104-10082 
Vector Name pLV[shRNA]-mCherry/Puro-U6>Scramble_shRNA 
Date Created (Pacific Time) 2017-05-08 
Vector Size 8338 bp 
Vector Type Lentivirus shRNA knockdown vector (3rd generation) 














RSV promoter 1-229 229 promoter 





























Human U6 small 











































mCherry and Puro 















Truncated HIV-1 3' long 
terminal repeat 
None 






























Validation by Restriction Enzyme Digestion 
Restriction 
Enzymes 
Cutting Sites DNA Fragments (bp) 
XhoI 2200 8338 
ApaLI 2854, 4409, 6369, 7615 1555, 1960, 1246, 3577 
ApaLI+XhoI 2200, 2854, 4409, 6369, 
7615 






10.3 Appendix 3: 8%, 10% and 12% acrylamide resolving gels and 
stacking gel recipes 
 



















HCl pH 8.8 at 
room temp, 0.4% 
(w/v) SDS 
2.5 ml 25% 2.5 ml 25% 2.5 ml 25% - - 
Stacking gel buffer; 
0.5M Tris-HCL pH 
6.8 at room temp, 
0.4% (w/v) SDS 
- - - - - - 1.34 ml 25% 
50% (v/v) 
glycerol 
0.65 ml 6.5% 0.65 ml 6.5% 0.65 ml 6.5% -  
30% (w/v) APS 32 µl 0.32% 32 µl 0.32% 32 µl 0.32% 54 µl 1% 





2.64 ml 26.7% 3.3 ml 33.4% 3.96 ml 40% 0.63 ml 12% 
Distilled H2O 4.07 ml 41% 3.4 ml 34% 2.74 ml 28% 3.4 ml 62% 
 
HCl; hydrochloride, SDS; sodium dodecyl sulphate, APS; ammonium 









EDTA, ethylenediamine tetraacetic acid, Tris; Tris base, acetic acid and EDTA. 
 
Agarose gel concentration 1% 1.5% 2% 
Agarose 1.6g 2.4g 3.2g 
1x TAE buffer 
(40mM Tris, 20mM acetate, 1mM 
EDTA, pH8.6) 
160ml 160ml 160ml 
SYBR safe 10μl 10μl 10μl 
